---
document_datetime: 2023-09-21 21:51:38
document_pages: 137
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/libtayo-h-c-004844-ii-0026-epar-assessment-report-variation_en.pdf
document_name: libtayo-h-c-004844-ii-0026-epar-assessment-report-variation_en.pdf
version: success
processing_time: 192.4247053
conversion_datetime: 2025-12-20 18:16:00.053574
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

13 October 2022 EMA/862705/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## LIBTAYO

International non-proprietary name: cemiplimab

Procedure No. EMEA/H/C/004844/II/0026

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 7                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................8                                                 |
| 2. Scientific discussion................................................................................                   | 9                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................9 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................9             |
| 2.1.2. About the product                                                                                                   | ........................................................................................... 12            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 12                                                                                                        |
| 2.1.4. General comments on compliance with GCP........................................................                     | 12                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................      | 12                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 12                                                                                                        |
| 2.2.2. Discussion on non-clinical aspects .....................................................................            | 13                                                                                                        |
| 2.2.3. Conclusion on the non-clinical aspects                                                                              | ............................................................... 13                                        |
| 2.3. Clinical aspects ..................................................................................................   | 13                                                                                                        |
| 2.3.1. Introduction....................................................................................................    | 13                                                                                                        |
| 2.3.2. Pharmacokinetics ............................................................................................       | 15                                                                                                        |
| 2.3.3. Pharmacodynamics..........................................................................................          | 43                                                                                                        |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 54                                                                                                        |
| 2.3.5. Conclusions on clinical pharmacology.................................................................               | 55                                                                                                        |
| 2.4. Clinical efficacy ..................................................................................................  | 55                                                                                                        |
| 2.4.1. Main study                                                                                                          | ..................................................................................................... 55  |
| 2.4.2. Discussion on clinical efficacy............................................................................         | 99                                                                                                        |
| 2.4.3. Conclusions on the clinical efficacy ..................................................................             | 102                                                                                                       |
| 2.5. Clinical safety ..................................................................................................    | 102                                                                                                       |
| 2.5.1. Introduction..................................................................................................      | 102                                                                                                       |
| 2.5.2. Patient exposure                                                                                                    | ........................................................................................... 105           |
| 2.5.3. Adverse events                                                                                                      | ............................................................................................. 108         |
| 2.5.4. Serious adverse event/deaths/other significant events.......................................                        | 110                                                                                                       |
| 2.5.5. Laboratory findings........................................................................................         | 120                                                                                                       |
| 2.5.6. Safety in special populations...........................................................................            | 121                                                                                                       |
| 2.5.7. Safety related to drug-drug interactions and other interactions ...........................                         | 122                                                                                                       |
| 2.5.8. Discontinuation due to adverse events.............................................................                  | 123                                                                                                       |
| 2.5.9. Post marketing experience .............................................................................             | 125                                                                                                       |
| 2.5.10. Discussion on clinical safety ..........................................................................           | 125                                                                                                       |
| 2.5.11. Conclusions on clinical safety                                                                                     | ........................................................................ 128                              |
| 2.5.12. PSUR cycle .................................................................................................       | 128                                                                                                       |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 128                 |
| 2.7. Update of the Product information......................................................................               | 130                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 130                                                                                                       |
| Balance...........................................................................                                         | 131                                                                                                       |
| 3. Benefit-Risk                                                                                                            | ...................................................................................... 131                |
| 3.1.1. Disease or condition 3.1.2. Available therapies and unmet medical                                                   | need..................................................... 131                                             |
| 3.1.3. Main clinical studies.......................................................................................        | 131                                                                                                       |

<div style=\"page-break-after: always\"></div>

3.2. Favourable effects  ............................................................................................ 131

3.3. Uncertainties and limitations about favourable effects  ........................................... 132

3.4. Unfavourable effects  ......................................................................................... 132

3.5. Uncertainties and limitations about unfavourable effects ....................................... 133

3.6. Effects Table  .................................................................................................... 133

3.7. Benefit-risk assessment and discussion  ............................................................... 133

3.7.1. Importance of favourable and unfavourable effects  ............................................ 133

3.7.2. Balance of benefits and risks .......................................................................... 134

3.7.3. Additional considerations on the benefit-risk balance ......................................... 134

3.8. Conclusions  ..................................................................................................... 134

4. Recommendations  ............................................................................... 134

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                       |
|----------------|--------------------------------------------------------------------------------------------------|
| 1L             | First line                                                                                       |
| 2L             | Second line                                                                                      |
| AC             | Adenocarcinoma                                                                                   |
| ADA            | Anti-drug antibody                                                                               |
| ADR            | Adverse drug reaction                                                                            |
| AE             | Adverse event                                                                                    |
| ALT            | Alanine aminotransferase                                                                         |
| AST            | Aspartate aminotransferase                                                                       |
| BCC            | Basal cell carcinoma                                                                             |
| BOR            | Best objective response                                                                          |
| CI             | Confidence interval                                                                              |
| C max1         | Maximum concentration after first dose                                                           |
| CPS            | Combined proportion score                                                                        |
| CR             | Complete response                                                                                |
| CSCC           | Cutaneous squamous cell carcinoma                                                                |
| CSR            | Clinical study report                                                                            |
| CTCAE          | Common Terminology Criteria for Adverse Events                                                   |
| C trough1      | Trough concentration after first dose                                                            |
| CYP            | Cytochrome P450                                                                                  |
| DCR            | Disease control rate                                                                             |
| DOR            | Duration of response                                                                             |
| DP             | Drug product                                                                                     |
| ECG            | Electrocardiogram                                                                                |
| ECOG           | Eastern Cooperative Oncology Group                                                               |
| EMA            | European Medicines Agency                                                                        |
| EORTC QLQ-C30  | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 |
| E-R            | Exposure-response                                                                                |
| EU             | Europe/European Union                                                                            |
| EudraCT        | European Clinical Trials Database                                                                |
| FAS            | Full analysis set                                                                                |
| FDA            | Food and Drug Administration                                                                     |
| FIH            | first-in-human                                                                                   |
| GM-CSF         | Granulocyte-macrophage colony-stimulating factor                                                 |

<div style=\"page-break-after: always\"></div>

| HHI          | Hedgehog (pathway) inhibitor                             |
|--------------|----------------------------------------------------------|
| HPV          | Human papilloma virus                                    |
| IC           | Investigator choice                                      |
| IDMC         | Independent Data Monitoring Committee                    |
| IgG          | Immunoglobulin G                                         |
| imAE         | Immune-mediated adverse event (also referred to as irAE) |
| IRR          | Infusion-related reaction                                |
| iSAP         | Integrated Statistical Analysis Plan                     |
| ISS          | Integrated Summary of Safety                             |
| ITT          | Intention-to-treat                                       |
| IV           | Intravenous(ly)                                          |
| K-M          | Kaplan-Meier                                             |
| MAH          | Marketing Authorisation Holder                           |
| MedDRA       | Medical Dictionary for Regulatory Activities             |
| N            | Total number of patients                                 |
| NAb          | Neutralizing antibody                                    |
| NCCN         | National Comprehensive Cancer Network                    |
| NCI          | National Cancer Institute                                |
| NCT          | National Clinical Trial                                  |
| NE           | Not evaluable                                            |
| NSCLC        | Non-small cell lung cancer                               |
| ORR          | Objective response rate                                  |
| OS           | Overall survival                                         |
| PD-1         | Programmed cell death 1                                  |
| PD-L1, PD-L2 | Programmed death-ligand 1, programmed death-ligand 2     |
| PFS          | Progression-Free survival                                |
| PH           | Proportional hazards                                     |
| PK           | Pharmacokinetic(s)                                       |
| PopPK        | Population PK                                            |
| PPC          | Posterior predictive check                               |
| PR           | Partial response                                         |
| PRO          | Patient reported outcome                                 |
| PT           | Preferred term                                           |
| Q2W          | Every 2 weeks                                            |
| Q3W          | Every 3 weeks                                            |
| R/M          | Recurrent/Metastatic                                     |
| RECIST       | Response Evaluation Criteria in Solid Tumors             |
| QoL          | Quality of life                                          |

<div style=\"page-break-after: always\"></div>

| SAE    | Serious adverse event                |
|--------|--------------------------------------|
| SAF    | Safety analysis set                  |
| SAP    | Statistical Analysis Plan            |
| SCC    | Squamous cell carcinoma              |
| SD     | Stable disease                       |
| SJS    | Stevens-Johnsons syndrome            |
| SMO    | Smoothened                           |
| SOC    | System Organ Class                   |
| TEAE   | Treatment-emergent adverse event     |
| TPS    | Tumor proportion score               |
| TTR    | Time to response                     |
| ULN    | Upper limit of normal                |
| US     | United States                        |
| UV     | Ultraviolet                          |
| VEGF-A | Vascular endothelial growth factor A |
| WHO    | World Health Organization            |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Regeneron Ireland Designated Activity Company (DAC) submitted to the European Medicines Agency on 8 November 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include monotherapy treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy for Libtayo; sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0293/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0293/2021 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 21 April 2017 (EMEA/H/SA/3225/4/2017/II). The Scientific Advice pertained to clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Aaron Sosa Mejia

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 8 November 2020   |
| Start of procedure:                                  | 27 November 2020  |
| CHMP Rapporteur Assessment Report                    | 21 January 2021   |
| PRAC Rapporteur Assessment Report                    | 28 January 2021   |
| PRAC Outcome                                         | 10 February 2021  |
| CHMP members comments                                | 29 October 2021   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 18 February 2022  |
| Request for supplementary information (RSI)          | 24 February 2022  |
| CHMP Rapporteur Assessment Report                    | 24 May 2022       |
| PRAC Rapporteur Assessment Report                    | 27 May 2022       |
| PRAC Outcome                                         | 10 June 2022      |
| CHMP members comments                                | 13 June 2022      |
| Updated CHMP Rapporteur Assessment Report            | 16 June 2022      |
| Request for supplementary information (RSI)          | 23 June 2022      |
| PRAC Rapporteur Assessment Report                    | 16 September 2022 |
| PRAC members comments                                | 21 September 2022 |
| Updated PRAC Rapporteur Assessment Report            | 22 September 2022 |
| CHMP Rapporteur Assessment Report                    | 29 September 2022 |
| PRAC Outcome                                         | 29 September 2022 |
| CHMP members comments                                | 03 October 2022   |
| Updated CHMP Rapporteur Assessment Report            | 07 October 2022   |
| An Oral explanation took place on:                   | 12 October 2022   |
| CHMP opinion:                                        | 13 October 2022   |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Claimed the therapeutic indication

The initially claimed indication was for LIBTAYO as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.

The recommended indication is for LIBTAYO as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

The recommended dose is 350 mg cemiplimab every 3 weeks (Q3W) administered as an intravenous infusion over 30 minutes.

Treatment may be continued until disease progression or unacceptable toxicity (see SmPC section 4.2).

## Epidemiology and risk factors, screening tools/prevention

Cervical cancer is the fourth most frequently diagnosed cancer in women and the fourth highest cause of cancer death in women, with an estimated global incidence of 604,000 new cases and 342,000 deaths globally in 2020 (Sung, 2021). The highest incidence rates are in the Caribbean, Africa, Eastern Europe, and South America (Forman, 2012). In 2018 the world aged-standardized incidence rate (per 100,000 women) ranged from 6.8 in Western Europe to 16.0 in Central-eastern Europe (Arbyn, 2020). The most significant cause of cervical cancer is persistent human papillomavirus (HPV) infection.

Screening with the Papanicolaou (Pap) test since the 1950s, with subsequent incorporation of HPV DNA testing, has been associated with decreased cervical cancer mortality in the US and other developed countries (Wang, 2004). Although vaccination against high risk strains of HPV is projected to gradually decrease the global incidence of cervical cancer in the coming decades, the burden of this disease remains profound (Simms, 2019).

## Biologic features

Squamous cell carcinomas account for approximately 70%-80% of cervical cancers and adenocarcinomas for 20%-25% (ESMO Clinical practice guideline on Cervical Cancer).

These histologic subtypes differ substantially in terms of HPV and mutation status (HPV16 for SCC, HPV18 for adenocarcinoma), immune infiltrate, response to therapy, and patient outcome. Several retrospective studies showed that patients with adenocarcinoma have a higher risk of developing metastases, resulting in a poorer prognosis (Rotman J, 2020).

Approximately 5-11% of all cervical cancers are reported to be HPV-negative, which can be attributed to truly negative and false-negative results. The truly HPV-negative cervical cancers are almost all cervical adenocarcinomas with unclear aetiology (Xing B, 2021).

<div style=\"page-break-after: always\"></div>

Cervical carcinoma may evade immune response by expression of PD-L1 (programmed-death ligand 1), the ligand for the immune-checkpoint receptor PD-1 (programmed death-1) on T cells (Heeren, 2016). Additionally, analysis of TCGA (The Cancer Genome Atlas) for expression of selected genes (PD-1, PD-L1, CD8A) showed that cervical cancer clusters with other tumour types for which anti-PD-1 therapy improves overall survival (Rischin D, 2020).

## Clinical presentation, diagnosis and stage/prognosis

Almost half of the newly diagnosed adult cervical cancer patients have Stage I localized cancer, with a 5year survival rate of over 90%. Five-year survival rates decrease with stage at diagnosis, becoming as low as 15-17% for metastatic disease (Lorin, 2015; Munich cancer registry 2016; SEER Cervical Cancer).

Following treatment of early-stage cervical cancer, distant metastases or multiple recurrence sites develop in 15% to 61% of patients, usually within the first two years of completing treatment. Recurrent cervical cancer presents as disease isolated to the pelvis (locoregional recurrence) or with disease involving other organs or outside the pelvis. If a vaginal recurrence is suspected, the area of concern should be biopsied to prove recurrent disease. All patients suspected of recurrent disease should undergo positron emission tomography (PET)/computed tomography (CT) for evaluation of local and distant disease.

## Management

Treatment options for cervical cancer in adults include surgery (conization, hysterectomy, pelvic exenteration), radiation, and chemotherapy alone or in combination, depending on the stage of the disease (ESMO Guideline). For patients with a local recurrence, surgical resection is recommended, rather than nonsurgical approaches, if they are appropriate surgical candidates based on tumour recurrence, age, and comorbidities. In select patients, surgical resection may present a curative option. However, for patients with a local recurrence who have not received radiation therapy (RT), RT in combination with chemotherapy is an acceptable alternative, and is preferred in those who are not surgical candidates, provided they have not previously undergone pelvic or intravaginal RT. For women with recurrent cervical cancer and who are not surgical candidates, and for those who present with metastatic disease, systemic therapy is recommended.

Cisplatin was the first established systemic therapy for treatment of recurrent or metastatic (R/M) cervical cancer, but single agent activity was modest (Eskander, 2014) (Tewari, 2019). Cisplatin-based doublets with topotecan or paclitaxel have shown superiority to cisplatin monotherapy in terms of response rate and PFS, especially in patients previously exposed to CRT where cisplatin was used as radiosensitizer (Moore, 2004; Long, 2005; ESMO Guideline).

The addition of bevacizumab, a monoclonal directed against vascular endothelial growth factor A (VEGFA), to doublet chemotherapy study improved overall survival (OS) compared to doublet chemotherapy alone in the GOG-240 study (16.8 vs 13.3 months; hazard ratio [HR 0.77]) (Tewari, 2017; EPAR Avastin).

Carboplatin + paclitaxel was reported to have a more favourable toxicity profile than cisplatin + paclitaxel and was associated with non-inferior OS in a phase 3 study (Kitagawa, 2015). Carboplatin + paclitaxel (with bevacizumab, if appropriate) may be the preferred first line treatment for recurrent/metastatic (R/M) cervical cancer for patients that are not candidates for cisplatin (ESMO Guideline). Topotecan + paclitaxel (with bevacizumab, if appropriate) may also be considered for patients who are not platinum candidates (Tewari, 2014b) (Tewari, 2017).

<div style=\"page-break-after: always\"></div>

The role of frontline immunotherapy in cervical cancer has recently been established. Pembrolizumab, a humanized monoclonal antibody that binds to human programmed cell death 1 (PD 1), was recently approved in EU in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD L1 with a Combined Positive Score (CPS) ≥ 1 (EPAR Keytruda).

In patients progressing following first-line therapy, different cytostatic agents, including vinorelbine, topotecan, gemcitabine or nanoparticle albumin-bound paclitaxel have been evaluated. However, response rates were low and duration of responses was short. Therefore, no ESMO recommendation is given about the most effective second-line treatment (ESMO Guideline). No systemic therapy has been associated with improvement in OS. Patients who progress following 1L chemotherapy and those who are not candidates for combination therapy, might be candidates for single-agent therapy. A choice among active agents must be tailored to the individual patient, with consideration to prior therapies received, residual toxicity, and performance status.

The following response rates have been reported in the literature with single agents:

- Carboplatin -ORR 15% (Weiss, 1990).
- Paclitaxel (175 mg/m 2  IV every three weeks with dose reduction to 135 mg/m 2  if patients received prior RT), ORR 20 to 25% (McGuire, 1996; Curtin, 2001; Kudelka, 1997).
- Topotecan (1.5 mg/m 2  IV daily for five days every 21 days) -ORR 19% (Thigpen, 2003; Bookman, 2000; Muderspach 2001; Abu-Rustum 2000).
- Nanoparticle, albumin-bound paclitaxel (125 mg/m 2  on days 1, 8, and 15 every 28 days) - ORR 29%t (Alberts 2012).
- Vinorelbine (30 mg/m 2  intravenous [IV] push weekly for two weeks every 21 days) - ORR 15% (Morris, 1998; Lacava, 1997; Muggia 2004).
- Pemetrexed (900 mg/m 2  IV every three weeks) - ORR 15% (Miller, 2008; Lorusso 2010).
- Ifosfamide (1.2 g/m 2  IV daily for five days every 28 days) - ORR 22 percent (Thigpen, 2003; Sutton 1996).
- Irinotecan (350 mg/m 2  IV every three weeks, or 125 mg/m 2  weekly for four weeks followed by a twoweek washout period) - ORR 15 percent (Look, 1998; Lhommé, 1999).
- Tisotumab vedotin (2 mg/kg intravenously every three weeks) was studied in a single-arm trial of 101 patients with recurrent or metastatic cervical cancer who had received no more than two prior systemic regimens in the recurrent or metastatic setting, including at least one prior platinum-based chemotherapy regimen. ORR to tisotumab was 24% (Coleman, 2021).
- Pembrolizumab (200 mg IV every three weeks) was evaluated in a single-arm trial KEYNOTE-158 including 82 patients from a cohort of patients with advanced, pretreated cervical cancer and PD-L1 expression of 1 percent or more. Pembrolizumab showed ORR of 15% (Chung, 2019; FDA Label for Keytruda). Similar findings were observed in the KEYNOTE-028 trial, in which the ORR was 17% percent and duration of response was 5.4 months (Frenel, 2017).

Tisotumab vedotin and pembrolizumab are not currently approved in EU in the post-chemotherapy setting of cervical cancer.

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

Cemiplimab is a monoclonal antibody that binds to programmed cell death 1 (PD-1) and blocks its interaction with programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). In Europe, cemiplimab is currently approved for the treatment of advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and first line treatment of non-small cell lung cancer (NSCLC) with PDL1 ≥ 50% and no genetic drivers.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## Development program for cemiplimab in cervical cancer:

In the first-in-human (FIH) study with cemiplimab, R2810-ONC-1423, durable anti-tumour responses were observed among patients with advanced cervical cancer. Among the 23 patients combined from the dose escalation and expansion cohorts, ORR was 17% (4/23) by investigator assessment. Durations of the 4 responses were &gt;1 year in 2 patients, and 11.2 months, and 6.4 months, respectively in the other 2 patients. The FIH experience with cemiplimab suggested that PD-1 blockade produces a modest response rate in ≥ 2L cervical cancer, and that these responses are often durable.  Although the ORR of cemiplimab in this setting may be similar to that of chemotherapy, the potential for durable responses with cemiplimab was hypothesized to translate into an OS benefit (versus chemotherapy) in a phase 3 randomized trial. Study R2810-ONC-1676 was designed to test this hypothesis.

The MAH received Scientific advice from the CHMP on 21 April 2017 (EMEA/H/SA/3225/4/2017/II). The overall recommendations from the CHMP were followed along design and conduct of the pivotal trial.

## 2.1.4. General comments on compliance with GCP

The MAH declared that the clinical studies presented in this application were conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation guidelines for Good Clinical Practice and applicable regulatory requirements. Consultations with health authorities in the US and EU have been conducted regarding the clinical development program and study design. Furthermore, it was stated that no inspections have occurred for trial R2810-ONC-1676 and none are currently planned.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

A claim of exclusion from preparation of environmental risk assessment studies was made according to Section 2 of the 2006 CHMP Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (ERA Guideline EMEA/CHMP/SWP/4447/00 corr 2) because cemiplimab is a monoclonal antibody consisting of linked naturally occurring amino acids. Per the ERA Guideline, \"Vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids are exempted because they are unlikely to result in significant risk to the environment.\"

<div style=\"page-break-after: always\"></div>

The Applicant concluded that, the claim for ERA exemption was justified and in conformity with the ERA guideline since the marketing authorisation request concerned a monoclonal antibody consisting of naturally occurring amino acids. Cemiplimab is significantly metabolized in vivo and is expected to be readily and rapidly degraded in wastewater treatment systems and in the environment. The antibody's structure and mode of action do not indicate any specific risk to the environment.

## 2.2.2. Discussion on non-clinical aspects

The MAH provided a justification in accordance with the Guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 corr 2) for not submitting ERA studies. Cemiplimab is a protein composed of natural amino acids. Proteins are biodegradable in the environment and thus do not pose any environmental risk. Therefore, according to the 'Guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 corr 2), it is acceptable that no ERA studies were submitted for cemiplimab.

## 2.2.3. Conclusion on the non-clinical aspects

Considering its nature, cemiplimab is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

Table 1: Tabular overview of clinical studies

<!-- image -->

| Study (NCT and EudraCT Numbers)                                                  | Study Population                                                                                                               | Study Phase Study Design                                                                                                                                                                                                        | Dose and Regimen                                                                                                                                                                                                                                                                                                                                  | DataIncludedinThis Application/DataCutoff Datesfor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Duration of Follow-up                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Status R2810-ONC-1676 (NCT 03257267; EudraCT2017-000350- 19) Study ongoing | Adult patients with metastatic cervical fecurrentor cancer                                                                     | Phase 3 Open-label, randomized, multicenter study                                                                                                                                                                               | 350 mg cemiplimab administeredIVover30min Q3W up to 96 weeks. Planned treatment duration is                                                                                                                                                                                                                                                       | Efficacy, Safety, and PK Efficacy data from R/M cervical cancer patients in the FAS(n=608patients [477 SCC histology and 131 AC and 65AC]and304chemotherapy[238 histology]; 304 cemiplimab [239 SCC SCC and 66 AC]) Safetydatafrom allpatientsin theSAF (n = 590 patients [465 SCC and 125 AC]; 300cemiplimab[234 SCC and 66AC] and 290 chemotherapy [231 SCC and 59 AC) PKdatafrom all cemiplimab-treated patients in thePKA set(n=295patients [231 SCC and 64 AC]) ADA data from all cemiplimab-treated patients in the ADA analysis set (n = 206 patients [164 SCC and 42 AC histology]) Datacutoffforalldata:04Jan2021 | Planned study period was up to 96 weeks. Median duration of follow-up was (range:6.0 to 38.2) in the 18.2months FAS                                                                                                                                                        |
| R2810-ONC-1423 (NCT 02383212; 41) EudraCT2015-002132- Study complete             | Adult patients (N = 398) with advanced solid tumormalignancies 20 patients with Expansion Cohorts 23 and 24 R/M CC enrolled in | Phase 1 (FIH) Open-label, repeat-dose, multicenter study monotherapy and combination with cemiplimab as (n = 130 patients) therapy (n =268 patients). included radiotherapy, Combinations GM-CSF, and cytotoxic chemotherapies. | Cemiplimab administered IV over 30minutes Q2W at: - 1 mg/kg (n = 27 patients) -3mg/kg(n=333patients) 30 minutes (n=12 patients) Cemiplimab3mg/kgQ3W administered IV over - 200 mg (n = 20 patients) -10 mg/kg(n=6patients) follow-up of approximately For allpatients,planned treatment duration was up to 48 weeks, and posttreatment 5.5months. | Efficacy data for CSCC patients* (n = 26 patients; 16 mCSCC and 10 laCSCC). Safetydatafrom allpatientsintheSAF (n = 398 patients) PK datafrom thePK analysis set CC in Expansion Cohorts 23 and 24 combined]) (n = 398 patients [including 20 with R/M ADA datafrom theADA analysis set combinedl) CC in Expansion Cohorts 23 and 24 (n =337 patients[including 14 with R/M Datacutoffforefficacy,safety,and PK/ADA:30 Apr 2019                                                                                                                                                                                            | Planned study period was 16.5months (approximately 11 months [48weeks] of Median duration of treatment follow-up) 5.5 months ofpost- planned treatment+ follow-up was 13.3months patients in the FAS. 26 advanced CSCC (range: 1.1 to 21.0) for all                        |
| Study (NCT and EudraCT Numbers)                                                  |                                                                                                                                |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                            |
| Study Status                                                                     | Study Population                                                                                                               | StudyPhase Study Design                                                                                                                                                                                                         | Dose and Regimen                                                                                                                                                                                                                                                                                                                                  | DataIncluded in This Application/DataCutoff Datesfor Efficacy,Safety,andPK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Duration of Follow-up                                                                                                                                                                                                                                                      |
| R2810-ONC-1540 (NCT 02760498; EudraCT 2016-000105- 36) Study ongoing             | Adult patients (N = 193) with advanced CSCC (mCSCC [Groups 1 and3]orlaCSCC [Group 2])                                          | Phase 2 Open-label, nonrandomized, multicenter study                                                                                                                                                                            | Cemiplimab administered IV over 30 minutes at: - 3 mg/kg Q2W (Groups 1 and 2) - 350 mg Q3W (Group 3) Planned treatment duration was up to 96 weeks for Groups 1 and 2 and up to 54 weeks in Group 3                                                                                                                                               | Efficacy data from CSCC patients (n=193patients;115metastatic CSCC [59 in Group 1 and 56 in Group 3] and 78 locally advanced CSCC) Safety datafrom allpatientsin theSAF (n = 193 patients) PK data from the PK analysis set (n = 188 patients) ADA datafrom theADA analysis set (n = 140 patients) Data cutoffs for efficacy, safety and PK/ADA: 20 Sep 2018(Groups 1 and3) and 10 Oct 2018 (Group 2)                                                                                                                                                                                                                      | Planned study period was up to~39months (~ 21 months [96 weeks Groups 1 and2;54 weeks Group 3] of planned treatment + ~1.5 years ofposttreatment follow-up). Median duration of follow-up was 9.4 months (range: 0.6 to 27.9) for all193 advanced CSCC patients in theFAS. |
| R2810-ONC-1620 (NCT 02760498; EudraCT 2016-003122- 16) Study ongoing             | Adult patients with mBCC (Group 1) andlaBCC (Group 2)                                                                          | Phase 2 Open-label, nonrandomized, 2-group, multicenter study                                                                                                                                                                   | 350 mg cemiplimab administered IV over 30 min Q3W Planned treatment duration is up to 93 weeks.                                                                                                                                                                                                                                                   | Efficacy data from BCC patients in the FAS (n = 112 patients; 84 laBCC and 28mBCC) Safety datafrom allpatientsin theSAF (n =138 patients) PK data from the PKA set (n = 132 patients) ADA datafrom theADA analysis set (n =125 patients) Data cutoff safety: 30Jun 2020 Data cutoff for PK/ADA: 17 Feb 2020                                                                                                                                                                                                                                                                                                                | Planned study period was up to ~39 months (~ 21 months [93 weeks ofplanned treatment + ~1.5 years of posttreatment follow-up). Median duration of follow-up was 13.26 months (range: 0.5 to 27.2) in the FAS                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study (NCT and EudraCT Numbers) Study Status                        | Study Population                                                                                            | Study Phase Study Design                                   | Dose and Regimen                                                                                          | DataIncludedinThis Application/DataCutoff Datesfor Efficacy,Safety,and PK                                                                                                                                                                                                                                                                                                                   | Duration of Follow-up                                                                                                                                                                                                              |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R2810-ONC-1624 (NCT 03088540; EudraCT2016-004407- 31) Study ongoing | Adult patients (N = 710) with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% oftumor cells | Phase 3 Open-label, randomized, 2-group, multicenter study | 350 mg cemiplimab administered IV over 30 min MEO OR chemo Planned treatment duration was up to108 weeks. | EfficacydatafromNSCLCpatients in the ITT (n =710 patients; 356cemiplimab,354chemo),mITT-1(n =563patients;283cemiplimab,280 chemo),mITT-2(n=475;238 cemiplimab,237chemo) SafetydatafromallpatientsintheSAF (n=697patients;355 cemiplimab, 342 PBC) PK data from the PK analysis set (n = 345 patients; all cemiplimab) ADA data from the ADA analysis set (n = 221 patients; all cemiplimab) | Planned study period was up to ~48 months (~ 2 years [2 years of planned treatment + ~7 months of posttreatment follow-up). Median duration of follow-up was 13.08 months (range: 0.1 to 32.4 months) for all patients in the ITT. |
|                                                                     |                                                                                                             |                                                            |                                                                                                           | Data cutoff:01 Mar 2020 Data cutoff for PK/ADA: 28 Feb 2020                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                    |

Excludes anogenital SCC (1 patient).

Abbreviations:AC,adenocarcinoma;ADA,anti-drug antibody,BCC,basal cell carcinoma,chemo,chemotherapy;CC=cervical cancer,CSCC,cutaneous squamous cell carcinoma; EudraCT, European Clinical Trials Database; FAS, full analysis set; GM-CSF, granulocyte-macrophage colony stimulating factor; ITT, intent-to-treat; IV, intravenous(ly); laBCC, locally advanced basal cell carcinoma; laCSCC, locally advanced mCSCC; mBCC, metastatic basal cell carcinoma; mCSCC, metastatic CSCC; n, number of patients in the group; mITT, modified intent-to-treat; N, total number of patients; NCT, National Clinical Trial; NSCLC, Non-small cell lung cancer, PD-L1, programmed death-ligand 1; PK, pharmacokinetics; PKA, PK analysis set; Q2W, every 2 weeks; Q3W, every 3 weeks; R/M, recurrent or metastatic;SAF,safety analysisset;SCC,squamous cell carcinoma.

Source: Module 2.7.2 Table 1; Module 5.3.5.1 R2810-ONC-1676 Primary Analysis CSR; Module 5.3.5.2 R2810-ONC-1620 Interim CSR; Module 5 3 5 2. CSR

## 2.3.2. Pharmacokinetics

The proposed dose of cemiplimab is 350 mg Q3W administered as an IV infusion over 30 minutes until disease progression or unacceptable toxicity. This cemiplimab dosing regimen is currently approved for the treatment of advanced CSCC, BCC and first line treatment of NSCLC.

The clinical pharmacology package included data from pharmacokinetics (PK), pharmacodynamics, exposure-response (E-R) for efficacy and safety, and immunogenicity assessment of cemiplimab in the target population. The MAH also submitted PK data assessing consistency across studies in the R/M cervical cancer and by histology (SCC vs AC), as well as PK data in other patient populations (tumourtypes) that have been previously reported.

Within the population of patients with R/M cervical cancer, the PK of cemiplimab was assessed across studies (Study 1423 and Study 1676), as well as between patients.

Table 1 provides a summary of the clinical studies that were conducted in patients with R/M cervical cancer.

## Study 1676

Study 1676 is an open-label, randomized, multicenter, phase 3 study to compare the OS in patients with R/M cervical cancer that had progressed after platinum-containing chemotherapy, treated with either cemiplimab (REGN2810) as monotherapy at 350 mg Q3W IV or with investigator's choice (IC) chemotherapy. R/M cervical cancer patients with SCC and AC histology were enrolled in this study. All patients underwent screening procedures to determine eligibility within 28 days prior to initial administration of cemiplimab or chemotherapy. After the screening period, patients received up to 96 weeks of treatment, consisting of 16 cycles of 6 weeks each. This study has completed enrollment and is ongoing at the time of this application. The percent change from baseline in tumour target lesions was assessed as a pharmacodynamic marker of efficacy.

<div style=\"page-break-after: always\"></div>

Blood samples for assessment of cemiplimab concentrations and detection of immunogenicity in serum were collected at various pre-specified times over the treatment period according to the study schedule. Blood samples for drug concentrations assessment were collected using a sparse sampling schedule: predose and post-dose on day 1 of cycle 1, then pre-dose and post-dose on day 1 of cycles 2 through cycle 6, and cycles 7, 9, 11, 13, and 15. Blood samples were also collected at follow-up visit 1 (approximately 30 days after the last dose of cemiplimab) collection of a blood sample at follow-up visit 2 (approximately 4 months after the last dose of cemiplimab) was optional.

The numbers of patients with R/M cervical cancer in the Study 1676 primary analysis sets are presented in Table 2.

Table 2: Patients with R/M cervical cancer in the primary analysis sets (study 1676)

| AnalvsisSet   | SCC350mgQ3W N (%)   | AC350mgQ3W N (%)   | Total N (%)   |
|---------------|---------------------|--------------------|---------------|
| Safety        | 234 (100%)          | 66 (100%)          | 300 (100%)    |
| PK            | 231 (98.7%)         | 64 (97.0%)         | 295 (98.3%)   |
| ADA           | 164 (70.1%)         | 42 (63.6%)         | 206 (68.7%)   |

N=Number of patients; AC=Adenocarcinoma/adenpsqwawous, carcimoma; ADA=Anti-drug antibody; PK=Phammacokinetic; Q3W=Every 3 weeks; SCC=Squamous cell carcinoma

Note: Percentages are based on the total in the safety analysis set.

Note: Data cutoff 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR Appendix 16.1.15 (CP Report) Table 1.

## Pharmacokinetic results

Observed cemiplimab PK parameters in patients with R/M cervical cancer in the cemiplimab group in Study 1676 are summarized in Table 3. Steady state was reached by week 12 in the overall population of patients with R/M cervical cancer upon repeated cemiplimab 350 mg Q3W IV dosing and maintained throughout the period. As such, week 18 was selected as the representative time point to report steadystate concentrations. Cemiplimab exposure (Ctrough and Cmax, mean [SD]) at steady state in the overall population of patients with R/M cervical cancer ranged between a Ctrough of 65.6 (30.0) mg/L and a Cmax of 186 (60.8) mg/L. Cemiplimab PK parameters were similar in the subpopulations of patients with histology types SCC and AC.

<div style=\"page-break-after: always\"></div>

Table 3: Observed cemiplimab exposure (Ctrough and Cmax) after the first dose and at steady state in patients with R/M cervical cancer at 350 mg Q3W monotherapy (study 1676)

|                |     | After theFirstDose   | After theFirstDose   | After theFirstDose   | After theFirstDose   | At SteadyState   | At SteadyState   | At SteadyState   | At SteadyState   |
|----------------|-----|----------------------|----------------------|----------------------|----------------------|------------------|------------------|------------------|------------------|
|                |     | eh (mg/L)            | eh (mg/L)            | Cx (mg/L)            | Cx (mg/L)            | Cueh (mg/L)      | Cueh (mg/L)      | Cx (mg/L)        | Cx (mg/L)        |
| Histology Type | N   |                      | nMean (SD)           |                      | nMean(SD)            |                  | Mean (SD)        | n                | Mean (SD)        |
| All            | 295 | NR                   | NR (NR)              |                      | 134 (58.7)           | 113              | 65.6 (30.0)      | 112              | 186 (60.8)       |
| SCC            | 231 | NR                   | NR (NR)              |                      | 135 (61.3)           | 91               | 64.8 (31.0)      | 90               | 181 (59.0)       |
| AC             | 64  | NR                   | NR (NR)              | 60                   | 128 (47.8)           | 22               | 68.9 (25.8)      | 22               | 204 (65.7)       |

N=Number of patients in PK analysis set; n=Number of patients for deseriptive statistics; AC=Adenocarcinoma/adenosquarowx. carcinoma; C=Peak concentration; Cgk=Trough concentration; LLOQ=Lower limit of quantitation; PK=Phanmacokinetic; Q=Quartile; Q3W=Every 3 weeks; SCC=Squamous cell carcinoma; SD=Standard deviation; NR=Not reported (no PK sample collection at Cycle 1 Day 22).

Note: Descriptive statistics included all available PK data in the 295 patients on cewviplimab 350 mg Q3W; although 3 patients who received two doses of cewviplivmab,showed end-of-infusion concentratioms after the first dose that were BLQ, ome of them wifh possible inversion of PK samples between pre-dose (174 mg/L) and end-of-infusion (BLQ). Overall reliable PK data were therefore available from a total of 292 patients in Study 1676. Concentrations below fhe LLOQ were set to 0. After first dose: Coe,at Cycle 1 Day 1l end of infusion. At steady state: Cuac, at Cyele 4 Day 1 pre-infusion; Cox,at Cycle 4 Day 1 end of infusion.

Week 18 was selected as the representative time point to report steady-state concentratiomns.

Data Cutoff: 04 Jan 2021

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR Appendix 16.1.15 (CP Report) Table 4.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Treatment Group                    |   WK0 |   WK6 |   WK12 |   WK18 |   WK24 |   WK30 |   WK36 | WK48   |   WK60 | WK72   |   WK84 |
|------------------------------------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| SCC 350 mg Q3W Ctrough             |   227 |   169 |    116 |     91 |     72 |     60 |     51 | 38     |     28 | 23     |     12 |
| SCC 350 mg Q3W Cmax                |   224 |   160 |    115 |     90 |     69 |     59 |     50 |        |     28 | 23     |     11 |
| AC 350 mg Q3W Ctrough              |    61 |    42 |     31 |     22 |     20 |     17 |     10 | 6      |      3 | 2      |      2 |
| AC 350 mg Q3W Cmax                 |    60 |    41 |     31 |     22 |     20 |     16 |     11 | 6      |      3 | N      |      2 |
| R/M CC (SCC+AC) 350 mg Q3W Ctrough |   288 |   211 |    147 |    113 |     92 |     77 |     61 | 44     |     31 | 25     |     14 |
| R/M CC (SCC+AC) 350 mg Q3W Cmax    |   284 |   201 |    146 |    112 |     89 |     75 |     61 | 44     |     31 | 25     |     13 |

N=Number of patients; AC=Adenocarcinoma/adenpsqwawous,carcinoma; LLOQ=Lower limit of quantitation; Q3W=Every 3 weeks; SCC=Squamous cell carcinoma; R/M CC=recurent or metastatic cervical cancer; WK=Week Data Cutoff: 04 Jam 2021.

Note: Concentrations below fhe LLOQ were set to O. Numbers in the table indicate the mumber of patients at each visit. Cuouss. indicates pre-infusion concentration at each visit; Coss,indicates end of imfusion concentration at each visit. At nominal time 0, pre-dose value is shown instead of Cuons, For a graphical representation of these data usimg a logarithmic scale (logio) for concentration see Figure 15.

Data source: Module 5.3.5.1 Study 1676 Primary Amalysis CSR Appendix 16.1.15 (CP Report).

Figure 1: Observed Mean (±SD) Cemiplimab Ctrough and Cmax Over Time and by Histology Type in Patients with R/M Cervical Cancer (Study 1676)

<div style=\"page-break-after: always\"></div>

## First-in-Human Study 1423 in Patients with Various Tumour Types

The FIH Study 1423 evaluated a range of cemiplimab doses (dose escalation phase: 1 to 10 mg/kg Q2W IV), included dense sampling for measurement of PK parameters after the first dose, and enrolled patients with multiple solid tumour types (including CSCC, BCC, NSCLC, and R/M cervical cancer), allowing for comparison of PK parameters across tumour types. This study also included comparison of PK parameters for cemiplimab administered as monotherapy or combination therapy (cemiplimab plus radiotherapy and/or chemotherapy).

## Study Design

Study 1423 was a FIH, open-label study in patients with advanced solid tumours to evaluate repeat IV dosing with cemiplimab, as monotherapy and as combination therapy (with radiotherapy and/or chemotherapy). The study consisted of both 1a dose escalation phase and a dose expansion phase. Patients were eligible to receive up to 48 weeks of treatment, after which there was a 24-week follow-up period. The 48 weeks of treatment consisted of up to 6 cycles of 8 weeks each. In the dose escalation phase, 60 patients were each assigned to 1 of 3 dose escalation cohorts (1 mg/kg, 3 mg/kg, or 10 mg/kg Q2W administered IV as monotherapy or in combination with other anti-cancer treatments (radiotherapy and/or chemotherapy). During dose escalation, safety was assessed, and no maximum tolerated dose was identified. The expansion phase, which included 24 cohorts, assessed the PK, immunogenicity, safety, and efficacy of cemiplimab in different tumour types after dosing as monotherapy or in combination with other anti-cancer treatments (radiotherapy or chemotherapy).

The descriptive PK of cemiplimab in serum using dense sampling after the first dose was evaluated by Non compartmental analysis (NCA) and during the treatment and follow-up periods.

## Pharmacokinetic Results

A total of 23 patients with R/M cervical cancer were enrolled in Study 1423: 3 patients in dose escalation cohorts where tumour type was not specified in the data base and these patients were therefore reported as 'all solid tumours': 2 patients at 1 mg/kg Q2W and 1 patient at 3 mg/kg Q2W (Papadopoulos, 2020), and 20 patients in the expansion cohorts EXP23 and EXP24 that were identified with R/M cervical cancer in the database: 10 patients in expansion cohort 23 (EXP23) who received cemiplimab 3 mg/kg Q2W as monotherapy, and 10 patients in expansion cohort 24 (EXP24), who received cemiplimab 3 mg/kg Q2W with radiotherapy (XRT 9 Gy x 3). The ORR was 10% in EXP23 and 10% in EXP24.

Overall, the PK of cemiplimab was linear and dose-proportional over a dosing range of 1 to 10 mg/kg Q2W IV in Study 1423.

<div style=\"page-break-after: always\"></div>

Table 4: Observed Pharmacokinetic Parameters of Cemiplimab in Patients with R/M Cervical Cancer and All Patients Who Received Cemiplimab 3 mg/kg Q2W as Monotherapy or Combination Therapy (Study 1423)

<!-- image -->

| Patients at 3 mg/kg Q2W   | Assessment       |   N | Cwvuzh. (mg/L) Mean (SD)   | Cwy (mg/L) Mean (SD)   | AUC2w (day*mg/L) Mean (SD)   | t12* (days) Mean (SD)   |
|---------------------------|------------------|-----|----------------------------|------------------------|------------------------------|-------------------------|
| R/M CC (EXP23, MONO)      | After First Dose |  10 | 20.7 (9.34)                | 75.1 (21.5)            | 516 (155)                    | 9.47 (1.82)             |
| R/M CC (EXP23, MONO)      | At Steady State  |  10 | 61.3 (10.6)                | 135 (19.4)             | NR                           | NR.                     |
| R/M CC (EXP24, RADIO)     | After First Dose |  10 | 16.7 (7.88)                | 69.7 (12.8)            | 446 (187)                    | 8.24 (2.54)             |
| R/M CC (EXP24, RADIO)     | At Steady State  |  10 | 44.3 (10.4)                | 105 (21.5)             | NR                           | NR                      |
| All R/M CC (EXP23+EXP24)  | After First Dose |  20 | 18.8 (8.69)                | 72.4 (17.5)            | 481 (171)                    | 8.85 (2.15)             |
| All R/M CC (EXP23+EXP24)  | At Steady State  |  20 | 52.8 (13.2)                | 120 (24.8)             | NR                           | NR.                     |
| All Patients MONO+COMBO   | After First Dose | 333 | 21.0 (12.6)                | 70.0 (30.3)            | 443 (168)                    | 11.2 (5.19)             |
| All Patients MONO+COMBO   | At Steady State  | 333 | 60.5 (25.3)                | 129 (40.1)             | NR                           | NR                      |

at the end of the dosing interval; N=mumber of patients; NR=not reported; Q2W=every 2 weeks; SD=standard deviation; t±*=estimated elimination half-life is underestimated as assessed over a dosing interval; R/M CC=recurrent or metastatic cervical cancer; MONO=monotherapy; RADIO=in combination with radiotherapy; COMBO =in combination with radliotherapy and/or chemotherapy; all patients=all patients with solid tumors in Study 1423 at 3 mg/kg Q2W (MONO and COMBO). Note: Patients with cervical cancer in Study 1423 were in Expansion Cohorts (EXP): EXP23 (MONO) and EXP24 (RADIO).

Data source: Module 5.3.5.2 Study 1423 Fimal CSR Appendix 5 (CP Report)

## COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES

This current submission presents the observed and population-predicted cemiplimab concentrations in serum in patients with R/M cervical cancer in the FIH Study 1423 at 3 mg/kg Q2W IV as monotherapy (EXP23, N=10) and in combination with radiotherapy (EXP24, N=10), and in the pivotal Study 1676 at 350 mg Q3W IV as monotherapy (N=295).

<div style=\"page-break-after: always\"></div>

<!-- image -->

N=Nummber of patients.

R/M CC=recurent/metastatic cervical cancer; CSCC=cutameous squamous cell carcinoma (advanced CSCC);

BCC=basal cell carcinoma (advanced BCC); NSCLC=non-small cell lung cancer (advanced NSCLC).

ALL=all solid tumors, MONO=Monotherapy:; RADIO=in combination with radiotherapy ; COMBO=in combination with radiotherapy and/or chemotherapy

Concentrations below the LLOQ were set to 0.

SD=standard deviation; Q2W=every 2 weeks;

Figure 2: Observed Mean (±SD) Cemiplimab Concentration-Time Profiles After the First Dose in Patients with R/M Cervical Cancer Compared to Those with Other Solid Tumor Types Receiving Cemiplimab 3 mg/kg Q2W as Monotherapy or in Combination Therapy (FIH Study 1423)

<div style=\"page-break-after: always\"></div>

Similarity in the observed cemiplimab exposure (Ctrough and Cmax) at 3 mg/kg Q2W after the first dose and at steady state across patients with different tumour types in Study 1423 is presented in Table 5.

Table 5: Observed Cemiplimab Exposure (Ctrough and Cmax) after the First Dose and at Steady State in Patients with R/M Cervical Cancer compared to Patients with Other Solid Tumour Types Receiving Cemiplimab 3 mg/kg Q2W as Monotherapy or in Combination Therapy (Study 1423)

|        |            |              |     | After theFirstDose   | After theFirstDose   | AtSteadyState   | AtSteadyState   |
|--------|------------|--------------|-----|----------------------|----------------------|-----------------|-----------------|
| Cancer |            | Therapy      |     | Cuek (mg/L)          | (mg/L)               | Cuoub (mg/L)    | (mg/L)          |
| Type   | Cohort     |              | N   | Mean (SD)            | Mean (SD)            | Mean (SD)       | Mean (SD)       |
| R/M CC | EXP23      | MONO         | 10  | 20.7 (9.34)          | 75.1 (21.5)          | 61.3 (10.6)     | 135 (19.4)      |
|        | EXP24      | RADIO        | 10  | 16.7 (7.88)          | 69.7 (12.8)          | 44.3 (10.4)     | 105 (21.5)      |
| CSCC   | EXP7, EXP8 | MONO         | 25  | 24.1 (21.4)          | 66.6 (19.6)          | 63.2 (24.1)     | 124 (27.8)      |
| BCC    | EXP25      | MONO         | 4   | 22.8 (5.35)          | 58.1 (13.4)          | 50.9 (17.4)     | 106 (55.3)      |
| NSCLC  | EXP2       | RADIO        | 33  | 18.9 (9.53)          | 69.3 (19.1)          | 50.7 (21.4)     | 133 (46.1)      |
| ALL    | DE and EXP | MONO         | 98  | 20.9 (12.4)          | 71.3 (42.1)          | 59.3 (21.8)     | 122 (35.1)      |
|        |            | RADIO        | 189 | 21.5 (13.6)          | 69.8 (24.4)          | 61.0 (26.4)     | 136 (42.0)      |
| ALL    | DE and EXP | MONOandCOMBO | 333 | 21.0 (12.6)          | 70.0 (30.3)          | 60.5 (25.3)     | 129 (40.1)      |

All=all solid tumors. DE= dose escalation cohort; EXP=expansion cohort; BCC=basal cell carcinoma; CSCC=cutaneous squamous cell carcinoma; MONO=cerwiplimab, monotherapy:; NSCLC=non-small cell lumg cancer; N=nummber of patients in each analysis set; Q2W=every 2 weeks; Q3W=every 3 weeks; RADIO=cewipliva + radiotherapy; R/M CC=recurent or metastatic cervical camcer; SD=standard deviation; N=Nummber of patients in each Analysis Set SD=Standard Deviation; mCSCC=metastatic CSCC: laCSCC=locally Q2W=every 2 weeks: Q3W=every 3 weeks:

Steady state is defined at cyele 3 day l, 4-week cycles.

MONO=monotherapy; RLADIO=in combination with radiotherapy; COMBO=in combination with radiotherapy and/or chemotherapy

Data source: Module 5.3.5.2 Study 1423 Final CSR Appendix 5 (CP Report)

As previously demonstrated to support switch of dosing regimens from 3 mg/kg Q2W to 350 mg Q3W, the observed cemiplimab concentrations (Ctrough and Cmax) at steady state were similar in patients receiving 350 mg Q3W compared to patients receiving 3 mg/kg Q2W IV as presented in

Table 6 for individual studies and combined data for each dose level across studies.

Observed cemiplimab exposure (Ctrough and Cmax) during therapy at 350 mg Q3W was also compared between patients with R/M cervical cancer in Study 1676 and patients with advanced CSCC, BCC, and NSCLC in the respective pivotal studies. Cemiplimab exposure was compared across tumor types over time (Figure 4) and at steady state (

Figure 3 ); numerical results are summarized in

Table 6.

Based on the popPK model, at 350 mg Q3W, the mean cemiplimab concentrations at steady-state ranged between a Ctrough of 59 mg/l and a concentration at end of infusion (Cmax) of 171 mg/l. Steady state exposure is achieved after approximately 4 months of treatment.

<div style=\"page-break-after: always\"></div>

Table 6: Observed Mean Cemiplimab Exposure After the First Dose and at Steady State (Ctrough and Cmax) in Patients with R/M CC (Study 1676) Compared to those with Advanced CSCC, Advanced BCC, Advanced NSCLC, and All Patients Receiving Cemiplimab 350 mg Q3W and All Patients Receiving Cemiplimab 3 mg/kg Q2W

|                             |                |                                                               |            | After theFirst Dose   | After theFirst Dose     | After theFirst Dose   | After theFirst Dose              | At Steady State   | At Steady State                     | At Steady State   | At Steady State                  |
|-----------------------------|----------------|---------------------------------------------------------------|------------|-----------------------|-------------------------|-----------------------|----------------------------------|-------------------|-------------------------------------|-------------------|----------------------------------|
| Cancer Type-                |                |                                                               |            | Cek (mg/L)            | Cek (mg/L)              | Cx (mg/L)             | Cx (mg/L)                        | Ceh (mg/L)        | Ceh (mg/L)                          | Cmx(mg/L)         | Cmx(mg/L)                        |
| Histology                   | Study          | Group-Dose                                                    | N          | n                     | Mean (SD)               | n                     | Mean (SD)                        | n                 | Mean (SD)                           | n                 | Mean (SD)                        |
| All R/MCC RMCC-SCC R/MCC-AC | 1676           | Group 1+2: 350 mg Q3W Group 1: 350 mg Q3W Group 2: 350 mg Q3W | 295 231 64 | NR NR NR              | NR (NR) NR (NR) NR (NR) | 284 224 60            | 134 (58.7) 135 (61.3) 128 (47.8) | 113 [6 22         | 65.6 (30.0) 64.8 (31.0) 68.9 (25.8) | 112 90 22         | 186 (60.8) 181 (59.0) 204 (65.7) |
|                             | 1540 1540      | Group 3: 350 mg Q3TW Group 1+2: 3 mg/kg Q2W                   | 53         | 47 123                | 34.2 (32.0) 24.3 (12.0) | 52 131                | 132 (203) 88.1 (96.2)            | 34                | 62.7 (28.3) 68.4 (26.1)             | 33 96             | 151 (46.2) 150 (79.0)            |
| CSCC                        | 1423 and 1540  | 3 mg/kg Q2W                                                   | 135 161    | 150 119               | 24.2 (13.9)             | 158                   | 90.6 (115)                       | 96 112            | 68.1 (25.9)                         | 112               | 147 (74.7)                       |
| BCC                         | 1620           | Group 1+2 - 350 mg Q3W                                        | 132        | 320                   | 29.8 (15.1) 22.8 (16.8) | 123                   | 104 (39.9)                       | 90                | 66.2 (32.1)                         | 83                | 184 (84.3)                       |
| NSCLC                       | 1624           | PKAS - 350 mg Q3W                                             | 345        |                       | 21.9 (12.5)             | 336                   | 121 (63.3)                       | 175               | 60.0 (28.7)                         | 175               | 189 (105)                        |
| Solid Tumors                | 1423 amnd 1540 | 3 mg/kg Q2W                                                   | 468        | 438                   |                         | 463                   | 77.2 (72.2)                      | 232               | 63.8 (25.9)                         | 227               | 138 (60.5)                       |
| CSCC,BCC,                   | 1540, 1620,    |                                                               |            |                       |                         |                       |                                  |                   |                                     |                   |                                  |
| NSCLC,RMCC                  | 1624, and 1676 | 350 mg Q3W                                                    | 825        | 486                   | 25.7 (18.8)             | 795                   | 124 (77.0)                       | 412               | 63.1 (29.8)                         | 403               | 184 (86.7)                       |

R/M CC=recurent/metastatic cervical cancer; SCC=squamous cell carcinoma; AC=adenocarcinoma/adexpsquamous carcinoma; CSCC=cutaneous squamous cell carcinoma; BCC=basal cell carcinoma; NSCLC=non-small cell lung cancer.

N=Number of patients inPKAnalysis Set. n=Number of patients for descriptive statistics.

SD: Standard Deviation; Q=Quartile. Concentrations below the LLOQ were set to 0.

After the First Dose: C is Pre-Infusion at Cycle 1 Day 15 (3 mg/kg Q2W; Study 1423 and 1540), Cycle 1 Day 22 (350 mg Q3W; Study 1423 and 1540), and Cycle 2 Day 1 (350 mg Q3W; Study 1624); C is End-of-Infusion at Cycle 1 Day 1.

Data source: Module 5.3.5.2 Study 1423 Fimal CSR Appendix 5(CP Report), Module 5.3.5.2 Study 1540 Interim CSR Appendix 5 (CP Report), Module 5.3.5.2 Study 1620 Interim CSR Appendix 5 (CP Report), Module 5.3.5.1 Study 1624 Primary Analysis CSR Appendix 16.1.15 (CP Report), Module 5.3.5.1 Study 1676 Primary Analysis CSR Appendix 16.1.15 (CP Report)

<!-- image -->

Treatment Group

N=Number of patients for dlescriptive statistics.

Concentrations below the LLOQ were set to 0.

Trestment Group

At Steady State: (A) Cr is at Pre-Infusion at Cycle 3 Day 1 (Study 1540 and 1620) and at Cycle 9 Day 1 (Study 1624) and at Cycle 4 Day 1 (Study 1676); (B)Cis at End-ofR/M CC=recurrent/metastatic cervical cancer; CSCC=cutaneous squamous cell carcinoma; BCC=basal cell carcinoma; NSCLC=non-small cell lumg cancer.

Bottom and top edges of box are 25th and 75th percentiles,respectively; Horizontal line is Median (50th percentile);Diamond is Mean; Vertical lines extending from top to bottom are the maximum value below upper fence and minimum value above lower fence respectively; circles are outliers defined by the '1.5 rule

Data source:Module5.3.5.2Study 1540Interim CSRAppendix5（CPReport),Module5.3.5.2Study 1620Interim CSRAppendix5(CPReport),Module 5.3.5.1 Study 1624 Primary Analysis CSR Appendix 16.1.15 (CP Report), Module 5.3.5.1 Study 1676 Primary Analysis CSR Appendix 16.1.15 (CP Report)

Figure 3: Box Plot of Observed Cemiplimab Exposure at Steady State (Ctrough and Cmax) in Patients who Received Cemiplimab 350 mg Q3W as Monotherapy in the Pivotal Studies (Studies 1540, 1620, 1624, and 1676)

<div style=\"page-break-after: always\"></div>

<!-- image -->

N=Number of patients in the PK Analysis Set; SD=standard deviation; R/M CC=recurrent/metastatic cervical cancer (SCC+AC histology); CSCC=cutaneous squamous cell carcinoma; BCC=basal cell carcinoma; NSCLC=non-small cell lung cancer. For Study 1676 only, pre-dose value is showm instead of Ctwgk at nominal time 0. Concentrations below the LLOQ were set to 0. For a graphical representation of these data using a logarithmic scale (logio) for concentration see Figure 16.

Data source: Module 5.3.5.2 Study 1540 Interim CSR Appendix 5 (CP Report), Module 5.3.5.2 Study 1620 Interim CSR Appendix 5 (CP Report), Module 5.3.5.1 Study 1624 Primary Analysis CSR Appendix 16.1.15 (CP Report), Module 5.3.5.1 Study 1676 Primary Analysis CSR Appendix 16.1.15 (CP Report)

Figure 4: Observed Mean (±SD) Cemiplimab Ctrough and Cmax Concentrations Over Time in Patients Who Received Cemiplimab 350 mg Q3W Monotherapy in the Pivotal Studies (Studies 1540, 1620, 1624, and 1676)

<div style=\"page-break-after: always\"></div>

## Population PK analyses

The primary objectives of the population PK analysis were to:

1. Update the existing population PK model for cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), non-small cell lung cancer (NSCLC) or other solid tumour types from studies R2810-ONC-1423, R2810-ONC-1540, R2810-ONC-1620 and R2810-ONC-1624 (referred to as Studies 1423, 1540, 1620 and 1624).
2. Identify and quantify the effects of intrinsic and extrinsic covariates, which may explain variability in PK parameters in the updated model.
3. Perform an external validation of cemiplimab PK patients with cervical cancer (CC) from Study R2810ONC-1676 (referred to as Study 1676) to assess consistency in cemiplimab PK across various solid tumour types.

The population PK of cemiplimab was previously described by a 2-compartment model with zero-order IV infusion and first-order elimination, which included a sigmoid Emax function to describe time-varying change in clearance (CL), and an additive and proportional residual error model. The previous population PK model was based on data from Studies 1423, 1540, 1620 and 1624, which consisted of 1062 patients and 17193 PK samples, whereas the updated model included a total of 1063 patients and 17312 postdose PK samples. Data summaries of number of patients and post-dose cemiplimab concentrations can be seen across study, dose regimen and tumour type in Table 7 and Table 8.

Table 7: Summary of Populations, Studies and Samples Included in the Population PK Analysis for 1063 Patients

| Study Tumor Type                      | Dose Regimen   |   Number of Patients |   Number of Post-Dose PK Samplesa |
|---------------------------------------|----------------|----------------------|-----------------------------------|
| Study 1423 All Solid Tumors (N = 398) | 1 mg/kg Q2W    |                   27 |                               899 |
| Study 1423 All Solid Tumors (N = 398) | 10 mg/kg Q2W   |                    6 |                               188 |
| Study 1423 All Solid Tumors (N = 398) | 200 mg Q2W     |                   20 |                               680 |
| Study 1423 All Solid Tumors (N = 398) | 3 mg/kg Q2W    |                  333 |                              7940 |
| Study 1423 All Solid Tumors (N = 398) | 3 mg/kg Q3W    |                   12 |                               293 |
| Study 1540 b CSCC (N = 188)           | 3 mg/kg Q2W    |                  135 |                              1959 |
| Study 1540 b CSCC (N = 188)           | 350 mg Q3W     |                   53 |                               512 |
| Study 1620 BCC (N = 132)              | 350 mg Q3W     |                  132 |                              1621 |
| Study 1624 NSCLC (N = 345)            | 350 mg Q3W     |                  345 |                              3220 |
| Total                                 |                |                 1063 |                             17312 |

PK = Pharmacokinetic; BCC = Basal cell carcinoma; CSCC = Cutaneous squamous-cell carcinoma; NSCLC = Nonsmall cell lung cancer; Q2W = Once every 2 weeks; Q3W = Once every 3 weeks

b Study 1540 Groups 1-3 only

a Includes only quantifiable post-dose PK samples

<div style=\"page-break-after: always\"></div>

Table 8: Summary of Population by Tumor Type in the Population PK Analysis for 1063 Patients

| Tumor Type   | Study ID   | Nunber of Patients   |   Total Patients | Nunber of Post-Dose PK Samplesa   |   Total Post-Dose PK Samplesa |
|--------------|------------|----------------------|------------------|-----------------------------------|-------------------------------|
| BCC          | Study 1423 | 4                    |              136 | 86                                |                          1707 |
| BCC          | Study 1620 | 132                  |              136 | 1621                              |                          1707 |
| CSCC         | Study 1423 | 26                   |              214 | 783                               |                          3254 |
| CSCC         | Study 1540 | 188                  |              214 | 2471                              |                          3254 |
| NSCLC        | Study 1423 | 71                   |              416 | 1980                              |                          5200 |
| NSCLC        | Study 1624 | 345                  |              416 | 3220                              |                          5200 |
| Others       | Study 1423 | 297                  |              297 | 7151                              |                          7151 |
| Total        |            |                      |             1063 |                                   |                         17312 |

PK = Pharmacokinetic; BCC = Basal cell carcinoma; CSCC = Cutaneous squamous-cell carcinoma; NSCLC = Nonsmall cell lung cancer

Note: “\"Others\" includes non-specified in dose escalation cohorts in study 1423.

All cemiplimab post-dose PK samples were included in the master dataset but data below the lower limit of quantification (LLOQ) was omitted from the analysis (M1-method). In total, 81 samples (0.5%) of post-dose concentrations were below the LLOQ and omitted from the analysis. Observations with absolute conditional weighted residuals (CWRES) or absolute individual weighted residuals (IWRES) above 5 were classified as outliers. The dataset did not exclude observations previously identified as concentration outliers. Data excluded from the analysis dataset included (1) inversion samples, (2) duplicated PK samples, (3) missing PK observations and (4) PK observations with unknown or missing sampling information. A total of 1390 PK samples were excluded from the population PK analysis ( Table 9 ).

Table 9: Summary of Data Excluded from the Population PK Analysis for 1063 Patients

| ReasonforExclusion                 |   Number of PK Samples |   Number of Patients |
|------------------------------------|------------------------|----------------------|
| Data Collection Issue              |                      8 |                    4 |
| Inversiona                         |                    262 |                  104 |
| Post 1st dose concentration < LLOQ |                     78 |                   70 |
| Pre 1st dose concentration         |                   1003 |                 1003 |
| Pre 1st dose concentration > LLOQ  |                     39 |                   39 |

PK = Pharmacokinetic; LLOQ = Lower limit of quantification

a Inversion is defined as predose concentration higher than the corresponding end of infusion (eoi) concentration (ie, Ctrough &gt; Ceoi), and both Ctrough and Ceoi Were excluded

Note: 3 of the 262 PK samples classified as ^Inversion' also had concentration &lt; LLOQ; therefore, the total number

The population PK of cemiplimab were characterized by non-linear mixed-effects modelling using NONMEM (Version 7.4, ICON Development Solutions, Ellicott City, Maryland). Dataset was constructed using SAS (Version 9.4). Statistical software R (Version 4.0.2) was used for data post-processing and figures.

<div style=\"page-break-after: always\"></div>

## Base model

The population PK base model of cemiplimab was previously described by a 2-compartment model with zero-order intravenous infusion, a first-order elimination, and a sigmoid Emax function to describe a timevarying change in CL. However, the updated model did not include body weight on CL, volume of distribution in the central compartment (Vc) on CL or time-varying albumin on CL in the structural model, as these were evaluated in the covariate selection process. The interindividual variability (IIV) terms on Emax and T50 from were removed from the updated base model as data could not sufficiently support the estimation of IIV for these parameters. The off-diagonal covariance between inter-individual random effects on inter-compartmental clearance (CLQ) and volume of central compartment/volume of peripheral compartment (V1V2) was also removed. The residual error model was simplified from the previous model to include only a log-additive residual error term. In the base model, the approximate percent coefficient of variation (CV%) were 39.2% and 30.1% and ETA-shrinkage were 5.6% and 7.2% for CLQ and V1V2, respectively.

## Covariate model

Potential extrinsic and intrinsic covariates that are predictive of cemiplimab PK variability were tested using a step-wise approach, which included both forward selection and backward elimination. Covariates that improved goodness-of-fit (GOF) as determined by the objective function value (OFV) were retained in the forward selection using: 𝑝𝑝 &lt; 0.01; χ𝑑𝑑𝑑𝑑=1 2 = 𝛥𝛥𝛥𝛥𝛥𝛥𝛥𝛥 &gt; 6.63 and in backward elimination: 𝑝𝑝 &lt; 0.001; χ𝑑𝑑𝑑𝑑=1 2 = 𝛥𝛥𝛥𝛥𝛥𝛥𝛥𝛥 &gt; 10.83 . Furthermore, covariates were also evaluated by successful minimization and covariance step, GOF-plots, plausibility of parameter estimates and their precision, and clinical relevance and significance. Baseline IgG and baseline PDL-1 expression were analysed in a post-hoc covariate analysis. An increase in CL was predicted with increasing baseline IgG, however the exponent of IgG on CL was similar to the previous population PK model and therefore not anticipated to result in a meaningful effect on exposure. PDL-1 expression did not appear to have a meaningful effect on baseline CL or steady-state clearance.

The covariates that were retained in the final covariate model were: body weight, sex, time-varying albumin, baseline ALT, CSCC tumour type, and BCC tumour type on CL; baseline body weight, sex and baseline albumin on V1; BCC tumour type on Emax; and other tumour type on T50.

## Final model

PK parameter estimates of the updated final model can be seen in Table 10. Parameters in the final model were estimated with percent relative standard errors (%RSE) below 8%. ETA-shrinkage increased slightly from 5.6% and 7.2% to 7.8% and 8.5% for CLQ and V1V2, respectively. IIV terms for CLQ and V1V2 and residual error were reduced as compared to the base model. Cemiplimab clearance had an inverse linear relationship with time-varying albumin level, which indicates lower clearance as albumin levels increase. Also, cemiplimab demonstrated weight-dependent clearance. As with the previous model, NSCLC patients had higher CL, which led to lower exposure than in patients with CSCC or BCC. Estimated exponents for CLQ and V1V2 with body weight were 0.539 and 0.499, respectively.

<div style=\"page-break-after: always\"></div>

Table 10: Summary of Parameter Values after Modeling with Analysis Dataset or Bootstrap Datasets for the Updated Final Model (1063 Patients)

| Parameter (Units)   | Updated Final Model   | Updated Final Model   | Bootstrap Datasets (N = 474)a   | Bootstrap Datasets (N = 474)a   | Bootstrap Datasets (N = 474)a   |
|---------------------|-----------------------|-----------------------|---------------------------------|---------------------------------|---------------------------------|
| Parameter (Units)   | Estimate              | %RSE                  | Mean                            | Median                          | 95% CI                          |
| TVCLO (L/day)       | 0.254                 | 1.56                  | 0.254                           | 0.254                           | (0.241, 0.269)                  |
| TVQ (L/day)         | 0.652                 | 3.65                  | 0.650                           | 0.651                           | (0.581,0.728)                   |
| TVV1 (L)            | 3.35                  | 1.26                  | 3.35                            | 3.35                            | (3.27, 3.44)                    |
| TVV2 (L)            | 2.52                  | 1.66                  | 2.52                            | 2.51                            | (2.29, 2.81)                    |
| TVEMAX              | -0.174                | 4.82                  | -0.181                          | -0.180                          | (-0.232,-0.136)                 |
| TVT50 (day)         | 73.7                  | 7.56                  | 90.8                            | 74.4                            | (46.2, 245)                     |
| HILL                | 2.50 b                |                       |                                 |                                 |                                 |
| CLWGTBL             | 0.539                 | 9.19                  | 0.539                           | 0.539                           | (0.443,0.639)                   |
| VsswGTBL            | 0.499                 | 10.0                  | 0.499                           | 0.501                           | (0.412, 0.569)                  |
| CLsEX               | -0.137                | 13.2                  | -0.133                          | -0.134                          | (-0.167, -0.0925)               |
| VlsEx               | -0.0801               | 23.3                  | -0.0798                         | -0.0794                         | (-0.115, -0.0471)               |
| V1ALBBL             | -0.217                | 28.4                  | -0.221                          | -0.225                          | (-0.361,-0.0870)                |
| CLALB               | -1.11                 | 2.42                  | -1.12                           | -1.11                           | (-1.24, -0.984)                 |
| CLALTBL             | -0.0729               | 22.2                  | -0.0724                         | -0.0720                         | (-0.108,-0.0370)                |
| CLcscc              | -0.216                | 9.55                  | -0.219                          | -0.219                          | (-0.257, -0.181)                |
| CLBCC               | -0.211                | 12.2                  | -0.209                          | -0.209                          | (-0.261, -0.158)                |
| EMAXBcC             | -0.872                | 12.6                  | -0.841                          | -0.870                          | (-1.00,-0.517)                  |
| T50OTHER            | -0.491                | 12.1                  | -0.537                          | -0.518                          | (-0.987, -0.169)                |
| RE                  | 0.241 c               | 0.15                  | 0.241 c                         | 0.240c                          | (0.227,0.258)                   |
| ETA1 -CL_Q          | 0.0892                | 4.05                  | 0.0886                          | 0.0884                          | (0.0759, 0.101)                 |
| ETA2-V1V2           | 0.0709                | 2.03                  | 0.0692                          | 0.0674                          | (0.0459, 0.105)                 |

* Results are summarized for 474/500 runs that were successful and had condition number &lt;1000

N = Number of patients; %RSE = Percent relative standard error; 95% CI = 95 percent confidence interval; TVCL0 = Typical value of clearance at baseline; TVQ = Typical value of inter-compartmental clearance; TVV1 = Typical value of central volume of distribution; TVV2 = Typical value of peripheral volume of distribution; TVEMAX = Typical value of maximum change in CL with time; TVT50 = Typical value of time to reach 50% of the maximum change in CL; HILL = Hill exponent (y) in the sigmoid Emax function describing the change in CL with time; CLwGTBL = Covariate impact of baseline body weight on CL\\_Q: VsswGTBL = Covariate impact of baseline body weight on V1\\_V2; CLsex = Covariate impact of female sex on CL; V1sex = Covariate impact of female sex on V1; V1ALBBL = Covariate impact of baseline albumin on V1; CLALe = Covariate impact of time-varying albumin on CL; CLALTBL = Covariate impact of baseline alanine aminotransferase on CL; CLcscc = Covariate impact of cutaneous squamous-cell carcinoma (CSCC) tumor type on CL; CLBcc = Covariate impact of basal cell carcinoma (BCC) tumor type on CL; EMAXBcc = Covariate impact of BCC tumor type on EMAX; T50oTHER = Covariate impact of OTHER tumor type on T50; RE = Residual error

b The HILL parameter in the sigmoid Emax function for time-varying CL was fixed at 2.50

<div style=\"page-break-after: always\"></div>

- Residual enofisi represented as a positive value by calculating g the square root of (estimate)

Note: 2.5th and 97.5th percentiles are reported as the 95% CI

Time dependent clearance was modeled using a sigmoid E. max felationship: TVCL = TVCLO · exp Emar-T T50l+TY

The final model was evaluated by means of bootstrap analysis, GOF-plots and visual predictive checks (VPCs). GOF-plots of the final model across tumour types (NSCLC, CSCC, BCC and other tumour type) can be seen in Figure 5. Model stability was evaluated using bootstrap analysis. 474/500 (94.8%) model runs converged successfully with a condition number under 1000.

## Population: NSCLC

<!-- image -->

## Population: CSCC

TUMOR= 1

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

GM = Geometric mean; PRED = Typical individual prediction; IPRED = Individual model prediction; NSCLC = Non-small cell lung cancer; CSCC = Cutaneous squamous-cell carcinoma; BCC = Basal cell carcinoma

Figure 5: Final Model Goodness-of-Fit Plots (1063 Patients)

The updated final model was evaluated in each tumour type (NSCLC, CSCC, BCC and other tumour type) by prediction-corrected VPCs (pcVPCs), which can be seen in Figure 6.

<div style=\"page-break-after: always\"></div>

## NSCLC

<!-- image -->

## CSCC

<!-- image -->

<div style=\"page-break-after: always\"></div>

Prediction Corrected Concentration (mg/L)

1000

009

200

001

50

100

200

300

Time Since First Dose (day)

## OtherTumorType

<!-- image -->

NSCLC = Non-small cell lung cancer; CSCC = Cutaneous squamous-cell carcinoma; BCC = Basal cell carcinoma;

90%CI=90percentconfidenceinterval

Figure 6: Prediction-Corrected Visual Predictive Check Plots for the Final Model (1063 Patients)

400

500

600

<div style=\"page-break-after: always\"></div>

## External validation of Study 1676

The updated population PK model was used to externally validate cemiplimab PK in 295 patients from Study 1676 by means of posterior predictive check (PPC). Study 1676 (data cut-off date: 4 th  of January 2021) consisted of adult females ≥ 18 years old with recurrent, persistent, and/or metastatic CC who received cemiplimab as monotherapy, administered 350 mg IV once every 3 weeks (Q3W). 3 patients had no quantifiable concentrations and were not included in the external validation. Study 1676 therefore comprised of 292 patients with 2030 PK samples. Summary of data exclusion in the external validation can be seen in Table 11.

Table 11: Summary of Data Excluded from the Population PK External Validation

| ReasonforExclusion                    |   Number of PK Samples |   NumberofPatients |
|---------------------------------------|------------------------|--------------------|
| Data Collection Issue                 |                      0 |                  0 |
| Inversiona                            |                     54 |                 21 |
| No post 1st dose concentration > LLOQ |                      7 |                  3 |
| Post 1st dose concentration < LLOQ    |                     11 |                 11 |
| Pre 1st dose concentration            |                    276 |                276 |
| Pre 1st dose concentration > LLOQ     |                      6 |                  6 |

PK = Pharmacokinetic; LLOQ = Lower limit of quantification

a Inversion is defined as predose concentration higher than the corresponding end of infusion (eoi) concentration (ie, Ctrough &gt; Ceoi), and both Ctrough and Ceoi were excluded

Note: 2 of the 54 PK samples classified as ^Inversion' also had concentration &lt; LLOQ; therefore, the total number of post 1st dose concentrations &lt; LLOQ was 13 (11 + 2)

A smoothed parametric bootstrap procedure was utilised to incorporate uncertainty in parameter estimates. Parameter estimates from the updated final model was assumed to have a multivariate normal distribution with the mean vector set to the population parameter estimates and the covariance matrix set to the covariance matrix of the estimates from the updated model. The multivariate normal distribution was utilised as an approximate posterior distribution to generate 500 sets of population parameter values, which were then used to simulate datasets that replicated the design, subject population, dose regimen, sample size and covariate distribution for Study 1676. From the simulated datasets conditioned upon the observed study design, 90% confidence intervals were calculated and overlaid for the 5 th , 50 th  and 95 th  percentiles of observed cemiplimab concentrations. The result of the PPC can be seen in Figure 7.

<div style=\"page-break-after: always\"></div>

<!-- image -->

90% CI = 90 percent confidence interval

Figure 7: External Posterior Predictive Check for Study 1676 including Cervical Cancer Patients

<div style=\"page-break-after: always\"></div>

Post-hoc PK parameter estimates were generated for CC patients and are summarized in Table 12.

Table 12: Descriptive Statistics for Post-Hoc Cemiplimab PK Parameters in the PopPK Patient Population (N = 292) with Cervical Cancer in Study 1676 Estimated Using the Updated Final PopPK Model

| Parameter                           | Mean (Cv%)   |      SD |
|-------------------------------------|--------------|---------|
| Clearance at the first dose (L/day) | 0.208 (22.4) |  0.0467 |
| Clearance at steady-state (L/day)   | 0.191 (29.4) |  0.056  |
| Percent change in clearance (%)     | -7.8         | 18.7    |
| Half-life at the first dose (day)   | 19.0 (14.5)  |  2.76   |
| Half-life at steady-state (day)     | 21.0 (19.4)  |  4.07   |
| Accumulation Index                  | 1.96 (17.2)  |  0.336  |
| Vss (L) t                           | 5.16 (12.2)  |  0.629  |
| Percent AUC3wks after the 5th dose  | 93.5 (14.8)  | 13.8    |

t Vss = V1 + V2

N = Number of patients; CV = Coefficient of variation; SD = Standard deviation; Vss = Volume of distribution; V1 = Volume of the central compartment; V2 = Volume of the peripheral compartment; AUC3wks = Area under the concentration time curve for a 3-week dosing interval; AUC3wks = Area under the concentration time curve for a 3week dosing interval

## Exposure predictions for Study 1676

The final population PK model was used to generate exposure metrics after first dose (Table 13) and steady-state concentration in patients with CC from Study 1676 with Q3W.

Table 13: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen After the First Dose and at Steady-State for Patients with Cervical Cancer in Study 1676 (N = 292)

| TumorType (Study)   | N   | Mean (CV%)Exposure Metric   | Mean (CV%)Exposure Metric   | Mean (CV%)Exposure Metric   | Mean (CV%)Exposure Metric   | Mean (CV%)Exposure Metric   | Mean (CV%)Exposure Metric   |
|---------------------|-----|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                     |     | First Dose                  | First Dose                  | First Dose                  | Steady-State                | Steady-State                | Steady-State                |
|                     |     | AUC3wks (mg·day/L)          | Cmax (mg/L)                 | Cmin (mg/L)                 | AUC3wks,ss (mg·day/L)       | Cmax,ss (mg/L)              | Cmin,ss (mg/L)              |
| cC (Study 1676)     | 292 | 993 (13.6)                  | 125 (11.9)                  | 27.3 (18.3)                 | 1949 (22.6)                 | 185 (14.7)                  | 60.1 (30.2)                 |

Q3W =Every 3 weeks; N =Number of patients; CV = Coefficient of variation; AUC3wks =Area under the concentration time curvefor a 3-week dosing interval;Cmax=Maximum concentration;Cmin=Minimum concentration;SS=Steady-state;CC=Cervicalcancer

## Absorption

Please refer to the description of individual studies and comparison across studies above.

## Distribution

Study 1676 based on the external validation of the PopPK model (PopPK 21056), PK parameters are similar and best described by a 2-compartment model. Please refer description of individual studies and

<div style=\"page-break-after: always\"></div>

comparison across studies above. Volume (Vd) after the first dose could only be assessed by NCA in 4/10 patients in EXP23 and in 3/10 patients in EXP24 in study 1423 and ranged from 3.1 L to 5.3 L.

Based on the PopPK model, cemiplimab is primarily distributed in the vascular system with a volume of distribution at steady-state (Vss) of 5.35.9 l. Median Tmax occurs at the end of the 30-minute infusion.

## Elimination

Linear elimination and with a time varying decrease in clearance was described. Please refer description of individual studies and comparison across studies above.

Clearance after the first dose could only be assessed by NCA in 4/10 patients in EXP23 and in 3/10 patients in EXP24 in study 1423 and ranged from 0.24 L/day to 0.37 L/day.

Based on the popPK model, clearance of cemiplimab is linear at doses of 1 mg/kg to 10 mg/kg every two weeks. Cemiplimab clearance after the first dose is approximately 0.25 l/day. The total clearance appears to decrease by approximately 11% over time, resulting in a steady state clearance (CLss) of 0.22 l/day; the decrease in CL is not considered clinically relevant. The within dosing interval half-life at steady state is 22 days.

## Dose proportionality and time dependencies

Please refer to the description of individual studies and comparison across studies above.

Table 14: Percent of steady state AUC3wks achieved during 5 th  and 6 th  dosing periods in patients with solid tumours (studies 1423, 1540, 1620, and 1624) and in patients with R/M cervical cancer in study 1676

| Patient Population                                    |   Number of Patients | Parameter                                             | Time Since First Dose (Weeks)   | Mean (CV%)   |   SD |
|-------------------------------------------------------|----------------------|-------------------------------------------------------|---------------------------------|--------------|------|
| Solid Tumor Patients (Studies 1423, 1540, 1620, 1624) |                 1062 | PercentIndividualPredicted AUC3wksafterthe5thdose     | 12 to 15                        | 92.1 (11.6)  | 10.7 |
|                                                       |                 1062 | PercentIndividualPredicted AUC3wks after the 6th dose | 15 to 18                        | 95.0 (10.4)  |  9.9 |
| CC Patients                                           |                  292 | Percent Typical Predicted AUC3wks after the 5th dose  | 12 to 15                        | 93.5 (14.8)  | 13.8 |
| (Study 1676)                                          |                  292 | Percent Typical Predicted AUC3wks after the 6th dose  | 15 to 18                        | 96.1 (13.9)  | 13.3 |

CV = Coefficient of variation; SD = Standard deviation; AUC3wks = Area under the concentration time curve for a 3week dosing interval;CC=Cervicalcarcinoma

<div style=\"page-break-after: always\"></div>

## Special populations

Table 15: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State in Patients with CC Categorized by Age Group (Study 1676)

| Age (years)   | N   | Mean (CV%) Age (years)   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|---------------|-----|--------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Age (years)   | N   | Mean (CV%) Age (years)   | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| <65           | 258 | 48.6 (20.1)              | 1953 (22.6)                                  | 185 (14.8)                                   | 60.3 (30.1)                                  |
| ≥65           | 34  | 70.1 (6.15)              | 1918 (22.7)                                  | 185 (14.1)                                   | 58.2 (30.6)                                  |
| <65           | 258 | 48.6 (20.1)              | 1953 (22.6)                                  | 185 (14.8)                                   | 60.3 (30.1)                                  |
| [65, 75)      | 29  | 68.8 (4.21)              | 1904 (24.5)                                  | 184 (15.1)                                   | 57.8 (32.6)                                  |
| ≥75           | 5   | 78.0 (2.72)              | 1996 (9.48)                                  | 194 (4.99)                                   | 60.2 (17.6)                                  |
| <65           | 258 | 48.6 (20.1)              | 1953 (22.6)                                  | 185 (14.8)                                   | 60.3 (30.1)                                  |
| [65, 75)      | 29  | 68.8 (4.21)              | 1904 (24.5)                                  | 184 (15.1)                                   | 57.8 (32.6)                                  |
| [75, 85)      | 5   | 78.0 (2.72)              | 1996 (9.48)                                  | 194 (4.99)                                   | 60.2 (17.6)                                  |
| ≥85           | 0   | NA                       | NA                                           | NA                                           | NA                                           |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steadystate minimum concentration; NA = not applicable

Source: PopPK report R2810-PK-21056-SR-01V1 Table 35

<div style=\"page-break-after: always\"></div>

Table 16: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State in the Overall Patient Population with Solid Tumors Categorized by Age (Studies 1423, 1540, 1620, and 1624)

| Age (years)   | N   | Mean (CV%) Age (years)   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|---------------|-----|--------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Age (years)   | N   | Mean (CV%) Age (years)   | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| <65           | 517 | 54.8 (13.8)              | 1843 (38.3)                                  | 170 (27.3)                                   | 57.7 (49.4)                                  |
| ≥65           | 545 | 73.2 (8.52)              | 1885 (35.9)                                  | 171 (26.9)                                   | 59.6 (45.0)                                  |
| <65           | 517 | 54.8 (13.8)              | 1843 (38.3)                                  | 170 (27.3)                                   | 57.7 (49.4)                                  |
| [65, 75)      | 343 | 69.2 (3.91)              | 1831 (38.2)                                  | 169 (28.3)                                   | 57.3 (48.0)                                  |
| ≥75           | 202 | 79.9 (5.56)              | 1977 (31.7)                                  | 176 (24.5)                                   | 63.3 (39.6)                                  |
| <65           | 517 | 54.8 (13.8)              | 1843 (38.3)                                  | 170 (27.3)                                   | 57.7 (49.4)                                  |
| [65, 75)      | 343 | 69.2 (3.91)              | 1831 (38.2)                                  | 169 (28.3)                                   | 57.3 (48.0)                                  |
| [75, 85)      | 168 | 78.4 (3.62)              | 1963 (32.9)                                  | 175 (25.4)                                   | 62.8 (40.9)                                  |
| ≥85           | 34  | 87.5 (3.34)              | 2045 (25.9)                                  | 180 (19.9)                                   | 66.1 (33.4)                                  |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steadystate minimum concentration

Note: One subjection from Study 1423, was excluded from the summary of exposure metrics due to extremely high predicted Vss of 183.6 L that is inconsistent with the typical distribution volume for monoclonal antibodies (also excluded in the prior PopPK analysis). Therefore, exposure predictions are reported for a total of N = 1062 subjects. Source: PopPK report R2810-PK-21056-SR-01V1 Table 29

Table 17: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State and Relevant Covariates in Patients with CC Categorized by Baseline Creatinine Clearance (Study 1676)

| Renal Function Category (Baseline CRCL)   | N   | Mean (CV%) Baseline CRCL   | Mean (CV%) Baseline Body Weight (kg)   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|-------------------------------------------|-----|----------------------------|----------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                           |     | (mL/min)                   |                                        | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| Normal CRCL ≥90 mL/min                    | 85  | 119 (23.5)                 | 75.7 (23.6)                            | 1797 (24.9)                                  | 171 (16.5)                                   | 55.4 (32.6)                                  |
| Mild Impairment CRCL 60 to 89 mL/min      | 124 | 74.4 (11.5)                | 62.8 (21.8)                            | 2023 (20.5)                                  | 189 (12.4)                                   | 63.0 (28.0)                                  |
| Moderate Impairment CRCL 30 to 59 mL/min  | 83  | 47.6 (16.2)                | 55.6 (19.7)                            | 1995 (22.0)                                  | 193 (13.4)                                   | 60.4 (30.0)                                  |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; CRCL = Creatinine clearance; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steady-state minimum concentration Source: PopPK report R2810-PK-21056-SR-01V1 Table 37

<div style=\"page-break-after: always\"></div>

Table 18: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State and Relevant Covariates in the Overall Patient Population with Solid Tumors Categorized by Baseline Creatinine Clearance (Studies 1423, 1540, 1620, and 1624)

| Renal Function Category (Baseline CRCL)   | N   | Mean (CV%) Baseline CRCL   | Mean (CV%) Baseline Body Weight (kg)   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|-------------------------------------------|-----|----------------------------|----------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                           |     | (mL/min)                   |                                        | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| Normal CRCL ≥90 mL/min                    | 497 | 120 (25.6)                 | 82.5 (23.1)                            | 1731 (36.9)                                  | 161 (25.8)                                   | 54.0 (48.2)                                  |
| Mild Impairment CRCL 60 to 89 mL/min      | 391 | 74.8 (11.3)                | 72.2 (20.9)                            | 1929 (34.7)                                  | 174 (24.7)                                   | 61.2 (44.3)                                  |
| Moderate Impairment CRCL 30 to 59 mL/min  | 167 | 49.5 (14.7)                | 65.1 (20.3)                            | 2084 (35.5)                                  | 189 (27.3)                                   | 66.0 (44.4)                                  |
| Severe Impairment CRCL 15 to 29 mL/min    | 7   | 25.3 (10.1)                | 49.7 (24.4)                            | 2488 (67.0)                                  | 243 (54.3)                                   | 75.9 (79.8)                                  |

Q3W = Every 3 weeks; CRCL = Creatinine clearance; N = Number of patients; CV = Coefficient of variation; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steady-state minimum concentration

Note: One subject from Study 1423, was excluded from the summary of exposure metrics due to extremely high predicted Vss of 183.6 L that is inconsistent with the typical distribution volume for monoclonal antibodies (also excluded in the prior PopPK analysis). Therefore, exposure predictions are reported for a total of N = 1062 subjects. Source: PopPK report R2810-PK-21056-SR-01V1 Table 31

<div style=\"page-break-after: always\"></div>

Table 19: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State and Relevant Covariates in Patients with CC Categorized by Baseline Total Bilirubin (Study 1676)

| Hepatic Function (Baseline Total Bilirubin)   | N   | Mean (CV%) Baseline Value   | Mean (CV%) Baseline Value   | Mean (CV%) Baseline Value   | Mean (CV%) Baseline Value   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|-----------------------------------------------|-----|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Hepatic Function (Baseline Total Bilirubin)   | N   | Total Bilirubin (µmol/L)    | Body Weight (kg)            | AST (IU/L)                  | ALT (IU/L)                  | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| Normal (TB ≤1x ULN)                           | 283 | 7.19 (48.0)                 | 64.6 (25.5)                 | 23.7 (73.6)                 | 18.5 (77.1)                 | 1944 (22.6)                                  | 185 (14.7)                                   | 59.8 (30.1)                                  |
| Mild Impairment (TB >1 to ≤1.5x ULN)          | 6   | 22.9 (6.71)                 | 61.5 (17.9)                 | 28.1 (44.6)                 | 31.3 (43.9)                 | 2264 (23.9)                                  | 201 (14.0)                                   | 73.8 (32.1)                                  |
| Moderate Impairment (TB >1.5 to ≤3x ULN)      | 1   | 35.9 (NA)                   | 58.9 (NA)                   | 40.0 (NA)                   | 57.0 (NA)                   | 1765 (NA)                                    | 173 (NA)                                     | 52.1 (NA)                                    |
| NA                                            | 2 a | 6.84 (NA)                   | 60.4 (NA)                   | 19.0 (NA)                   | 14.0 (NA)                   | 1887 (NA)                                    | 184 (NA)                                     | 56.7 (NA)                                    |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; TB = Total bilirubin; AST = Aspartate aminotransferase; ALT = Alanine aminotransferase; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steady-state minimum concentration; NA = Not applicable

a ULN values were not available for 2 patients

Source: PopPK report R2810-PK-21056-SR-01V1 Table 38

<div style=\"page-break-after: always\"></div>

Table 20: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State and Relevant Covariates in the Overall Patient Population with Solid Tumors Categorized by Baseline Total Bilirubin (Studies 1423, 1540, 1620, and 1624)

| Hepatic Function (Baseline Total Bilirubin)   | N    | Mean (CV%) Baseline Value   | Mean (CV%) Baseline Value   | Mean (CV%) Baseline Value   | Mean (CV%) Baseline Value   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|-----------------------------------------------|------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Hepatic Function (Baseline Total Bilirubin)   | N    | Total Bilirubin (µmol/L)    | Body Weight (kg)            | AST (IU/L)                  | ALT (IU/L)                  | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| Normal (TB ≤1x ULN)                           | 1023 | 8.58 (44.4)                 | 75.6 (23.9)                 | 25.3 (70.6)                 | 23.9 (86.3)                 | 1868 (36.9)                                  | 171 (27.0)                                   | 58.8 (47.0)                                  |
| Mild Impairment (TB >1 to ≤1.5x ULN)          | 22   | 23.9 (17.3)                 | 79.7 (26.3)                 | 42.0 (85.1)                 | 25.4 (76.1)                 | 1723 (36.6)                                  | 164 (30.0)                                   | 52.4 (44.1)                                  |
| Moderate Impairment (TB >1.5 to ≤3x ULN)      | 3    | 43.1 (15.5)                 | 85.5 (35.6)                 | 42.0 (47.6)                 | 38.7 (60.1)                 | 1584 (11.0)                                  | 144 (13.4)                                   | 48.6 (21.1)                                  |
| NA                                            | 14   | 8.43 (2.02)                 | 77.5 (24.5)                 | 21.1 (24.9)                 | 19.0 (12.7)                 | 1894 (47.3)                                  | 163 (32.2)                                   | 62.2 (58.0)                                  |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; TB = Total bilirubin; AST = Aspartate aminotransferase; ALT = Alanine aminotransferase; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steady-state minimum concentration

Note: one subject from Study 1423 was excluded from the summary of exposure metrics due to extremely high predicted Vss of 183.6 L that is inconsistent with the typical distribution volume for monoclonal antibodies (also excluded in the prior PopPK analysis). Therefore, exposure predictions are reported for a total of N = 1062 subjects. Source: PopPK report R2810-PK-21056-SR-01V1 Table 32

<div style=\"page-break-after: always\"></div>

Table 21: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State in Patients with CC Categorized by Baseline Albumin (Study 1676)

| Baseline Albumin (g/L)        | N   | Mean (CV%) Baseline Albumin (g/L)   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|-------------------------------|-----|-------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Baseline Albumin (g/L)        | N   | Mean (CV%) Baseline Albumin (g/L)   | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| <5 th percentile [20, 28.2]   | 15  | 24.9 (11.8)                         | 1345 (22.9)                                  | 154 (14.2)                                   | 34.2 (33.1)                                  |
| 5-95 th percentile (28.2, 47] | 269 | 39.3 (11.8)                         | 1972 (21.5)                                  | 186 (14.2)                                   | 61.1 (28.4)                                  |
| >95 th percentile (47, 50.7]  | 8   | 48.8 (2.81)                         | 2303 (12.3)                                  | 204 (10.7)                                   | 75.4 (14.6)                                  |
| ≤30                           | 26  | 26.9 (12.2)                         | 1509 (27.5)                                  | 161 (16.0)                                   | 41.4 (39.3)                                  |
| (30, 35]                      | 46  | 33.3 (4.21)                         | 1670 (23.7)                                  | 171 (15.0)                                   | 48.1 (32.8)                                  |
| >35                           | 220 | 41.4 (8.58)                         | 2060 (19.1)                                  | 191 (13.1)                                   | 64.8 (24.9)                                  |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steadystate minimum concentration

Source: PopPK report R2810-PK-21056-SR-01V1 Table 34

Table 22: Summary of Individual Predicted Estimates of Exposure of Cemiplimab for the 350 mg Q3W Regimen at Steady-State in the Overall Patient Population with Solid Tumors Categorized by Baseline Albumin (Studies 1423, 1540, 1620, and 1624)

| Baseline Albumin (g/L)        | N   | Mean (CV%) Baseline Albumin (g/L)   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   | Mean (CV%) Exposure Metric at Steady-State   |
|-------------------------------|-----|-------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Baseline Albumin (g/L)        | N   | Mean (CV%) Baseline Albumin (g/L)   | AUC 3wks,ss (mg ⋅ day/L)                     | C max,ss (mg/L)                              | C min,ss (mg/L)                              |
| <5 th percentile [20, 29.3]   | 55  | 26.6 (8.48)                         | 1397 (46.5)                                  | 146 (27.1)                                   | 39.4 (67.4)                                  |
| 5-95 th percentile (29.3, 46] | 965 | 38.4 (10.3)                         | 1870 (35.9)                                  | 171 (26.6)                                   | 58.9 (45.5)                                  |
| >95 th percentile (46, 93]    | 42  | 49.7 (15.2)                         | 2341 (35.4)                                  | 199 (27.6)                                   | 78.5 (41.8)                                  |
| ≤30                           | 76  | 27.5 (8.90)                         | 1404 (42.5)                                  | 147 (24.9)                                   | 39.6 (62.3)                                  |
| (30, 35]                      | 217 | 33.3 (4.08)                         | 1661 (36.2)                                  | 157 (25.1)                                   | 50.5 (47.3)                                  |
| >35                           | 769 | 40.6 (9.51)                         | 1967 (35.2)                                  | 177 (26.8)                                   | 62.9 (44.0)                                  |

Q3W = Every 3 weeks; N = Number of patients; CV = Coefficient of variation; AUC3wks,ss = Steady-state area under the concentration time curve for a 3-week dosing interval; Cmax,ss = Steady-state maximum concentration; Cmin,ss = Steadystate minimum concentration

Note: one subject from Study 1423, was excluded from the summary of exposure metrics due to extremely high predicted Vss of 183.6 L that is inconsistent with the typical distribution volume for monoclonal antibodies (also excluded in the prior PopPK analysis). Therefore, exposure predictions are reported for a total of N = 1062 subjects. Source: PopPK report R2810-PK-21056-SR-01V1 Table 25

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Primary and secondary pharmacology

## Pharmacodynamic Results in Patients with R/M Cervical Cancer

Due to the insufficient number of patients with R/M cervical cancer in the FIH Study 1423 (2 responders out of 20 patients total in EXP23 and EXP24), pharmacodynamic analysis was performed exclusively in patients with R/M cervical cancer in the pivotal Study 1676. Data for patients on cemiplimab therapy are presented here for all patients with R/M cervical cancer (N=304) and the subgroup with SCC histology (N=239) on cemiplimab 350 mg Q3W.

In Study 1676, the percent change from baseline in target lesions was assessed as a pharmacodynamic marker of efficacy using radiologic imaging according to RECIST 1.1. Patients with confirmed response status of CR or PR according to RECIST 1.1 contributed to ORR (50 responders in the total patient population and 42 in the subgroup with SCC histology).

Spider plots provide a comprehensive perspective regarding the depth and kinetics of responses, illustrating the percent changes in target lesion measurements over time for individual patients. Spider plots for changes in target lesions relative to baseline were provided for patients who received cemiplimab 350 mg Q3W in the SCC subgroup ( Figure 8 ) and the total population ( Figure 9 ).

In the SCC histology subgroup, as well as in the total population, the estimated median DOR was 16.4 months in patients receiving cemiplimab 350 mg Q3W.

<!-- image -->

N= 42 responders (CR. or PR) out of 239 patients in the subgroup with SCC histology on cewiplimab, 350 mg Q3W. Data cutoff as of Jan 4, 2021. Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR Post-text Figure 14.2.3.2scc

Figure 8: Spider Plot for Change in Target Lesions Relative to Baseline over Time in R/M Cervical Cancer Patients with SCC Histology who Received Cemiplimab 350 mg Q3W in Study 1676

<div style=\"page-break-after: always\"></div>

<!-- image -->

N= 50 responders (CR. or PR) out of 304 patients in the total population of patients with R/M cervical cancer on cemiplimab 350 mg Q3W. Data cutoff as of Jan 4, 2021. Source: Module 3.3.5.1 Study 1676 Primary Analysis CSR Post-text Figure 14.2.3.2all

Figure 9: Spider Plot for Change in Target Lesions Relative to Baseline over Time in All Patients with R/M Cervical Cancer who Received Cemiplimab 350 mg Q3W in Study 1676

## Exposure-Response Relationships in Patients with R/M Cervical Cancer in the Pivotal Study 1676

Descriptive and model-based E-R relationships analyses were conducted for efficacy and safety endpoints using post-hoc estimates of exposure metrics Ctrough, Cmax, and average concentration (Cav) after the first dose, with emphasis on Ctrough for efficacy endpoints and on Cmax for safety endpoints, as considered to be the most sensitive exposure metrics for these clinical assessments.

E-R relationship analyses for efficacy were conducted on OS as primary endpoint, and PFS, ORR (based on BOR), and DOR as secondary endpoints, while E-R relationships for safety were conducted on immune-mediated adverse event (irAEs) (all and grade ≥ 3) as safety endpoints.

E-R relationship analyses for efficacy and safety, performed on patients with R/M cervical cancer from Study 1676 who received cemiplimab 350 mg Q3W are presented in this section.

## Exposure-Response Relationship Analyses for Efficacy

In the descriptive exposure-efficacy analysis, Kaplan-Meier curves of OS by quartile of Ctrough after the first dose (Ctrough,1) is presented in Figure 10 .

<div style=\"page-break-after: always\"></div>

<!-- image -->

The vertical hatches through the Kaplan-Meier curves represent the last documented times that patients were observed to be alive. These censored patients may have dropped out of the study, or, since not all patients were enrolled in the study at the same time, they may have been censored at the time that the data cutoff occured for this analysis. A drop in the Kaplan-Meier curve indicates the time of death due to any cause. The table provided undermeath the Kaplan-Meier plot describes the number of patients alive in each quartile at each time point, which. for those patients, occuured before the data cutoff date.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 1

Figure 10: Kaplan-Meier Curves of OS Stratified by Quartiles of Individual Predicted Cemiplimab Ctrough After the First Dose in Patients with R/M Cervical Cancer

To address the limitations associated with the descriptive E-R analysis (K-M analysis of OS by Ctrough,1), a Cox proportional hazards (PH) model was implemented. This Cox PH modelling showed that Ctrough,1 was a significant predictor of OS hazard when it was the sole predictor in the model (Table 23), but after adjusting for baseline values of albumin, weight, and ECOG performance status, Ctrough,1 was no longer significant since the 95% confidence interval for the hazard ratio (HR) contains 1 (Figure 11).

<div style=\"page-break-after: always\"></div>

Table 23: Summary of Results from Cox PH Models of OS Fit with Predicted Exposure Metrics and Baseline Covariates as the Only Individual Predictor in Each Model in Patients with R/M Cervical Cancer

| Exposure Metric                    |   AIC |   BIC |   P-Value |
|------------------------------------|-------|-------|-----------|
| Baseline PD-L1 (%)                 |   591 |   593 |  0.209    |
| Baseline Albumin (g/L)             |  1718 |  1721 |  4.93e-10 |
| BaselineECOG Score                 |  1757 |  1760 |  1.23e-05 |
| Cwazt, After the First Dose (mg/L) |  1758 |  1761 |  1.68e-05 |
| C After the First Dose (mg/L)      |  1768 |  1771 |  0.00364  |
| Baseline Weight (kg)               |  1773 |  1776 |  0.068    |
| Cx After the First Dose (mg/L)     |  1776 |  1779 |  0.644    |

Lower AIC or BIC values indicate better model fits. In general, a difference of more than 10 in AIC between the best model and the next best model provides evidence that the model with the lowest AIC is the best model. Models where the difference in AIC is 4 or less suggests fhat either model would be appropriate.

Source:Module 5.3.3.5 R2810-PK-21058-SR-01V1Table 1

<!-- image -->

| Variable         | N     | Hazard Ratio   | Point Estimate (95% CI)   |
|------------------|-------|----------------|---------------------------|
| Ctrough          | 293   |                | 0.87 (0.71, 1.07)         |
| Baseline Albumin | 293   |                | 0.73 (0.59, 0.89)         |
| Baseline Weight  | 293   |                | 0.85 (0.71, 1.02)         |
| Baseline ECOG    | 0 138 |                | Reference                 |
|                  | 1 155 |                | 1.73 (1.26, 2.38)         |

1.5

2

Note: Cooh was fit based on after first dose values in this model. Point estimates are interpreted in temms of an increase in one umit of SD from the mean value of the variable.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 2

Figure 11: Forest Plot of Cox PH Model of OS with Individual Predicted Cemiplimab Ctrough After the First Dose and Baseline Covariates as Model Predictors in Patients with R/M Cervical Cancer

<div style=\"page-break-after: always\"></div>

Kaplan-Meier (K-M) curves of PFS (Figure 12) and DOR (Figure 13) are presented below.

<!-- image -->

The vertical hatches through the Kaplan-Meier curves represent the last documented times that patients were observed to be alive with no disease progression. A drop in the Kaplan-Meier curves indicates the time of disease progression or death due to any cause. The table provided umdermeath the plot describes the number of patients alive

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 3

Figure 12: Kaplan-Meier Curves of PFS Stratified by Quartiles of Individual Predicted Cemiplimab Ctrough After the First Dose in Patients with R/M Cervical Cancer

<!-- image -->

The vertical hatches through the Kaplan-Meier curves indicate the last kmown date where the patient is still alive and has not experienced progressive or recurrent disease.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 6

Figure 13: Kaplan-Meier Curves of DOR Stratified by Quartiles of Individual Predicted Cemiplimab Ctrough After the First Dose in Patients with R/M Cervical Cancer

<div style=\"page-break-after: always\"></div>

Exposure metrics between 'responders' and 'all others' were unlikely to differ from one another due to the overlapping distribution of values and comparable mean and median values (

Figure 14 ). Logistic regression models with BOR as the response and continuous exposure metric as the independent variable showed a flat relationship in both the fitted model and in the trend of observed data (Figure 15). Additionally, univariate logistic regression models compared to the intercept-only model did not reveal any advantage over the intercept-only model (

Table 24).

<!-- image -->

The lower and upper hinges correspond to the first and third quartiles (the 25t and 75 percentiles). The upper whisker extends from the hinge to the largest value no fiurther than 1.5 * IQR from the hinge (where IQR is the interquartile range, or distance between the first and third quartiles). The lower whisker extends from the hinge to the smallest value at most 1.5 * IQR of the hinge. Data beyond the end of the whiskers are called ^outlying² points and are plotted individually. Note: Using a conservative approach, only patients who achieved PR or CR were considered *\"responders\"\\_ The rest of the patient population, including patients who did not achieve CR or PR, who were not able to be classified as CR or PR, who were not evaluable, or who had stable disease, were considered as 'all others? for these analyses. BOR was detenmined by the investigator.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 4

Figure 14: Boxplot of Individual Predicted Cemiplimab Ctrough After the First Dose by BOR in Patients with R/M Cervical Cancer

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: The blue line and grey shaded area represent the fitted logistic regression model and 95% confidence band where the entire range of exposure was used as a predictor in the model. The dark red jittered points represent individual patient values of BOR. The four black points represent mean BOR in quartiles of exposure, and the vertical green lines are the 95% confidence interval derived from the normal approximation of the binomial proportional confidence interval. Refer to Table 9 for dlescriptive statistics of quartiles.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 5

Figure 15: Logistic Regression of ORR based on BOR versus Individual Predicted Cemiplimab Ctrough After the First Dose with ORR (Mean of Best Overall Response) by Quartiles of Exposure in Patients with Cervical Carcinoma

Table 24: Summary of Results from Logistic Regression Models of BOR Fit with Individual Predicted Exposure Metrics After the First Dose and Baseline Covariates as the Only Predictor in Each Model in Patients with R/M Cervical Cancer

| Exposure Metric                 |   AIC |   BIC |   P-Value |
|---------------------------------|-------|-------|-----------|
| Cwx After theFirstDose (mg/L)   |   266 |   273 |  0.0144   |
| Intercept-Only Model            |   270 |   274 |  1.29e-24 |
| Baseline Weight (kg)            |   269 |   276 |  0.0464   |
| Baseline ECOG Score             |   269 |   277 |  0.0832   |
| Cx After the First Dose (mg/L)  |   271 |   278 |  0.185    |
| Baseline Albumin (g/L)          |   271 |   279 |  0.484    |
| CtvatAfter the FirstDose (mg/L) |   272 |   280 |  0.7      |

Lower AIC or BIC values indicate better model fits. In general, a difference of more than 10 in AIC between the best model and the next best model provides evidence that the model with the lowest AIC is the best model. Models where the difference in AIC is 4 or less suggests that either model would be appropriate. Models are compared to the intercept-only model. Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Table 2

<div style=\"page-break-after: always\"></div>

## Exposure-Response Relationships for Safety

The exposure-safety relationship analyses for all irAEs and irAEs grade ≥ 3 with Cmax after the first dose (Cmax,1) as the representative exposure metric for safety were conducted in all patients with R/M cervical cancer in Study 1676. In addition, average concentration after the first dose (Cav,1) and Ctrough after the first dose (Ctrough,1) were also evaluated.

<!-- image -->

A drop in the Kaplan-Meier curves indicates the time in which the patient experiences an irAF grade ≥3, and the censored events describe the last lmown date where the patient has not experienced any ijAEs grade ≥3. The table provided umdemeath the plot describes the number of patients who have not experienced jrAE grade ≥3 in each quartile at each time point.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 7

Figure 16: Kaplan-Meier Curves of Grade 3 or Higher irAEs Stratified by Quartiles of Individual Predicted Cemiplimab Cmax After the First Dose in Patients with R/M Cervical Cancer

<div style=\"page-break-after: always\"></div>

Table 25: Summary of Results from Cox PH Models of Grade 3 or Higher irAEs Fit with Predicted Exposure Metrics and Baseline Covariates as the Only Individual Predictor in Each Model in Patients with R/M Cervical Cancer

| Exposure Metric                  |   AIC |   BIC |   P-Value |
|----------------------------------|-------|-------|-----------|
| BaselineECOGScore                |   170 |   171 |     0.333 |
| Cav, After the First Dose (mg/L) |   171 |   172 |     0.755 |
| Cux After the First Dose (mg/L)  |   171 |   172 |     0.586 |
| CvaztAfter the First Dose (mg/L) |   171 |   172 |     0.45  |
| Baseline Weight (kg)             |   171 |   172 |     0.793 |
| Baseline Albumin (g/L)           |   171 |   172 |     0.967 |

Lower AIC or BIC values indicate better model fits. In general, a difference of more than 10 in AIC between the best model and the next best model provides evidence that the model with the lowest AIC is the best model. Models where the difference in AIC is 4 or less suggests that either model would be appropriate.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Table 3

<!-- image -->

A drop in the Kaplan-Meier curves indicates the time in which the patient experiences any irAE, and the censored events describe the last kmowm date where the patient has not experienced any iAEs, The table provided umdermeath the plot describes the number of patients who have not experienced any irAEs in each quartile at each time point. Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Figure 8

Figure 17: Kaplan-Meier Curves of irAEs Stratified by Quartiles of Individual Predicted Cemiplimab Cmax After the First Dose in Patients with R/M Cervical Cancer

<div style=\"page-break-after: always\"></div>

Table 26: Summary of Results from Cox PH Models of irAEs Fit with Predicted Exposure Metrics and Baseline Covariates as the Only Individual Predictor in Each Model in Patients with R/M Cervical Cancer

| Exposure Metric                  |   AIC |   BIC |   P-Value |
|----------------------------------|-------|-------|-----------|
| Baseline Weight (kg)             |   504 |   506 |     0.339 |
| Baseline Albumin (g/L)           |   504 |   506 |     0.451 |
| C: After the First Dose (mg/L)   |   505 |   507 |     0.78  |
| x After the First Dose (mg/L)    |   505 |   507 |     0.676 |
| CovazAfter the First Dose (mg/L) |   505 |   507 |     0.536 |
| BaselineECOG Score               |   505 |   507 |     0.601 |

Lower AIC or BIC values indicate better model fits. In general, a difference of more than 10 in AIC between the best model and the next best model provides evidence that the model with the lowest AIC is the best model. Models where the difference in AIC is 4 or less suggests that either model would be appropriate. Models are compared to the intercept-only model.

Source: Module 5.3.3.5 R2810-PK-21058-SR-01V1 Table 4

## SPECIAL STUDIES

## Immunogenicity

Immunogenicity assessments were presented for Study 1676 in patients with R/M cervical cancer and across all clinical studies in patients with solid tumors (Studies 1423, 1540, 1620, 1624, and 1676).

## Immunogenicity

## Study 1676

Immunogenicity in patients with R/M cervical cancer in the anti-drug antibody (ADA) data set (N=206) was low with no apparent difference in the occurrence of immunogenicity (ADA) in patients with SCC and AC. Pre-existing ADA occurred in 6 patients with R/M cervical cancer (2.9%). Treatment-emergent ADA (1.9% in total) was observed in 4 patients with SCC, 1 was transient and 3 were indeterminate; all were low titers (&lt;1,000). None of the ADA-positive samples revealed the presence of neutralizing antibody. No effect of immunogenicity/ADA on exposure was observed in patients with R/M cervical cancer in this study.

## Study 1423

Among 337 patients in the ADA Analysis Set in Study 1423, ADA incidence was low, with treatmentemergent ADA in 9 patients (2.7%). Treatment-emergent ADA was reported in 9 patients (1 patient at 1 mg/kg Q2W, 7 patients at 3 mg/kg Q2W, and 1 patient at 10 mg/kg Q2W): persistent ADA was observed in 2 patients (1 at 1 mg/kg Q2W and 1 at 3 mg/kg Q2W), transient ADA was observed in 2 patients (both at 3 mg/kg Q2W) and indeterminate ADA was observed in 5 patients (4 at 3 mg/kg Q2W and 1 at 10 mg/kg Q2W). The ADA titers were generally low with only 1 patient exhibiting moderate ADA titer. No patients were positive for NAbs. No relationship was observed between ADA status and cemiplimab exposure in the few cases of treatment-emergent ADA.

Of the patients with R/M cervical cancer in the ADA Analysis Set in Study 1423, 1 patient at 10 mg/kg Q2W of the 3 patients in the dose escalation cohorts, and none of the patients in EXP 23 (n=7) and EXP 24 (n=7) at 3 mg/kg Q3W showed a positive ADA response.

## Immunogenicity in Patients with R/M Cervical Cancer from Study 1676

Immunogenicity in patients with R/M cervical cancer in Study 1676 (206 patients, including 164 patients with SCC histology and 42 patients with AC histology), was low with no apparent difference in the

<div style=\"page-break-after: always\"></div>

occurrence of immunogenicity (ADA) based on histology. Pre-existing ADA occurred in 6 patients with R/M cervical cancer (2.9%). Treatment-emergent ADA (1.9% in total) was observed in 4 patients with SCC, 1 was transient and 3 were indeterminate; all were low titers (&lt;1,000). None of the ADA-positive samples revealed the presence of neutralizing antibodies. No effect of immunogenicity/ADA on cemiplimab exposure was observed in patients with R/M cervical cancer in this study.

## Immunogenicity in All Patients with Solid Tumours

In the overall population of patients with solid tumours, immunogenicity was assessed in patients with solid tumours, including patients with R/M cervical cancer, after cemiplimab administration as monotherapy (Studies 1423, 1540, 1620, 1624 and 1676) or in combination with radiotherapy and/or chemotherapy (Study 1423).

The incidence of treatment-emergent ADA in all patients with solid tumours in the ADA analysis set (n=1029) was low (2.1%). Only 3 patients (0.3%) had a persistent ADA response: 1 patient at 1 mg/kg Q2W IV, 1 patient at 3 mg/kg Q2W IV, and 1 patient at 350 mg Q3W IV. The ADA titers were generally low. No patients were positive for NAbs. The incidence of treatment-emergent ADA in the subset of patients (n=591) who received cemiplimab 350 mg Q3W IV was similarly low (2.2%).

<div style=\"page-break-after: always\"></div>

## 2.3.4. Discussion on clinical pharmacology

The clinical pharmacology data package submitted in support of the proposed indication for cemiplimab in patients with R/M cervical cancer included data on PK, PD, E-R relationships for efficacy and safety, and immunogenicity of cemiplimab in the target population. The PK was also assessed for consistency across studies in the R/M cervical cancer and by histology (SCC vs. AC), as well as in other patient populations (tumour-types) that have been previously reported. Within the population of patients with R/M cervical cancer, the PK of cemiplimab was assessed across studies (Study 1423 and Study 1676), as well as between patients.

The previous population PK model for cemiplimab in patients with CSCC, BCC, NSCLC and other solid tumours was updated with data from Study 1423, 1540, 1620 and 1624, which comprised of 17312 samples from 1063 patients.

Consistent with the initial population PK model, the pharmacokinetics of cemiplimab could be described by a 2-compartment model with zero-order intravenous infusion, a first-order elimination, and a sigmoid Emax function to describe a time-varying change in CL. Interindividual variability terms on Emax and T50 were removed, the proportional error model was refined to a log-additive error model and the offdiagonal covariance between interindividual random effects on CLQ and V1V2 was removed. The population PK model was evaluated adequately by means of GOF-plots, bootstrap analysis and VPCs. Model stability was significantly improved (94.8% successful convergence rate in the bootstrap analysis). The suitability of the updated final population PK model in predicting cemiplimab concentrations in patients with CC was evaluated through an external PPC, which indicated that the updated model adequately described cemiplimab concentrations in patients with cervical cancer.

Descriptive analyses at the study level showed that the PK of cemiplimab in patients with R/M cervical cancer receiving 3 mg/kg Q2W IV in the FIH Study 1423 was comparable to that observed in patients with R/M cervical cancer receiving 350 mg Q3W IV in the pivotal Study 1676. Within Study 1676, the PK was also observed to be similar between patients with SCC and AC histology types.

Consistently across tumour types the concentration-time profiles over the dosing interval was characterized by initial brief distribution phase followed by a mono-exponential elimination phase.

Attainment of steady-state was determined by inspection of the concentration-time profiles and attainment of a plateau of Ctrough. From history it was expected for a monoclonal antibody (mAb) directed against PD-1 with observed linear kinetics at the defined dose level and dosing interval, steady-state was achieved by week 18 (i.e., after approximately 4 months of cemiplimab IV administration). Furthermore, predicted AUC3W after the fifth and sixth 350 mg every 3 weeks (Q3W) intravenous (IV) doses of cemiplimab showed that &gt;90% and &gt;95% of the exposure at plateau were reached after the fifth and sixth cemiplimab Q3W IV dose, respectively. The PopPK approach supported the selection of week 18 to report descriptive cemiplimab concentrations at steady state in the clinical pharmacology report of Study REGN2810-ONC-1676 (Study 1676).

Cemiplimab exposure data in special populations were also presented. Exposure at steady state in special populations between the target population of patients with R/M cervical cancer (292 patients in Study 1676) vs. the PopPK population (1062 patients) was compared for age, renal function, hepatic function, and baseline albumin, respectively.

No additional information or impact on exposures was observed on age, moderate or severe renal impairment, and/or moderate or severe hepatic impairment, in the target population in Study 1676 that would have an impact on the dosing profile for special populations.

<div style=\"page-break-after: always\"></div>

In the descriptive exposure-efficacy analysis, Kaplan-Meier curves of OS by quartile of Ctrough after the first dose (Ctrough,1) were performed. An apparent E-R was suggested by MAH with improved OS in the higher quartile of exposures. However, this univariate analysis was confounded by the correlation of Ctrough,1 with baseline levels of albumin, which itself was correlated with baseline ECOG performance status. Given these underlying confounding factors, it is difficult to conclude on the significance of the E-R relationship results, especially over such a narrow exposure range, as these confounding factors cannot be completely eliminated from the analysis with the available data.

Kaplan-Meier (K-M) curves of PFS and DOR did not reveal any trends, and the rank order of the quartiles was not preserved. Therefore, further analyses with Cox PH modelling were not deemed necessary for these endpoints.

Logistic regression analyses conducted on ORR showed no significant relationship with cemiplimab exposure as indicated by the flat E-R for ORR.

In the exposure-safety relationship analysis, Kaplan-Meier plots for irAEs grade ≥ 3 and for all irAEs suggested a trend where higher exposure quantiles (Cmax) were correlated with higher probabilities of experiencing irAEs. However, univariate Cox PH modelling for irAEs grade ≥ 3 and for all irAEs showedd that exposure metrics were not significant predictors of irAE hazard. Therefore, it is unlikely that an E-R relationship for all irAEs and irAEs grade ≥ 3 exists in patients with R/M cervical cancer in Study 1676. Similar results were observed for Ctrough and Cav.

Overall, no E-R relationships for both efficacy and safety endpoints were found in R/M patients with cervical cancer in Study 1676 who received cemiplimab 350 mg Q3W IV. These results are consistent with the knowledge gained from prior E-R relationship analyses of cemiplimab in patients with advanced CSCC, advanced BCC, and advanced NSCLC.

Consistent with the incidence of ADA observed across all studies, in patients with R/M cervical cancer who received cemiplimab 350 mg Q3W IV in Study 1676, the incidence of treatment emergent ADA (1.9%) and of persistent ADA (0%) was estimated to be low.

Since cemiplimab is a human monoclonal antibody and hence cleared from the circulation through catabolism, and not subject to protein transporters, no metabolic drug-drug interactions are expected. Hence it is acceptable that no formal pharmacokinetic drug interaction studies were submitted.

No changes to section 5.2 of the SmPC are required since the results from the popPK analysis were already updated as part of variation EMEA/H/C/004844/II/31.

## 2.3.5. Conclusions on clinical pharmacology

The presented clinical pharmacology data for cemiplimab support the approvability of cemiplimab 350 mg Q3W IV for the treatment of patients with R/M cervical cancer.

## 2.4. Clinical efficacy

## 2.4.1. Main study

##  Main study - R2810-ONC-1676

Study 1676 is an ongoing open-label, randomised 1:1, multicentre, pivotal phase III trial that evaluates the efficacy and safety of cemiplimab monotherapy vs. investigator's choice of chemotherapy

<div style=\"page-break-after: always\"></div>

(pemetrexed or topotecan or irinotecan or gemcitabine or vinorelbine) in women with recurrent or metastatic cervical cancer after progression to platinum-containing chemotherapy with or without bevacizumab. Patients were enrolled regardless of PD-L1 status. Figure 18 provides an overview of the key features of Study 1676.

Figure 18: Design scheme of Study 1676

<!-- image -->

<div style=\"page-break-after: always\"></div>

The study included 3 periods:  screening, treatment, and follow-up.  The screening period began with the signing of the informed consent form (ICF).  Cycle length was 6 weeks, and tumour imaging (efficacy assessment) was at the end of cycles 1 through 4, 6, 8, 10, 12, 14, and 16. Imaging was also performed during follow-up visit 1 (30 ±10 days from last dose of cemiplimab or IC of chemotherapy) and follow-up visit 2 (90 ±10 days after follow-up visit 1). The investigator decided whether imaging was done by CT or MRI, but subsequent assessments should have been made using the same modality.

Cross-over treatment at progression was not allowed.

An independent data monitoring committee (IDMC) composed of members who were independent from the sponsor and the study investigators monitored patient safety by conducting formal reviews of accumulated safety data. At prespecified interim analyses only, the IDMC also monitored and reviewed the interim primary efficacy analyses for OS in the SCC population. If requested, the IDMC could have access to the treatment allocation code or any other requested data for the purposes of a risk-benefit assessment. The IDMC acted in an advisory capacity to the sponsor.

## Methods

## Study participants

## Key inclusion criteria:

1. Recurrent, persistent, and/or metastatic cervical cancer with squamous cell histology, for which there is not a curative-intent option (surgery or radiation therapy with or without chemotherapy).
- a. Patients with the following histologies: squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma, were to be enrolled from the original protocol through protocol Amendment 4. For the purpose of this study, adenosquamous carcinoma was to be stratified as adenocarcinoma.
- b. Starting with protocol Amendment 5, only patients with squamous cell histology are eligible to enrol.
2. Tumour progression or recurrence after treatment with platinum therapy (must have been used to treat metastatic, persistent, or recurrent cervical cancer). NOTE: Platinum-therapy given in other settings (e.g., concurrent with radiation therapy as part of curative-intent therapy, after radiation [or chemoradiation] as adjuvant treatment in a patient with no evidence of disease) does not satisfy the eligibility requirement regarding prior platinum therapy.
3. Patient must have measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least 1 dimension (longest dimension to be recorded). Each lesion must be ≥10 mm when measu red by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam or must be ≥20 mm when measured by chest x-ray. Lymph nodes must be &gt;15 mm in short axis when measured by CT or MRI.

Tumours within a previously irradiated field will be designated as non-measurable lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.

4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
5. ≥ 18 years old
6. Hepatic function:

<div style=\"page-break-after: always\"></div>

a. Total bilirubin ≤1.5x upper limit of normal (ULN; if liver metastases ≤3x ULN). Patients with Gilbert's Disease and total bilirubin up to 3x ULN may be eligible after communication with and approval from the medical monitor.

- b. Transaminases ≤3x ULN (or ≤5.0x ULN, if liver metastases)
- c. Alkaline phosphatase ≤2.5x ULN (or ≤5.0x ULN, if liver or bone metastases)
7. Renal function: Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance &gt;45 mL/min
8. Bone marrow function:
- a. Hemoglobin ≥ 9.0 g/dL
- b. Absolute neutrophil count (ANC) ≥ 1.5x 10 9 /L
- c. Platelet count ≥ 75 x 10 9 /L
9. Anticipated life expectancy &gt;12 weeks
10. At least one of the following criteria regarding prior bevacizumab therapy:
- a. Received prior bevacizumab-containing therapy, which was discontinued due to progression of disease or toxicity
- b. Was deemed unsuitable for prior bevacizumab therapy for one of the following reasons: (i) unacceptable risk of fistula formation; (ii) poorly controlled hypertension; (iii) 'low risk' disease according to the Moore Criteria (Tewari 2015).
- c. Refused prior bevacizumab therapy.
- d. Did not have access to bevacizumab therapy due to logistical reasons (e.g., lived in a region in which bevacizumab was not commercially available for patients with cervical cancer, or did not have insurance coverage for bevacizumab).
11. At least one of the following criteria regarding prior paclitaxel therapy:
- a. Received prior paclitaxel-containing therapy, which was discontinued due to progression of disease or toxicity.
- b. Was deemed unsuitable for prior paclitaxel therapy for one of the following reasons: (i) neuropathy (ii) allergy to paclitaxel or its components.
- c. Refused prior paclitaxel therapy.

Key exclusion criteria:

1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest higher risk for severe irAEs. The following are not exclusionary: vitiligo, childhood asthma that hasresolved, type 1 diabetes, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment.
2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
3. Prior treatment with other systemic immune-modulating agents that was (a) within fewer than 4 weeks (28 days) of the enrollment date, or (b) associated with irAEs of any grade within 90 days prior to enrollment, or (c) associated with toxicity that resulted in discontinuation of the immunemodulating agent. Examples of immune-modulating include therapeutic vaccines, cytokine

<div style=\"page-break-after: always\"></div>

treatments (other than granulocyte colony stimulating factor or erythropoietin), or agents that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), 4-1BB (CD137), PI 3-K-delta, LAG3, or OX-40.

4. Known history of brain metastasis(es) that may be considered active (screening imaging of brain is not required unless there is clinical suspicion of brain metastases). Patients with previously treated brain metastases may participate provided that the lesions are stable (without evidence of progression for at least 6 weeks on imaging obtained during the screening period), there is no evidence of new or enlarging brain metastases, and the patient does not require any immunosuppressive doses of systemic corticosteroids for management of brain metastases within 4 weeks of the first dose of study drug (cemiplimab or IC chemo).
5. Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of study drug (cemiplimab or IC chemo).
6. Active bacterial, viral, fungal or mycobacterial infection requiring therapy, including known infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
7. Pneumonitis (interstitial pneumonitis, non-infectious pneumonia, interstitial lung disease) within the last 5 years.
8. History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments
9. Concurrent malignancy other than cervical cancer and/or history of malignancy other than cervical cancer within 3 years of date of first planned dose of study drug (cemiplimab or IC chemo), except for tumors with negligible risk of metastasis or death, such as adequately treated cutaneous squamous cell carcinoma or basal cell carcinoma of the skin or ductal carcinoma in situ of the breast. Patients with hematologic malignancies (eg, chronic lymphocytic leukemia) are excluded.
10. Any acute or chronic psychiatric problems that, in the opinion of the investigator, make the patient ineligible for participation.

11. Patients with a history of solid organ transplant (patients with prior corneal transplant(s) may be allowed to enroll after discussion with and approval from the medical monitor).

12. Any medical co-morbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that, in the opinion of the investigator, renders the patient unsuitable for participation in a clinical trial due to high safety risks and/or potential to affect interpretation of results of the study.
13. Pregnant or breastfeeding women.
14. Women of childbearing potential who are unwilling to practice highly effective contraception prior to the initial study drug treatment, during the study, and for at least 6 months after the last dose.
15. Prior treatment with idelalisib
16. Prior treatment with live vaccines within 30 days of initial administration of study drug (cemiplimab or IC chemo). Patients must not be treated with live vaccines during the study and up to 5 half-lives following the last dose of study drug

<div style=\"page-break-after: always\"></div>

## Treatments

Experimental arm: Cemiplimab at a flat dose of 350 mg Q3W IV, the currently approved dose and schedule.

Control arm: Investigator's choice (IC) chemotherapy agents were of 4 classes:

- Antifolate: pemetrexed (500 mg/m 2  IV on day 1, Q3W)
- Topoisomerase 1 inhibitor: topotecan (1.0 mg/m 2  on days 1 to 5, Q3W) or irinotecan (100 mg/m 2 weekly X 4, followed by 10 to 14 days rest, every 6 weeks [Q6W])
- Nucleoside analogue: gemcitabine (1000 mg/m 2  IV on days 1 and 8, Q3W)
- Vinca alkaloid: vinorelbine (30 mg/m 2  on days 1 and 8, Q3W).

The study design did not allow cross over between treatment arms.

Planned treatment for both arms was up to 96 weeks (up to 16 cycles of 6 weeks each), disease progression, unacceptable toxicity, or withdrawal of consent. For patients in the cemiplimab arm, there was an option for treatment past progression. Patients who experienced progressive disease on cemiplimab were permitted to continue treatment with cemiplimab, as long as they had not presented cemiplimab-related safety concerns and their disease was not rapidly progressive.

According to the protocol, treatment with cemiplimab beyond progression was permitted in patients who fulfilled the following conditions:

- Stable performance status
- The patient does not have rapid progression of disease
- The patient has not experienced adverse events that would require permanent discontinuation of cemiplimab
- The patient provides written informed consent prior to resuming treatment by signing the current version of the ICF (eg, the patient repeats the written informed consent that was done prior to initial study enrollment).
- It is understood that, if there is further progression after resumption of treatment ( ≥ 30% increase in tumor burden from the time of initial progressive disease by RECIST criteria; this includes an increase in the sum of all target lesions and/or the development of new lesions), that cemiplimab will be discontinued.

## Objectives

Primary objective: To compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology, treated with either cemiplimab or investigator's choice chemotherapy.

Secondary objectives (performed among SCC patients and among all eligible histologies [(SCC and adenocarcinoma/adenosquamous carcinoma]) were :

- To compare progression-free survival (PFS) of cemiplimab versus IC chemotherapy.

<div style=\"page-break-after: always\"></div>

- To compare objective response rate (ORR) (partial response [PR] + complete response [CR]) of cemiplimab versus IC chemotherapy per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.
- To compare the duration of response (DOR) of cemiplimab versus IC chemotherapy.
- To compare the safety profiles of cemiplimab versus IC chemotherapy by describing adverse events (AE).
- To compare quality of life (QOL) for patients treated with cemiplimab versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30).

Exploratory Objectives:

- To measure concentrations of cemiplimab in serum and characterize the pharmacokinetics (PK) of cemiplimab.
- To assess the immunogenicity of cemiplimab.
- To explore associations between the clinical efficacy of cemiplimab and molecular features in pretreatment tumour samples.
- To explore the pharmacodynamic activity of cemiplimab on the immune system in peripheral blood samples

## Outcomes/endpoints

Primary efficacy endpoint: OS, defined as the time from randomisation to the date of death. For patients who did not have a death date at the time of data cutoff, OS was censored at last known alive date.

Secondary endpoints:

-   PFS by investigator: defined as the time from randomisation to the date of the first documented tumour progression using RECIST 1.1 per investigator assessment, or death due to any cause. Patients who do not have a documented tumour progression or death will be censored on the date of their last evaluable tumour assessment. Patients who do not have any evaluable tumour assessments after randomization and do not die were to be censored on the date of randomization.
-   ORR by investigator: defined as the number of patients with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) using RECIST 1.1 per investigator assessment divided by the number of patients in the efficacy analysis set.  Best overall response was defined as the BOR between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first.

Other endpoints included duration of response (DOR) and patient reported outcomes (PRO).  Duration of response was defined as the time between the date of first response (CR or PR) to the date of the first documented tumour progression (per RECIST 1.1) or death due to any cause.

Patients with recurrent or metastatic cervical carcinoma were given the opportunity to report on their symptoms, functioning and overall QoL in Study 1676 using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) PRO instrument, version 3.

Patient safety was to be assessed through the collection of reported adverse events (AEs), clinical laboratory data, vital signs, ECG and physical exam. Unless otherwise noted, the baseline value was defined as the last available value before the first dose of study treatment.

<div style=\"page-break-after: always\"></div>

## Sample size

The primary endpoint was overall survival among patients treated with cemiplimab versus IC of chemotherapy. The median OS has been reported in range of 6.5 months to 8.1 months in the phase 2 setting. The sponsor assumed a median OS of 7 months for SCC patients treated with IC chemotherapy and a median OS of 10 months for SCC patients treated with cemiplimab. The assumptions corresponded to an approximately 42.8% increase in median OS and a hazard ratio (HR) of 0.7 if OS is distributed exponentially in both treatment groups.

Two interim efficacy analyses were planned using Lan-DeMets (O'Brien-Fleming) spending function at 70% and 85% of the total OS events, respectively. A total of 340 OS events in SCC patients was to yield approximately 90% power to detect an HR of 0.7 with an overall type I error of 0.025 (1-sided).

Considering the enrollment rate (2 patients/month for months 1 to 5, 9 patients/month for months 6 to 16, 20 patients/month for months 17 to 23, and 22 patients/month for month 24 and beyond) and 10% dropout rate per year, enrollment of 460 randomized SCC patients was to yield 340 OS events for analysis of OS around 42 months after the first SCC patient is randomized.

At the time when 460 SCC patients were enrolled in the study, a total enrollment in the study of approximately 590 patients was projected (SCC plus non-SCC). The actual number of patients to be enrolled was to depend on the proportion of adenocarcinoma patients in the patient population and the time when Amendment 5 was implemented at each of the study sites. If the HR was 0.7, the power for testing OS in the overall population was to be higher than 90%.

## Randomisation

Randomization was stratified according to:

1. Histology (squamous cell carcinoma vs. adenocarcinoma). Adenosquamous histology was considered adenocarcinoma for the purpose of stratification.
2. Geographic Region: North America (Canada, USA) vs. Asia (Japan, South Korea, Taiwan) vs. Rest of World (ROW) (Australia, Brazil, Poland, Russia, Spain, Belgium, Italy, Greece, UK)
3. Prior bevacizumab (yes/no)
4. ECOG performance status (0,1)

The stratification factors of 'prior bevacizumab use' and 'ECOG performance status' were used for balancing treatment assignment only and were not included in the statistical model for analysis of the primary endpoint.

## Blinding (masking)

This was an open-label study.

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Efficacy analysis population

The full analysis set (FAS) included all randomized patients. This was the intention to treat population. The FAS was based on the treatment allocated (as randomized). All efficacy endpoints were analysed using the FAS.

## Primary efficacy endpoint OS

The primary endpoint of OS was to be analysed in SCC patients by stratified log-rank test using geographic region (North America versus Asia-Pacific versus ROW) as a stratification factor. The HR and its 95% CI were to be estimated by a stratified Cox regression model with Efron's method for tie handling and using the treatment as covariate. The distribution of OS was to be estimated using the Kaplan-Meier method.

If the analysis of OS was statistically significant in the SCC patients, then the analysis of OS was to be performed in the overall population by stratified log-rank test using the following stratification factors (histology and geographic region). The HR and its 95% CI were to be estimated by a stratified Cox regression model with Efron's method for tie handling and using the treatment as covariate. The KaplanMeier estimate of median OS with its 95% CI and the estimates with the 95% CIs at specific time points were to be summarized by treatment group.

## Censoring rules for OS

A patient who has not died was to be censored at the last known alive date.

## Sensitivity analyses were to be performed for OS

- The first sensitivity analysis was to be performed using the stratification information (i.e., histology) collected in the clinical database.
- The second sensitivity analysis was to be performed using the Rank Preserving Structural Failure Time (RPSFT) model to account for the effect of the PD-1/PD-L1 treatments after disease progression in the chemotherapy arm
- The third sensitivity analysis was to be performed to account for the effect of the posttreatment immune check-point inhibitors (including PD1/PDL1, and others) in both arms after primary study period. Patients who received post-treatment immune checkpoint inhibitors were to be censored on the start date of post-treatment immune checkpoint inhibitors.

## Key secondary efficacy endpoints PFS and ORR

## PFS

The analysis of PFS was to be analysed using the same statistical method as described for the primary analysis of OS with regard to SCC and overall population.

## Censoring rules for PFS

Patients who do not have a documented tumour progression or death were to be censored on the date of their last evaluable tumour assessment. Patients who do not have any evaluable tumour assessments after randomization and do not die were to be censored on the date of randomization.

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses will be performed for PFS

The first sensitivity analysis was the same as the main analysis except that it considered initiation of new anti-cancer therapy as a progressive disease event for patients without documented radiological PD or death on or prior to initiation of new anticancer treatment.

The second sensitivity analysis was the same as the main analysis except that it considered clinical progression as a progressive disease event for patients without documented radiological PD or death on or prior to clinical progression.

## ORR

The ORR was to be analysed using Cochran-Mantel-Haenszel test stratified by the same stratification factors used in analysis of OS with regard to the SCC and overall population. ORR and the corresponding 95% exact CI will be calculated by Clopper-Pearson method for each treatment arm.

Patients with the best overall response of NE will be considered as non-responder.

One sensitivity analysis will be performed using the same method as above in ORR eligible patients, defined as all randomized patients who had baseline and at least one valid post-baseline tumor evaluation.

## Multiplicity considerations

The multiplicity was controlled at one-sided 0.025 level by group sequential design for interim and final analyses for OS in SCC patients and a hierarchical testing procedure for OS, PFS, QoL and ORR in SCC and overall population.

## Type I error control for interim and final analyses of OS in SCC patients using group sequential design

Two interim efficacy analyses were planned for the primary endpoint of OS in SCC patients using LanDeMets (O'Brien-Fleming) spending function at 70% and 85% of the total OS, respectively.

The first interim efficacy analysis was to be performed after observing approximately 238 OS events in SCC patients (70% of total OS events). The second interim efficacy analysis was to be performed after observing approximately 289 OS events in SCC patients (85% of total OS events). The final efficacy analysis was to be performed after observing approximately 340 OS events in SCC patients. The actual alpha spending was to be based on the actual number of OS events included in the analyses and determined.

<div style=\"page-break-after: always\"></div>

Type I error control for OS, PFS, QoL and ORR in SCC and overall population using hierarchical testing procedure

Table 27: statistical testing for efficacy results (listed in hierarchical order as pre-specified in SAP)

|   Endpoint | Endpoint                                                                               |
|------------|----------------------------------------------------------------------------------------|
|          1 | OS in SCC population                                                                   |
|          2 | OS in total population (also called the overall population)                            |
|          3 | PFS in SCC population                                                                  |
|          4 | Overall mean change from baseline in GHS/QoL scale in SCC population                   |
|          5 | Overall mean change from baseline in physical functioning scale in SCC population      |
|          6 | ORR in SCC population                                                                  |
|          7 | PFS in total population                                                                |
|          8 | ORR in total population                                                                |
|          9 | Mean change from baseline to cycle 2 in GHS/QoL scale in SCC population                |
|         10 | Mean change from baseline to cycle 2 in physical functioning scale in SCC population   |
|         11 | Overall mean change from baseline in GHS/QoL scale in total population                 |
|         12 | Overall mean change from baseline in physical functioning scale in total population    |
|         13 | Mean change from baseline to cycle 2 in GHS/QoL scale in total population              |
|         14 | Mean change from baseline to cycle 2 in physical functioning scale in total population |

GHS/QoL=global health status/quality oflife; ORR=overall response rate; OS=overall survival; PFS=progressionfree survival; SAP=statistical analysis plan; SCC=squamous cell carcinoma.

Source: CSR, page 37/135.

## Changes to the SAP and to the planned analyses

All changes in the planned analyses for the study were implemented by SAP amendment(s), as described in the SAP, see under study conduct, protocol amendments.

## Results

## Participant flow

A total of 752 patients were screened for study eligibility.

<div style=\"page-break-after: always\"></div>

Figure 19: Participant Flow - Study 1676

<!-- image -->

<div style=\"page-break-after: always\"></div>

Of the patients screened, 608 were randomized, 304 patients to the cemiplimab arm and 304 patients to the investigator's choice of chemotherapy arm. Table 28 shows patient disposition for the intention-totreat (ITT) population of the pivotal trial.

As of the data cut-off for the CSR (04 January 2021), the median follow-up duration (from randomisation to data cutoff date) for the total population was 18.18 months (range: 6.0 to 38.2 months).

Table 28: Study 1676 - Patient disposition (ITT)

|                                              | SCC and AC         | SCC and AC           |
|----------------------------------------------|--------------------|----------------------|
|                                              | Cemiplimab (N=304) | Chemotherapy (N=304) |
| Randomized but Never Treated, n (%)          | 5 (1.6%)           | 13 (4.3%)            |
| Treatment Ongoing, n (%)                     | 37 (12.2%)         | 7 (2.3%)             |
| Off Treatment, n (%)                         | 262 (86.2%)        | 284 (93.4%)          |
| Treatment completed                          | 13 (4.3%)          | 0                    |
| Treatment discontinued                       | 249 (81.9%)        | 284 (93.4%)          |
| Primary reason for treatment discontinuation |                    |                      |
| Adverse event                                | 25 (8.2%)          | 15 (4.9%)            |
| Death                                        | 14 (4.6%)          | 17 (5.6%)            |
| Noncompliance with study drug(s)             | 0                  | 1 (0.3%)             |
| Subject decision                             | 8 (2.6%)           | 10 (3.3%)            |
| Physician decision                           | 0                  | 2 (0.7%)             |
| Disease progression                          | 199 (65.5%)        | 229 (75.3%)          |
| Withdrawal of consent                        | 3 (1.0%)           | 10 (3.3%)            |
| Study ongoing, n (%)                         | 53 (17.4%)         | 11 (3.6%)            |
| Off study, n (%)                             | 251 (82.6%)        | 293 (96.4%)          |
| Study completed                              | 7 (2.3%)           | 0                    |
| Study discontinued                           | 244 (80.3%)        | 293 (96.4%)          |
| Primary reason for study discontinuation     |                    |                      |
| Adverse event                                | 9 (3.0%)           | 7 (2.3%)             |
| Death                                        | 92 (30.3%)         | 95 (31.3%)           |
| Lost to follow-up                            | 2 (0.7%)           | 2 (0.7%)             |
| Noncompliance with study drug(s)             | 0                  | 1 (0.3%)             |
| Subject decision                             | 34 (11.2%)         | 42 (13.8%)           |
| Physician decision                           | 1 (0.3%)           | 3 (1.0%)             |
| Disease progression                          | 98 (32.2%)         | 117 (38.5%)          |
| Withdrawal of consent                        | 8 (2.6%)           | 26 (8.6%)            |

Data cut-off as of 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.1.5.1all

<div style=\"page-break-after: always\"></div>

Table 29: Study 1676 - Actual treatment among randomised patients (ITT)

|                            | AssignedTreatmentperIWRS   | AssignedTreatmentperIWRS        | AssignedTreatmentperIWRS      | AssignedTreatmentperIWRS       | AssignedTreatmentperIWRS         | AssignedTreatmentperIWRS        | AssignedTreatmentperIWRS   |
|----------------------------|----------------------------|---------------------------------|-------------------------------|--------------------------------|----------------------------------|---------------------------------|----------------------------|
| AchualTreatmentStatus      | Cemiplimab (N=304)         | Chemotherapy Pemetrexed (N=111) | Chemotherapy Topotecan (N=21) | Chemotherapy Irinotecan (N=19) | Chemotherapy Gemcitabine (N=121) | Chemotherapy Vinorelbine (N=32) | ChemotherapyAll (N=304)    |
| Randomizedbutnever treated | 5 (1.6%)                   | 2 (1.8%)                        | 5 (23.8%)                     | 0                              | 3 (2.5%)                         | 3(9.4%)                         | 13 (4.3%)                  |
| Treated asassigned         | 299 (98.4%)                | 109 (98.2%)                     | 16 (76.2%)                    | 19 (100%)                      | 118 (97.5%)                      | 28 (87.5%)                      | 290 (95.4%)                |
| Treatedbutnotas assigned   | 0                          | 0                               | 0                             | 0                              | 0                                | 1 (3.1%)                        | 1 (0.3%)                   |
| Cemiplimab                 | NA                         | 0                               | 0                             | 0                              | 0                                | 1 (3.1%)                        | 1 (0.3%)                   |
| Pemetrexed                 | 0                          | NA                              | 0                             | 0                              | 0                                | 0                               | 0                          |
| Topotecan                  | 0                          | 0                               | NA                            | 0                              | 0                                | 0                               | 0                          |
| Irinotecan                 | 0                          | 0                               | 0                             | NA                             | 0                                | 0                               | 0                          |
| Gemcitabine                | 0                          | 0                               | 0                             | 0                              | NA                               | 0                               | 0                          |
| Vinorelbine                | 0                          | 0                               | 0                             | 0                              | 0                                | NA                              | 0                          |

Source: Post-text tables, page 55/1482

Protocol deviations

Table 30: Study 1676 - Important protocol deviations (ITT)

|                                                       | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Total (N=608)   |
|-------------------------------------------------------|----------------------|------------------------|-----------------|
| Number of important protocol deviations               | 39                   | 20                     | 59              |
| Patients with any important protocol deviation, n (%) | 33 (10.9%)           | 19 (6.3%)              | 52 (8.6%)       |
| Type of important protocol deviations, n (%)          |                      |                        |                 |
| Exclusion criteria met but subject enrolled           | 5 (1.6%)             | 1 (0.3%)               | 6 (1.0%)        |
| Inadequate informed consent administration            | 1 (0.3%)             | 1 (0.3%)               | 2 (0.3%)        |
| Inclusion criteria not met but subject enrolled       | 5 (1.6%)             | 4 (1.3%)               | 9 (1.5%)        |
| Other                                                 | 13 (4.3%)            | 5 (1.6%)               | 18 (3.0%)       |
| Procedure not performed                               | 0                    | 2 (0.7%)               | 2 (0.3%)        |
| Treatment deviation                                   | 11 (3.6%)            | 6 (2.0%)               | 17 (2.8%)       |

Data cutoff as of 04 Jan 2021.

AC=adenocarcinoma/adenosquamous histology; SCC=squamous cell carcinoma.

Source: PTT 14.1.1.6all.

<div style=\"page-break-after: always\"></div>

## Recruitment

The first patient was randomised on 30 October 2017 and the last patient was randomised on 7 July 2020.

Enrollment took place in 14 countries. The leading countries for patient enrollment were Brazil (89 patients), Russia (85 patients), and South Korea (76 patients). Enrollment included 172 patients from Europe (Spain, Poland, Italy, Belgium, Greece, United Kingdom), 56 patients from Japan, 34 patients from Taiwan, 30 patients from Australia, and 66 patients from North America (US, Canada).

## Conduct of the study

At the time of data cutoff (04 January 2021), Study 1676 had 7 protocol amendments.  Only the study conduct reflected in the latest protocol amendment prior to the database lock date was presented in this application. The major protocol amendments are presented in the following table.

<div style=\"page-break-after: always\"></div>

Table 31: Study 1676 - Major protocol amendments along study conduct

| Amendment/Date          | Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amend.6 26 May 2020     | Added 2 interim analyses to provide early efficacy assessment in the unmet-need population. Increased sample size to maintain 90% power with 2 protocol-specified interim analyses. Interim efficacy analyses to be reviewed by an IDMC. Added language to meet a requirement under the guidance of EU and the US authorities to address considerations related to conduct of a study during the COVID-19 pandemic, including statistical analysis language.                                                                                                                                      |
| Amend.5 8Mar 2019       | Updated study population to cap enrollment of patients with adenocarcinoma histology to mimic real world distribution. Updated the statistical plan to hierarchically analyze SCC population prior to total study population. SCC patient enrollment was increased to maintain statistical power. Removed interim futility rule because the OS benefit of immune checkpoint blockers in s                                                                                                                                                                                                         |
| Amend.4 16 Aug 2018     | Removed the requirement for patients to be platinum-refractory, defined as progression of disease within 6 months of last dose of platinum therapy. The term *platinum-refractory used to describe the patient population was removed from the protocol. Revised inclusion requiring platinum-therapy. Patients must have had disease progression after prior platinum therapy in recurrent or metastatic disease setting. but without the fequirement for progression within 6 months of last dose.                                                                                              |
| Amend. 3 JP 27 Apr 2018 | Inclusion criterion #5 clarified to include the following statement: For patients enrolling in Japan who are ≥18 and <20 years old, both the patient and parent/legal representative must provide signed informed consent. Per standard of care in Japan, for patients enrolling in Japan, there were to be at least 14 days of rest before subsequent irinotecan administration. GCP Statement section clarified to include the following text: *The clinical study will be conducted in compliance with Pharmaceutical and Medical Device Act, Japanese GCP, and other relevant laws in Japan\". |
| Amend.3 21 Mar 2018     | Updated the monitoring needed for IC chemotherapy of vinorelbine treatment, to align with the standard of care. Subgroup analyses of patients from Japan were included. MedDRA-derived PT for potential imAEs list was updated as per MedDRA version 20.1.                                                                                                                                                                                                                                                                                                                                        |
| Amend.2 3 Nov 2017      | Revised exclusion criteria per request from the South Korean Ministry of Food and Dnug Safety. Added ECOG performance status as a stratification factor for randomization to balance treatment assignment, per request from the US FDA. The ECOG performance status was not to be included in the primary analysis model for efficacy.                                                                                                                                                                                                                                                            |
| Amend. 1 14 Jul 2017    | An exclusion criterion was added to exclude patients who had previously been treated with idelalisib from being treated with REGN2810. Additional safety guidance language was added for the management of patients developing stomatitis or mucositis. An AESI was added to the list of AESIs that require accelerated reporting to thie Sponsor. An imAE of any grade in a patient previously treated with a PI-3-K inhibitor was added to the list of events that require accelerated reporting to the Sponsor.                                                                                |

Source: CSR, page. 28/135.

<div style=\"page-break-after: always\"></div>

## SAP amendments

Table 32: Modifications from the approved statistical analysis plan

| SAP vesion   | Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SAP v3.0     | This SAP was updated to include additional PRO endpoints: 1. Section 5.8.3, the adjusted mean estimates at cycle 2 was added. 2. Section 7.2, the PRO endpoints will be tested in SCC and then in overall population in the hierarchy.                                                                                                                                                                                                                                                                                                                                                      |
| SAP v2.0     | This SAP was updated according to R2810-ONC-1676 all Protocol Amendements, up to Amendement 6. The major changes include: 1. Section 2.2, updated sample size with interim analysis, targeted population and enrollement rate. 2. Section 5.8.1, the primary efficacy analysis will be performed with a hierarchical order of SCC patients, then overall population. 3. Sections 7 and 8, added multiplicity control to reflect interim analyses using Lan-DeMets O'Brien-Fleming alpha spending function, and hierarchical order in testing the primary endpoints and secondary endpoints. |
| SAP v0.2     | This is the original version of SAP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

Source: SAP v3.0, page 10/38.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 33: Study 1676 - Demographics and baseline characteristics (ITT)

|                                  | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Total (N=608)   |
|----------------------------------|----------------------|------------------------|-----------------|
| Age (years)                      |                      |                        |                 |
| n                                | 304                  | 304                    | 608             |
| Mean (SDv)                       | 51.1 (11.59)         | 51.2 (11.77)           | 51.1 (11.67)    |
| Median                           | 51.0                 | 50.0                   | 51.0            |
| Q1 : Q3                          | 42.0 : 60.0          | 43.0 : 59.0            | 43.0 : 59.0     |
| Min : Max                        | 22 : 81              | 24 : 87                | 22 : 87         |
| Age Groups (years), n (%)        |                      |                        |                 |
| <65                              | 269 (88.5%)          | 264 (86.8%)            | 533 (87.7%)     |
| ≥65                              | 35 (11.5%)           | 40 (13.2%)             | 75 (12.3%)      |
| Age Groups (years), n (%)        |                      |                        |                 |
| <65                              | 269 (88.5%)          | 264 (86.8%)            | 533 (87.7%)     |
| ≥65 and <75                      | 30 (9.9%)            | 29 (9.5%)              | 59 (9.7%)       |
| ≥75                              | 5 (1.6%)             | 11 (3.6%)              | 16 (2.6%)       |
| Race, n (%)                      |                      |                        |                 |
| White                            | 193 (63.5%)          | 192 (63.2%)            | 385 (63.3%)     |
| Black or African American        | 9 (3.0%)             | 12 (3.9%)              | 21 (3.5%)       |
| Asian                            | 88 (28.9%)           | 88 (28.9%)             | 176 (28.9%)     |
| American Indian or Alaska native | 2 (0.7%)             | 1 (0.3%)               | 3 (0.5%)        |
| Other                            | 8 (2.6%)             | 4 (1.3%)               | 12 (2.0%)       |
| Unknown                          | 1 (0.3%)             | 1 (0.3%)               | 2 (0.3%)        |
| Not reported                     | 3 (1.0%)             | 6 (2.0%)               | 9 (1.5%)        |
| Ethnicity, n (%)                 |                      |                        |                 |
| Not Hispanic or Latino           | 251 (82.6%)          | 250 (82.2%)            | 501 (82.4%)     |
| Hispanic or Latino               | 47 (15.5%)           | 44 (14.5%)             | 91 (15.0%)      |
| Not reported                     | 6 (2.0%)             | 10 (3.3%)              | 16 (2.6%)       |
| Geographic region, n (%)         |                      |                        |                 |
| North America                    | 32 (10.5%)           | 34 (11.2%)             | 66 (10.9%)      |
| Asia                             | 83 (27.3%)           | 83 (27.3%)             | 166 (27.3%)     |
| Rest of World                    | 189 (62.2%)          | 187 (61.5%)            | 376 (61.8%)     |
| Height (cm)                      |                      |                        |                 |
| n                                | 304                  | 304                    | 608             |
| Mean (SDv)                       | 160.73 (6.639)       | 159.99 (6.628)         | 160.36 (6.638)  |
| Median                           | 160.15               | 159.05                 | 160.00          |
| Q1 : Q3                          | 155.90 : 165.10      | 155.35 : 164.50        | 155.65 : 165.00 |
| Min : Max                        | 147.0 : 178.0        | 137.0 : 181.0          | 137.0 : 181.0   |
| Body Weight (kg)                 |                      |                        |                 |
| n                                | 304                  | 304                    | 608             |
| Mean (SDv)                       | 64.14 (16.166)       | 63.60 (16.140)         | 63.87 (16.142)  |
| Median                           | 61.80                | 61.20                  | 61.55           |
| Q1 : Q3                          | 51.90 : 73.00        | 52.00 : 73.20          | 52.00 : 73.00   |
| Min : Max                        | 35.9 : 128.7         | 35.0 : 120.0           | 35.0 : 128.7    |
| BMI (kg/m 2 )                    |                      |                        |                 |
| n                                | 304                  | 304                    | 608             |
| Mean (SDv)                       | 24.779 (5.9095)      | 24.783 (5.8057)        | 24.781 (5.8530) |
| Median                           | 23.480               | 23.720                 | 23.595          |
| Q1 : Q3                          | 20.740 : 27.870      | 20.510 : 28.305        | 20.645 : 28.250 |
| Min : Max                        | 14.17 : 49.00        | 14.20 : 46.62          | 14.17 : 49.00   |
| ECOG performance status, n (%)   |                      |                        |                 |
| 0                                | 142 (46.7%)          | 141 (46.4%)            | 283 (46.5%)     |
| 1                                | 162 (53.3%)          | 163 (53.6%)            | 325 (53.5%)     |

Data cut-off as of 04 Jan 2021.

AC, adenocarcinoma/adenosquamous histology; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile SCC, squamous cell carcinoma; SDv, standard deviation.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.2.1.1all

<div style=\"page-break-after: always\"></div>

Table 34: Study 1676 - Baseline tumour characteristics (ITT)

|                                              | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Total (N=608)    |
|----------------------------------------------|----------------------|------------------------|------------------|
| Histology/cytology per EDC n(%)              |                      |                        |                  |
| AC Histology                                 | 64 (21.1%)           | 71 (23.4%)             | 135 (22.2%)      |
| Adenocarcinoma                               | 54 (17.8%)           | 62 (20.4%)             | 116 (19.1%)      |
| Adenosquamous cell carcinoma                 | 10 (3.3%)            | 9 (3.0%)               | 19 (3.1%)        |
| SCC Histology                                | 240 (78.9%)          | 233 (76.6%)            | 473 (77.8%)      |
| Histology/cytology per IWRS n(%)             |                      |                        |                  |
| AC Histology                                 | 65 (21.4%)           | 66 (21.7%)             | 131 (21.5%)      |
| SCC Histology                                | 239 (78.6%)          | 238 (78.3%)            | 477 (78.5%)      |
| Histologic grade, n(%)                       |                      |                        |                  |
| Moderately differentiated                    | 81 (26.6%)           | 93 (30.6%)             | 174 (28.6%)      |
| Poorly differentiated                        | 64 (21.1%)           | 67 (22.0%)             | 131 (21.5%)      |
| Undifferentiated                             | 4 (1.3%)             | 2 (0.7%)               | 6 (1.0%)         |
| Unknown                                      | 123 (40.5%)          | 118 (38.8%)            | 241 (39.6%)      |
| Well differentiated                          | 32 (10.5%)           | 24 (7.9%)              | 56 (9.2%)        |
| FIGO stage at initial diagnosis, n(%)        |                      |                        |                  |
| Stage I                                      | 2 (0.7%)             | 1 (0.3%)               | 3 (0.5%)         |
| Stage IA                                     | 2 (0.7%)             | 2 (0.7%)               | 4 (0.7%)         |
| Stage IA1                                    | 1 (0.3%)             | 2 (0.7%)               | 3 (0.5%)         |
| Stage IA2                                    | 0                    | 2 (0.7%)               | 2 (0.3%)         |
| Stage IB                                     | 14 (4.6%)            | 6 (2.0%)               | 20 (3.3%)        |
| Stage IB1                                    | 24 (7.9%)            | 24 (7.9%)              | 48 (7.9%)        |
| Stage IB2                                    | 16 (5.3%)            | 24 (7.9%)              | 40 (6.6%)        |
| Stage II                                     | 12 (3.9%)            | 7 (2.3%)               | 19 (3.1%)        |
| Stage IIA                                    | 7 (2.3%)             | 9 (3.0%)               | 16 (2.6%)        |
| Stage IIA1                                   | 0                    | 2 (0.7%)               | 2 (0.3%)         |
| Stage IIA2                                   | 5 (1.6%)             | 4 (1.3%)               | 9 (1.5%)         |
| Stage IIB                                    | 60 (19.7%)           | 65 (21.4%)             | 125 (20.6%)      |
| Stage III                                    | 15 (4.9%)            | 10 (3.3%)              | 25 (4.1%)        |
| Stage IIIA                                   | 2 (0.7%)             | 6 (2.0%)               | 8 (1.3%)         |
| Stage IIIB                                   | 50 (16.4%)           | 55 (18.1%)             | 105 (17.3%)      |
| Stage IVA                                    | 15 (4.9%)            | 15 (4.9%)              | 30 (4.9%)        |
| Stage IVB                                    | 72 (23.7%)           | 63 (20.7%)             | 135 (22.2%)      |
| Unknown                                      | 7 (2.3%)             | 7 (2.3%)               | 14 (2.3%)        |
| Time from initial diagnosis to randomization |                      |                        |                  |
| (months) [a]                                 |                      |                        |                  |
| n                                            | 304                  | 304                    | 608              |
| Mean (SDv)                                   | 39.145 (38.0589)     | 39.580 (38.8464)       | 39.363 (38.4236) |
| Median                                       | 27.695               | 26.020                 | 26.910           |
| Q1 : Q3                                      | 16.115 : 47.050      | 16.475 : 46.505        | 16.315 : 46.520  |
| Min : Max                                    | 3.81 : 283.33        | 3.68 : 296.41          | 3.68 : 296.41    |
| Extent of Disease at screening, n(%)         |                      |                        |                  |
| Metastatic                                   | 284 (93.4%)          | 290 (95.4%)            | 574 (94.4%)      |
| Recurrent/Persistent                         | 20 (6.6%)            | 14 (4.6%)              | 34 (5.6%)        |
| Number of Target Lesions                     |                      |                        |                  |
| n                                            | 304                  | 303                    | 607              |
| Mean (SD)                                    | 2.34 (1.269)         | 2.25 (1.194)           | 2.29 (1.232)     |
| Median                                       | 2.00                 | 2.00                   | 2.00             |
| Q1 : Q3                                      | 1.00 : 3.00          | 1.00 : 3.00            | 1.00 : 3.00      |
| Min : Max                                    | 1.0 : 5.0            | 1.0 : 5.0              | 1.0 : 5.0        |
| Sum of Target Lesions (mm)                   |                      |                        |                  |
| n                                            | 304                  | 303                    | 607              |
| Mean (SD)                                    | 77.17 (52.511)       | 70.23 (47.701)         | 73.71 (50.246)   |

<div style=\"page-break-after: always\"></div>

|                        | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Total (N=608)   |
|------------------------|----------------------|------------------------|-----------------|
| Median                 | 68.00                | 58.00                  | 62.00           |
| Q1 : Q3                | 37.00 : 102.00       | 35.00 : 97.00          | 35.20 : 100.00  |
| Min : Max              | 10.1 : 359.0         | 10.0 : 278.0           | 10.0 : 359.0    |
| Metastatic Sites, n(%) |                      |                        |                 |
| Bone                   | 26 (8.6%)            | 34 (11.2%)             | 60 (9.9%)       |
| Breast                 | 2(0.7%)              | 1 (0.3%)               | 3 (0.5%)        |
| Kidney                 | 2 (0.7%)             | 3 (1.0%)               | 5 (0.8%)        |
| Liver                  | 78 (25.7%)           | 65 (21.4%)             | 143 (23.5%)     |
| Lung                   | 107 (35.2%)          | 94 (30.9%)             | 201 (33.1%)     |
| Lymph node             | 196 (64.5%)          | 182 (59.9%)            | 378 (62.2%)     |
| Other                  | 154 (50.7%)          | 180 (59.2%)            | 334 (54.9%)     |
| Ovary                  | 7 (2.3%)             | 5 (1.6%)               | 12 (2.0%)       |
| Parametrium            | 6 (2.0%)             | 6 (2.0%)               | 12 (2.0%)       |
| Pericardium            | 0                    | 3 (1.0%)               | 3 (0.5%)        |
| Pleural effusion       | 11 (3.6%)            | 7 (2.3%)               | 18 (3.0%)       |
| Rectum                 | 4 (1.3%)             | 0                      | 4 (0.7%)        |
| Skin                   | 1 (0.3%)             | 2 (0.7%)               | 3 (0.5%)        |
| Small intestine        | 1 (0.3%)             | 1 (0.3%)               | 2 (0.3%)        |
| Spleen                 | 1 (0.3%)             | 6 (2.0%)               | 7 (1.2%)        |
| Stomach                | 0                    | 1 (0.3%)               | 1 (0.2%)        |

Data cut-off as of 04 Jan 2021.

AC, adenocarcinoma/adenosquamous histology; EDC, electronic data capture; IWRS, Interactive voice response system; Max, maximum; Min, minimum; SCC, squamous cell carcinoma; SDv, standard deviation.

[a] Time from Initial Diagnosis to Randomization (months) = (Date of randomization - Date of initial diagnosis)/30.4375.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.1.8, 14.1.2.2.1all

<div style=\"page-break-after: always\"></div>

Table 35: Study 1676 - Summary of prior cancer systemic therapy by setting (ITT)

|                                                                          | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Total (N=608)       |
|--------------------------------------------------------------------------|----------------------|------------------------|---------------------|
| Number of patients with any prior cancer-related systemic therapy, n (%) | 304 (100%)           | 304 (100%)             | 608 (100%)          |
| Therapy setting, n (%)                                                   |                      |                        |                     |
| Concurrent with radiotherapy                                             | 139 (45.7%)          | 159 (52.3%)            | 298 (49.0%)         |
| Recurrent, persistent, and/or                                            | 301 (99.0%)          | 304 (100%)             | 605 (99.5%)         |
| metastatic                                                               |                      |                        |                     |
| Adjuvant                                                                 | 16 (5.3%)            | 14 (4.6%)              | 30 (4.9%)           |
| Neo-adjuvant                                                             | 19 (6.3%)            | 20 (6.6%)              | 39 (6.4%)           |
| Other                                                                    | 1 (0.3%)             | 4 (1.3%)               | 5 (0.8%)            |
| Number of prior lines (any setting), n                                   |                      |                        |                     |
| (%)                                                                      |                      |                        |                     |
| 1                                                                        | 81 (26.6%)           | 66 (21.7%)             | 147 (24.2%)         |
| 2                                                                        | 126 (41.4%)          | 128 (42.1%)            | 254 (41.8%)         |
| 3                                                                        | 54 (17.8%)           | 72 (23.7%)             | 126 (20.7%)         |
| 4                                                                        | 26 (8.6%)            | 21 (6.9%)              | 47 (7.7%)           |
| 5                                                                        | 9 (3.0%)             | 12 (3.9%)              | 21 (3.5%)           |
| 6                                                                        | 4 (1.3%)             | 3 (1.0%)               | 7 (1.2%)            |
| 7                                                                        | 3 (1.0%)             | 1 (0.3%)               | 4 (0.7%)            |
| 8                                                                        | 1 (0.3%)             | 1 (0.3%)               | 2 (0.3%)            |
| Number of prior lines (any setting)                                      |                      |                        |                     |
| n1                                                                       | 304                  | 304                    | 608                 |
| Mean (SD)                                                                | 2.3 (1.24)           | 2.4 (1.15)             | 2.3 (1.20)          |
| Median                                                                   | 2.0                  | 2.0                    | 2.0                 |
| Q1:Q3                                                                    | 1.0:3.0              | 2.0 :3.0               | 2.0 :3.0            |
| Min : Max                                                                | 1:8                  | 1:8                    | 1:8                 |
| Number of prior lines of systemic therapyforrecurrent or                 |                      |                        |                     |
| metastatic disease, n (%)                                                |                      |                        |                     |
| 1                                                                        | 177 (58.2%)          | 169 (55.6%)            | 346 (56.9%)         |
| 2                                                                        | 70 (23.0%)           | 83 (27.3%)             | 153 (25.2%)         |
| 3                                                                        | 31 (10.2%)           | 36 (11.8%)             | 67 (11.0%)          |
| 4                                                                        | 14 (4.6%)            | 9 (3.0%)               | 23 (3.8%)           |
| 5                                                                        | 7 (2.3%)             | 5 (1.6%)               | 12 (2.0%)           |
| 6                                                                        | 0                    | 1 (0.3%)               | 1 (0.2%)            |
| 7                                                                        | 2 (0.7%)             | 1 (0.3%)               | 3 (0.5%)            |
| Number of prior lines of systemic therapyforrecurrent or                 |                      |                        |                     |
| metastatic disease                                                       |                      |                        |                     |
| 11                                                                       | 301                  | 304                    | 605                 |
| Mean (SD)                                                                | 1.7 (1.08)           | 1.7 (0.99)             | 1.7 (1.04)          |
| Median                                                                   | 1.0                  | 1.0                    | 1.0                 |
| Q1:Q3                                                                    | 1.0 :2.0             | 1.0 : 2.0              | 1.0:2.0             |
| Min : Max                                                                | 1:7                  | 1:7                    | 1:7                 |
| Number of patients with prior                                            | 148 (48.7%)          | 149 (49.0%)            | 297 (48.8%)         |
| bevacizumab, n (%)                                                       |                      |                        |                     |
| Number of patients with prior                                            | 273 (89.8%)          | 287 (94.4%)            | 560 (92.1%)         |
| paclitaxel, n (%)                                                        |                      |                        |                     |
| Progressed afterpriorplatinum                                            |                      |                        |                     |
| therapy, n (%)                                                           |                      |                        |                     |
| <=6 months                                                               | 266 (87.5%)          | 268 (88.2%)            | 534 (87.8%)         |
| >6 months                                                                | 33 (10.9%)           | 30 (9.9%)              | 63 (10.4%)          |
| Missing*                                                                 | 5 (1 6%)             | 6 (2.0%)               | 11 (1 8%)           |
| Prior Platinum Agent, n(%)                                               |                      |                        |                     |
| CARBOPLATIN                                                              | 192 (63.2%)          | 200 (65.8%)            | 392 (64.5%)         |
| CISPLATIN                                                                | 245 (80.6%)          | 250 (82.2%)            | 495 (81.4%)         |
| NEDAPLATIN PLATINUM COMPOUNDS [a]                                        | 8(2.6%) 1(0.3%)      | 3 (1.0%) 0             | 11  (1.8%) 1 (0.2%) |

Datacutoffasof04Jan2021.

*Eleven patients had a PD date as an incomplete date; therefore, they cannot be included into any of the categories above (&lt;=6 or &gt;6 clarify)

AC=adenocarcinoma/adenosquamous histology, Max=maximum; Min=minimum; ;SCC=squamous cell carcinoma; SD=standard deviation.

Source:PTT 14.1.3.1.1all.,PTT14.1.3.3.1all.

<div style=\"page-break-after: always\"></div>

Table 36. Summary of Prior Cancer Systemic Therapy by Setting - Longest Duration: Using the Longest Duration when Patients had Multiple Lines (FAS) - Patients with SCC and non-SCC Histology

|                                                | Cemiplimab (N=304)   | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Chemotherapy (N=304)   | Total (N=608)   | Total (N=608)   |
|------------------------------------------------|----------------------|----------------------|------------------------|------------------------|-----------------|-----------------|
| Progressed after prior platinum therapy, n (%) |                      |                      |                        |                        |                 |                 |
| <=1 month                                      | 120                  | (39.5%)              | 114                    | (37.5%)                | 234             | (38.5%)         |
| >1 month and <=6 months                        | 102                  | (33.6%)              | 113                    | (37.2%)                | 215             | (35.4%)         |
| > 6 months and <=12 months                     | 50                   | (16.4%)              | 45                     | (14.8%)                | 95              | (15.6%)         |
| > 12 months                                    | 27                   | (8.9%)               | 26                     | (8.6%)                 | 53              | (8.7%)          |
| Missing                                        | 5                    | (1.6%)               | 6                      | (2.0%)                 | 11              | (1.8%)          |

Data cut off as of Jan 4th 2022

Source: Table 14.1.3.1.1all.ema.exp2

Table 37: Study 1676 - Treatment compliance (ITT)

|                                 | Chemotherapy                    | Chemotherapy                    | Chemotherapy                    | Chemotherapy                    | Chemotherapy                    | Chemotherapy                    | Chemotherapy                    |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | Cemiplimab (N=300)              | Pemetrexed (N=109)              | Topotecan (N=16)                | Irinotecan (N=19)               | Gemcitabine (N=118)             | Vinorelbine (N=28)              | Total (N=290)                   |
| Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) | Treatment Compliance [a], n (%) |
| < 60%                           | 3 (1.0%)                        | 0                               | 0                               | 0                               | 5 (4.2%)                        | 0                               | 5 (1.7%)                        |
| ≥ 60% - < 80%                   | 39 (13.0%)                      | 21 (19.3%)                      | 2 (12.5%)                       | 1 (5.3%)                        | 13 (11.0%)                      | 3 (10.7%)                       | 40 (13.8%)                      |
| ≥ 80% - ≤ 100%                  | 258 (86.0%)                     | 88 (80.7%)                      | 14 (87.5%)                      | 18 (94.7%)                      | 96 (81.4%)                      | 23 (82.1%)                      | 239 (82.4%)                     |
| > 100%                          | 0                               | 0                               | 0                               | 0                               | 4 (3.4%)                        | 2 (7.1%)                        | 6 (2.1%)                        |

Data cut-off as of 04 Jan 2021.

[a] Treatment Compliance = (Number of doses of study administered during treatment period/Number of doses of study drug planned to be administered during treatment period) *100%.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.4.4all

## Numbers analysed

Table 38: Study 1676 - Analysis sets (ITT)

| Analysis Set, n                                   |   Cemiplimab | Chemotherapy   | Total   |
|---------------------------------------------------|--------------|----------------|---------|
| Full Analysis Set (FAS)                           |          304 | 304            | 608     |
| Safety Analysis Set (SAF)                         |          300 | 290            | 590     |
| Pharmacokinetic Analysis Set (Cemiplimab only)    |          295 | NA             | NA      |
| Anti-drug Antibody Analysis Set (Cemiplimab only) |          206 | NA             | NA      |
| PD-L1 status available                            |          182 | 189            | 371     |

Data cutoff as of Jan 4th 2021

Source: Table 14.1.1.3all.ema.irl.q17

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Overview of hierarchical testing of primary and secondary endpoints as per SAP:

| Endpoint                                                                           | One-sided P- Value   |
|------------------------------------------------------------------------------------|----------------------|
| Primary Endpoints                                                                  |                      |
| 1. OS in squamous cell carcinoma patients                                          | 0.00306              |
| 2. OS in total population                                                          | 0.00011              |
| Secondary Endpoints                                                                |                      |
| 3. PFS in SCC patients                                                             | 0.00026              |
| 4. Overall mean change from baseline in GHS/QoL scale in SCC patients              | 0.00025              |
| 5. Overall mean change from baseline in physical functioning scale in SCC patients | 0.00008              |
| 6. ORR in SCC patients                                                             | 0.00014              |
| 7. PFS in total population                                                         | 0.00048              |
| 8. ORR in total population                                                         | 0.00004              |

Note: This overview only includes endpoints with a statistically significant result.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR

<div style=\"page-break-after: always\"></div>

Table 39: Study 1676 - Overall survival (ITT)

|                                                     | SCC                  | SCC                  | AC                   | AC                  | Total                | Total                |
|-----------------------------------------------------|----------------------|----------------------|----------------------|---------------------|----------------------|----------------------|
|                                                     | Cemiplimab (N=239)   | Chemotherapy (N=238) | Cemiplimab (N=65)    | Chemotherapy (N=66) | Cemiplimab (N=304)   | Chemotherapy (N=304) |
| Number of deaths, n (%)                             | 143 (59.8%)          | 161 (67.6%)          | 41 (63.1%)           | 50 (75.8%)          | 184 (60.5%)          | 211 (69.4%)          |
| Number of censored patients, n (%)                  | 96 (40.2%)           | 77 (32.4%)           | 24 (36.9%)           | 16 (24.2%)          | 120 (39.5%)          | 93 (30.6%)           |
| Median (95% CI), (months)[a]                        | 11.1 (9.2, 13.4)     | 8.8 (7.6, 9.8)       | 13.3 (9.6, 17.6)     | 7.0 (5.1, 9.7)      | 12.0 (10.3, 13.5)    | 8.5 (7.5, 9.6)       |
| Stratified log- rank test one- sided p-value [b][c] | 0.00306              |                      |                      |                     | 0.00011              |                      |
| HR (95% CI) [b][d]                                  | 0.727 (0.579, 0.914) |                      | 0.556 (0.363, 0.853) |                     | 0.685 (0.560, 0.838) |                      |
| Estimated Survival Probability ,% (95% CI)[a]       |                      |                      |                      |                     |                      |                      |
| 6 months                                            | 69.6 (63.3, 75.0)    | 68.5 (61.9, 74.1)    | 69.6 (56.5, 79.4)    | 57.7 (44.4, 68.9)   | 69.6 (64.0, 74.5)    | 66.1 (60.3, 71.3)    |
| 12 months                                           | 48.2 (41.3, 54.7)    | 35.3 (28.6, 42.1)    | 57.4 (43.9, 68.7)    | 26.0 (15.5, 37.8)   | 50.2 (44.1, 56.0)    | 33.2 (27.4, 39.0)    |
| 18 months                                           | 33.4 (26.3, 40.6)    | 16.1 (10.4, 22.8)    | 34.2 (21.5, 47.3)    | 17.7 ( 8.9, 29.0)   | 33.4 (27.2, 39.7)    | 16.9 (11.9, 22.6)    |
| 24 months                                           | 25.3 (17.8, 33.5)    | 13.6 ( 8.1, 20.4)    | 19.5 ( 8.4, 34.1)    | 10.1 ( 2.7, 23.3)   | 23.6 (17.1, 30.6)    | 12.8 ( 8.0, 18.8)    |
| 30 months                                           | 25.3 (17.8, 33.5)    | 10.8 ( 5.2, 18.8)    | NE (NE, NE)          | NE (NE, NE)         | 23.6 (17.1, 30.6)    | 11.0 ( 6.1, 17.5)    |
| 36 months                                           | NE (NE, NE)          | NE (NE, NE)          | NE (NE, NE)          | NE (NE, NE)         | NE (NE, NE)          | NE (NE, NE)          |

Data cut-off as of 04 Jan 2021.

[a] Based on Kaplan-Meier method.

[b] Stratified by geographic region (North America versus Asia versus ROW) for SCC and AC. Stratified by geographic region (North America versus Asia versus ROW) and Histology (SCC versus AC) according to IWRS for Total. [c] One-sided p-value converted from stratified log-rank test two-sided p-value. Significant threshold is set to 0.01508 using O'Brien Fleming alpha spending function.

[d] Based on stratified proportional hazards model (cemiplimab vs IC chemotherapy).

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTTs 14.2.1.1all, 14.2.1.1scc, and 14.2.1.1ade

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-off as of 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2.1.1all

Figure 20: Study 1676 -Kaplan-Meier curve of overall survival (ITT)

Table 40: Study 1676 - Summary of patients censored in overall survival (ITT)

|                                                          | Cemiplimab (N=304)   | Chemotherapy (N=304)   |
|----------------------------------------------------------|----------------------|------------------------|
| Number of patients without event, n (%)                  | 120 (39.5%)          | 93 (30.6%)             |
| Reason for censoring, n (%)                              |                      |                        |
| Alive at the cut-off date                                | 102 (33.6%)          | 65 (21.4%)             |
| Alive before the cut-off date                            | 1 (0.3%)             | 0                      |
| Withdrew consent                                         | 9 (3.0%)             | 25 (8.2%)              |
| Lost to follow-up                                        | 8 (2.6%)             | 3 (1.0%)               |
| Time from last known alive date to cut-off date (months) |                      |                        |
| n                                                        | 18                   | 28                     |
| Mean (SDv)                                               | 15.25 (10.826)       | 21.11 (7.655)          |
| Median                                                   | 15.10                | 23.13                  |
| Q1 : Q3                                                  | 3.68 : 25.89         | 15.02 : 26.22          |
| Min : Max                                                | 0.7 : 30.6           | 6.6 : 34.0             |
| Time from last known alive date to cut-off date (class)  |                      |                        |
| n                                                        | 18                   | 28                     |
| >2 months                                                | 17 (94.4%)           | 28 (100%)              |
| >4 months                                                | 13 (72.2%)           | 28 (100%)              |
| >6 months                                                | 12 (66.7%)           | 28 (100%)              |
| >8 months                                                | 12 (66.7%)           | 26 (92.9%)             |
| >10 months                                               | 11 (61.1%)           | 24 (85.7%)             |
| >12 months                                               | 10 (55.6%)           | 24 (85.7%)             |
| >14 months                                               | 9 (50.0%)            | 22 (78.6%)             |
| >16 months                                               | 9 (50.0%)            | 20 (71.4%)             |

Data cut-off as of 04 Jan 2021.

Q1, first quartile; Q3, third quartile; SDv, standard deviation.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.2.1.8all

<div style=\"page-break-after: always\"></div>

Table 41: Study 1676 - Progression free survival by investigator (ITT)

|                                                     | Total                | Total                | SCC                  | SCC                  | AC                   | AC                  |
|-----------------------------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------|
|                                                     | Cemiplimab (N=304)   | Chemotherapy (N=304) | Cemiplimab (N=239)   | Chemotherapy (N=238) | Cemiplimab (N=65)    | Chemotherapy (N=66) |
| Number of events, n (%)                             | 253 (83.2%)          | 269 (88.5%)          | 197 (82.4%)          | 214 (89.9%)          | 56 (86.2%)           | 55 (83.3%)          |
| Progressive Disease, n (%)                          | 212 (69.7%)          | 215 (70.7%)          | 163 (68.2%)          | 172 (72.3%)          | 49 (75.4%)           | 43 (65.2%)          |
| Number of deaths, n (%)                             | 41 (13.5%)           | 54 (17.8%)           | 34 (14.2%)           | 42 (17.6%)           | 7 (10.8%)            | 12 (18.2%)          |
| Number of censored patients, n (%)                  | 51 (16.8%)           | 35 (11.5%)           | 42 (17.6%)           | 24 (10.1%)           | 9 (13.8%)            | 11 (16.7%)          |
| Median (95% CI), (months)[a]                        | 2.8 (2.6, 3.9)       | 2.9 (2.7, 3.4)       | 2.8 (2.6, 4.0)       | 2.9 (2.7, 3.9)       | 2.7 (2.3, 4.0)       | 2.8 (2.0, 3.2)      |
| Stratified log- rank test one- sided p-value [b][c] | 0.00048              |                      | 0.00026              |                      |                      |                     |
| HR (95% CI) [b][d]                                  | 0.745 (0.625, 0.890) |                      | 0.705 (0.578, 0.861) |                      | 0.912 (0.623, 1.335) |                     |
| Estimated Event-Free Probability ,% (95% CI)[a]     |                      |                      |                      |                      |                      |                     |
| 6 months                                            | 33.5 (28.2, 38.9)    | 21.7 (17.1, 26.7)    | 34.5 (28.5, 40.5)    | 22.1 (16.9, 27.8)    | 30.1 (19.3, 41.6)    | 20.4 (11.2, 31.7)   |
| 12 months                                           | 18.8 (14.4, 23.6)    | 7.3 (4.6, 11.0)      | 21.0 (15.8, 26.6)    | 7.3 ( 4.2, 11.4)     | 10.6 (4.4, 20.0)     | 8.2 (2.7, 17.6)     |
| 18 months                                           | 13.0 (9.0, 17.8)     | 0.8 (0.1, 3.6)       | 14.5 ( 9.7, 20.1)    | 0.0 (NE, NE)         | 8.5 (3.0, 17.6)      | 4.1 (0.8, 12.2)     |
| 24 months                                           | 9.7 (6.0, 14.6)      | NE (NE, NE)          | 10.3 ( 5.9, 16.0)    | 0.0 (NE, NE)         | 8.5 (3.0, 17.6)      | NE (NE, NE)         |
| 30 months                                           | 7.8 (3.8, 13.6)      | NE (NE, NE)          | 7.7 ( 3.2, 14.8)     | 0.0 (NE, NE)         | NE (NE, NE)          | NE (NE, NE)         |
| 36 months                                           | NE (NE, NE)          | NE (NE, NE)          | NE (NE, NE)          | 0.0 (NE, NE)         | NE (NE, NE)          | NE (NE, NE)         |

Data cut-off as of 04 Jan 2021.

[a] Based on Kaplan-Meier method.

[b] Stratified by geographic region (North America versus Asia versus ROW) for SCC and AC. Stratified by geographic region (North America versus Asia versus ROW) and Histology (SCC versus AC) according to IWRS for Total.

[c] One-sided p-value converted from stratified log-rank test two-sided p-value.

[d] Based on stratified proportional hazards model (cemiplimab vs IC chemotherapy).

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.2.2.1all, 14.2.2.1scc, 14.2.2.1ade

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-off as of 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2.2.1all

Figure 21: Study 1676 - Kaplan-Meier curve of progression free survival by investigator (ITT)

<div style=\"page-break-after: always\"></div>

Secondary endpoint - ORR by investigator:

Table 42: Study 1676 - Best overall tumour response rate by investigator (ITT)

|                                            | Total                | Total                | SCC                  | SCC                  |                       |                     |
|--------------------------------------------|----------------------|----------------------|----------------------|----------------------|-----------------------|---------------------|
|                                            | Cemiplimab (N=304)   | Chemotherapy (N=304) | Cemiplimab (N=239)   | Chemotherapy (N=238) | Cemiplimab (N=65)     | Chemotherapy (N=65) |
| Best Overall Tumor Response, n (%)         |                      |                      |                      |                      |                       |                     |
| Complete Response (CR) [a]                 | 10 (3.3%)            | 3 (1.0%)             | 7 (2.9%)             | 2 (0.8%)             | 3 (4.6%)              | 1 (1.5%)            |
| Partial Response (PR) [a]                  | 40 (13.2%)           | 16 (5.3%)            | 35 (14.6%)           | 14 (5.9%)            | 5 (7.7%)              | 2 (3.0%)            |
| Stable Disease (SD) [b]                    | 125 (41.1%)          | 148 (48.7%)          | 93 (38.9%)           | 116 (48.7%)          | 32 (49.2%)            | 32 (48.5%)          |
| Progressive Disease (PD)                   | 105 (34.5%)          | 88 (28.9%)           | 86 (36.0%)           | 71 (29.8%)           | 19 (29.2%)            | 17 (25.8%)          |
| Not Evaluable (NE)                         | 24 (7.9%)            | 49 (16.1%)           | 18 (7.5%)            | 35 (14.7%)           | 6 (9.2%)              | 14 (21.2%)          |
| Response                                   |                      |                      |                      |                      |                       |                     |
| Objective Response Rate (ORR:CR+PR)        | 50 (16.4%)           | 19 (6.3%)            | 42 (17.6%)           | 16 (6.7%)            | 8 (12.3%)             | 3 (4.5%)            |
| 95% CI for ORR [c]                         | (12.5%, 21.1%)       | (3.8%, 9.6%)         | (13.0%, 23.0%)       | (3.9%, 10.7%)        | (5.5%, 22.8%)         | (0.9%, 12.7%)       |
| Stratified CMH test one-sided p- value [d] | 0.00004              |                      | 0.00014              |                      |                       |                     |
| Odds ratio (95% CI) [d]                    | 2.984 (1.707, 5.215) |                      | 3.002 (1.629, 5.530) |                      | 2.894 (0.732, 11.445) |                     |

Data cut-off as of 04 Jan 2021.

- [a] CR/PR must be confirmed by repeated assessments no less than 4 weeks apart
- [b] SD criteria must be met at least once for a minimum duration of 4 weeks after first dose date

[c] Clopper-Person exact confidence interval.

[d] One-sided p-value and odds ratio using geographic region stratified Cochran-Mantel-Haenszel test for SCC and AC; One-sided p-value and odds ratio using geographic region and histology stratified Cochran-Mantel-Haenszel test for Total. Due to the low response rate in the IC chemitherapy arm, the results from CMH test should be interpreted with caution.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.2.3.1all, 14.2.3.1scc, 14.2.3.1ade

<div style=\"page-break-after: always\"></div>

Secondary endpoint - DOR by investigator:

Table 43: Study 1676 - Kaplan-Meier estimation of duration of response by investigator (responders in ITT)

|                                                      | Cemiplimab (N=50)   | Chemotherapy (N=19)   |
|------------------------------------------------------|---------------------|-----------------------|
| KM Estimation of Duration of Response (CR or PR) [a] |                     |                       |
| n                                                    | 50                  | 19                    |
| Number of events, n (%)                              | 20 (40.0%)          | 16 (84.2%)            |
| Number of censored patients, n (%) [b]               | 30 (60.0%)          | 3 (15.8%)             |
| Median (95% CI), (months)[a]                         | 16.4 (12.4, NE)     | 6.9 (5.1, 7.7)        |
| Estimated Event-Free Probability , %(95% CI)[a]      |                     |                       |
| 6 months                                             | 79.0 (64.4, 88.1)   | 59.6 (33.1, 78.5)     |
| 12 months                                            | 69.0 (53.1, 80.4)   | 0.0 (NE, NE)          |
| 18 months                                            | 41.4 (20.7, 61.0)   | 0.0 (NE, NE)          |
| 24 months                                            | 41.4 (20.7, 61.0)   | 0.0 (NE, NE)          |
| 30 months                                            | 20.7 ( 1.8, 54.0)   | 0.0 (NE, NE)          |
| 36 months                                            | NE (NE, NE)         | 0.0 (NE, NE)          |

Data cut-off as of 04 Jan 2021.

[a] Based on patients with confirmed CR or PR.

[b] Censored patients were patients who did not die, were lost to follow up, or had withdrawn consent censored at the last known date of contact.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.2.3.5all

<!-- image -->

/sasdata/Data/Prodnction/BDM/R2810/R2810-ONC/R2810-ONC-1676/Iuterim\\_CERV\\_sBLA/Analysis\\_CSR/Programs/TFL/f\\_2\\_3\\_3\\_kmdor\\_a.sas (krishma.avula 14JUL2021 11:42 SAS Linux 9.4)

Figure 22: Study 1676 - Kaplan-Meier curve of duration of response by investigator (responders in ITT)

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - PROs:

<!-- image -->

Document: Mlquintiles.net\\Enterprise\\Sites\\NLHOF\\IntProjects\\Consulting\\Projects\\Regeneron\\2727286\\04 Report\\Drafts\\Regeneron\\_R2810-ONC-1676\\_PROReport\\_v1.0\\_20210628

Figure 23: Instrument completion rate - EORTC-QLQ-C30

<!-- image -->

Data cut-off as of 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2.4.6all

Figure 24: Longitudinal plots of change from baseline EORTC-QLQ-C30 - GHS/QoL

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-off as of 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2.4.7all

Figure 25: Longitudinal plots of change from baseline EORTC-QLQ-C30 - physical functioning

<div style=\"page-break-after: always\"></div>

Exploratory endpoint - Post treatment anticancer therapy:

Table 44: Study 1676 - Summary of post-trial anticancer systemic therapy (ITT)

|                                                                                     | Cemiplimab (N=304)   | Chemotherapy (N=304)   |
|-------------------------------------------------------------------------------------|----------------------|------------------------|
| Number of patients received any post treatment anti- cancer systemic therapy, n (%) | 110 (36.2%)          | 144 (47.4%)            |
| Number of patients received any post treatment immune check-point inhibitors, n (%) | 6 (2.0%)             | 47 (15.5%)             |
| Number of patients received any post treatment Anti PD-L1 [1], n (%)                | 4 (1.3%)             | 46 (15.1%)             |

Data cut-off as of 04 Jan 2021.

[1] The remaining 3 patients received ipilimumab.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.2.5.4all

Table 45: Study 1676 - Detailed post treatment anticancer systemic therapy (ITT)

| ATC Level 2, n (%) ATC Level 4, n (%)                               | Cemiplimab (N=304)   | Chemotherapy (N=304)   |
|---------------------------------------------------------------------|----------------------|------------------------|
| Number of patients received any post treatment anti-cancer systemic | 110 (36.2%)          | 144 (47.4%)            |
| therapy, n (%)                                                      |                      |                        |
| ANTINEOPLASTICAGENTS                                                | 110 (36.2%)          | 144 (47.4%)            |
| PYRIMIDINEANALOGUES                                                 | 31 (10.2%)           | 31 (10.2%)             |
| PLATINUMCOMPOUNDS                                                   | 28  (9.2%)           | 39 (12.8%)             |
| TAXANES                                                             | 27 (8.9%)            | 28  (9.2%)             |
| COMBINATIONSOFANTINEOPLASTICAGENTS                                  | 22 (7.2%)            | 16 (5.3%)              |
| OTHER ANTINEOPLASTIC AGENTS                                         | 22 (7.2%)            | 26 (8.6%)              |
| MONOCLONALANTIBODIES                                                | 17 (5.6%)            | 60 (19.7%)             |
| VINCAALKALOIDSANDANALOGUES                                          | 12 (3.9%)            | 16 (5.3%)              |
| ANTHRACYCLINESANDRELATEDSUBSTANCES                                  | 4 (1.3%)             | 3 (1.0%)               |
| FOLICACIDANALOGUES                                                  | 4 (1.3%)             | 3 (1.0%)               |
| ATC4CODENOTAVAILABLE                                                | 3 (1.0%)             | 4 (1.3%)               |
| PODOPHYLLOTOXINDERIVATIVES                                          | 2 (0.7%)             | 0                      |
| PROTEINKINASEINHIBITORS                                             | 2 (0.7%)             | 0                      |
| NITROGENMUSTARDANALOGUES                                            | 1 (0.3%)             | 5 (1.6%)               |
| ALLOTHERTHERAPEUTICPRODUCTS                                         | (0.3%)               | 0                      |
| DETOXIFYINGAGENTSFORANTINEOPLASTICTREATMENT                         | 1 (0.3%)             | 0                      |
| DRUGSFORTREATMENTOFBONEDISEASES                                     | (0.3%)               | 0                      |
| BISPHOSPHONATES                                                     | (0.3%)               | 0                      |
| IMMUNOSTIMULANTS                                                    | (0.3%)               | 0                      |
| ATC4CODENOTAVAILABLE                                                | 1 (0.3%)             | 0                      |

Source: Post text tables, page 1464-5/1482

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analyses:

Cerri (Everts/Total)Chemo (Everts/Total)

AllPaierts

A ge goup 1

65

&gt;=65

Race

White

Non-white

Histology pe

IWRS

Non-SCC

Geographic regicn group 1

NcrthAmerica

Asia

Rest of World

ECOG satus pe IwRS

0

1

Frior bevacizumab use per IwRS

Yes

No

# of prior lines of sy sterrictherapy

for recurreni or metast atic

1 line

&gt;1 line

184/304

211/304

166/269

18/35

115/193

67/107

143/239

41/65

16/32

54/83

114/189

73/146

111/158

B5/149

99/155

103/177

B0/124

186/264

25/40

135/192

71/105

167/238

50/66

22/34

54/83

135/187

88/146

123/158

97/147

114/157

120/169

91/135

Hazard Hatios (95% Cl)*

0.685 (0.560, 0.838)

0.673 (0.543, 0.835)

0.687 (0.349, 1.355)

0.692 (0.538, 0.890)

0.688 (0.483, 0.981)

0.727 (0.579, 0.914)

0.556 (0.363, 0.853)

0.516 (0.265, 1.004)

0.647 (0.436, 0.961)

0.730 (0.569, 0.938)

0.589 (0.426, 0.816)

0.740 (0.570, 0.960)

0.641 (0.475, 0.863)

0.758 (0.575, 1.000)

0.622 (0.475. 0.815)

0.805 (0.589. 1.100)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-off as of 04 Jan 2021.

*Stratified by geographic region (North America versus ROW per IWRS) and Histology (SCC versus adenocarcinoma per IWRS) except for Geographics region (cemiplimab vs chemotherapy)

For Geographical region subgroups stratified by Histology (SCC versus adenocarcinoma IWRS) (

chemotherapy)

Source: Figure 14.2osall7.ema

Figure 26: Study 1676 - Forest plot for overall survival by subgroup (ITT)

Cemiplimab vs

<div style=\"page-break-after: always\"></div>

|                     |         | Cerri (Events/Total)Chermo (EventsT otal)   | Hazard Ratios (95% Cl)*   |                      |
|---------------------|---------|---------------------------------------------|---------------------------|----------------------|
| All Paticnt         |         | 269/304                                     |                           | 0.745 (0.625, 0.890) |
| Age group 1         |         |                                             |                           |                      |
| 65                  | 226/269 | 232/264                                     |                           | 0.791 (0.655, 0.955) |
| >=65                | 27/35   | 37/40                                       |                           | 0.450 (0.253, 0.801) |
| Face                |         |                                             |                           |                      |
| white               | 160/193 | 170/192                                     |                           | 0.708 (0.566 0.885)  |
| Non-white           | 89/107  | 92/105                                      |                           | 0.764 (0.562, 1.038) |
| Histology per       |         |                                             |                           |                      |
| I'wRS               |         |                                             |                           |                      |
| SCC                 | 197/239 | 214/238                                     |                           | 0.705 (0.578. 0.861) |
| Non-SCC             | 56/65   | 55/66                                       |                           | 0.912 (0.623, 1.335) |
| Geogaphic rejon     |         |                                             |                           |                      |
| goup 1              |         |                                             |                           |                      |
| North Ameica        | 27/32   | 27/34                                       |                           | 1.023 (0.592 1.768)  |
| Asia                | 71/83   | 71/83                                       |                           | 0.748 (0.533, 1.050) |
| Rest of w/orld      | 155/189 | 171/187                                     |                           | 0.706 (0.565, 0.883) |
| ECOG staus          |         |                                             |                           |                      |
| per IwRS            |         |                                             |                           |                      |
| 0                   | 116/146 | 125/146                                     |                           | 0.725 (0.558 0.943)  |
| 1                   | 137/158 | 144/158                                     |                           | 0.808 (0.631, 1.035) |
| Prior bey acizumab  |         |                                             |                           |                      |
| usepe IwRS          |         |                                             |                           |                      |
| Yes                 | 124/149 | 127/147                                     |                           | 0.733 (0.568, 0.945) |
| No                  | 129/155 | 142/157                                     |                           | 0.756 (0.590, 0.969) |
| # of prior lines of |         |                                             |                           |                      |
| sy sterric therapy  |         |                                             |                           |                      |
| for recurrent or    |         |                                             |                           |                      |
| disease             |         |                                             |                           |                      |
| 1 lins              | 143/177 | 152/169                                     |                           | 0.739 (0.582, 0.939) |
| >1 line             | 109/124 | 117/135                                     |                           | 0.718 (0.544, 0.949) |
| Disease Status      |         |                                             |                           |                      |
| Metastatic          | 241/284 | 258/290                                     |                           | 0.761 (0.635,0.912)  |
| Recurrent/Persisten | 12/20   | 11/14                                       |                           | 0.789 (0.328,1.898)  |
| Progressed after    |         |                                             |                           |                      |
| prior platinum      |         |                                             |                           |                      |
| <=6months           | 226/266 | 239/268                                     |                           | 0.799 (0.663, 0.963) |
| >6months            | 24/33   | 24/30                                       |                           | 0.374 (0.193, 0.728) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-off as of 04 Jan 2021.

*Stratified by geographic region (North America versus ROW per IWRS) and Histology (SCC versus adenocarcinoma per IWRS) except for Geographics region (cemiplimab vs chemotherapy) For Geographical region subgroups stratified by Histology (SCC versus adenoca rcinoma IWRS) (Cemiplimab vs chemotherapy)

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2pfs.all7

Figure 27: Study 1676 - Forest plot for progression free survival according to investigator by subgroup (ITT)

## Subgroup analyses - Efficacy by PD-L1 status:

Patients were recruited regardless of PD-L1 status. Exploratory analysis of tumour cell PD-L1 expression in available archival tumour samples was performed using the analytically validated immunohistochemistry (IHC) assay. The PD-L1 assay was performed by a third-party vendor (Roche, Ventana) using the SP263 antibody clone. Based on the assay vendor instructions for use, to preserve antigenicity, slides should have been stained within 6 months from the date that sections were mounted on slides. Slides that were &gt;6 months old were considered to be outside the optimal testing window.

Table 46: Study 1676 - Baseline PD-L1 status per Ventana SP263 (ITT)

|                  | Cemiplimab (N=304)   | Chemotherapy (N=304)   | Total (N=608)   |
|------------------|----------------------|------------------------|-----------------|
| Total Population |                      |                        |                 |
| Without PD-L1    | 178 (58.6%)          | 176 (57.9%)            | 354 (58.2%)     |
| With PD-L1       | 126 (41.4%)          | 128 (42.1%)            | 254 (41.8%)     |
| TC ≥1%           | 82 (27.0%)           | 80 (26.3%)             | 162 (26.6%)     |
| TC <1%           | 44 (14.5%)           | 48 (15.8%)             | 92 (15.1%)      |

Data cut-off as of 04 Jan 2021.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.2.5all, 14.1.2.5scc, 14.1.2.5.ade

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-off as of 04 Jan 2021.

*Stratified by geographical region (North America vs Asia vs ROW per IWRS) and Histology (SCC vs AC IWRS) (cemiplimab vs chemotherapy).

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2.1.5all

Figure 28: Study 1676 - Forest plot of overall survival by PD-L1 expression (ITT)

<!-- image -->

Data cut-off as of 04 Jan 2021.

*Stratified by geographical region (North America vs Asia vs ROW per IWRS) and Histology (SCC vs AC IWRS) (cemiplimab vs chemotherapy).

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTF 14.2.2.4all

Figure 29: Study 1676 - Forest plot of progression free survival according to investigator by PD-L1 expression (ITT)

<div style=\"page-break-after: always\"></div>

Table 47: Updated Overall Survival by PD-L1 expression in patients with SCC and Non-SCC histology (Full Analysis Set [N=254] 1 )

<!-- image -->

2. Patients without PD-L1 samples
3. Patients with PD-L1 samples

[a] Based on Kaplan-Meier method.

[b] Based on geographic region (North America versus Asia versus ROW per IWRS) and Histology (SCC versus adenocarcinoma per IWRS) stratified proportional hazards model (cemiplimab vs chemotherapy).

SSC, Squamous cell carcinoma;  PD -L1, Programmed death-ligand 1;  CI , Confidence Interval

Source: PTT 14.2.1.6all (datacut 4 January 2022) and Study 1676 Primary Analysis CSR PTT 14.2.1.6all (datacut 4 January 2021)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cut-offasofJan4,2022

Figure 30: Study 1676 - Kaplan-Meier Curve of Overall Survival by PD-L1 Expression per Tumor Cell Method, (n=254, Biomarker Available Set): 1 Year Update Analysis

<div style=\"page-break-after: always\"></div>

## Subgroup analyses - Efficacy in patients treated with cemiplimab beyond PD

70 patients form the cemiplimab arm (70 out of 304, 23%) fulfilled the conditions for treatment with cemiplimab beyond documentation of PD.

Table 48: Overall Survival (FAS) - Patients Treated Beyond Progression Versus Those Who Were Not (Patients with SCC and non-SCC Histology)

|                                                 | Cemiplimab treated beyond progression (N=70)   | Cemiplimab not treated beyond progression (N=234)   |
|-------------------------------------------------|------------------------------------------------|-----------------------------------------------------|
| Number of deaths, n (%)                         | 42 (60.0%)                                     | 142 (60.7%)                                         |
| Number of censored patients, n (%)              | 28 (40.0%)                                     | 92 (39.3%)                                          |
| Median (95% CI), (months)[a] HR (95% CI) [b][c] | 13.9 (11.7, 17.9) 0.798 (0.559, 1.141)         | 10.5 (8.2, 12.9)                                    |
| Estimated Survival Probability , %(95% CI)[a]   |                                                |                                                     |
| 6 months                                        | 79.8 (68.3, 87.5)                              | 66.5 (60.0, 72.2)                                   |
| 12 months                                       | 62.6 (49.8, 73.1)                              | 46.4 (39.5, 53.0)                                   |
| 18 months                                       | 36.7 (24.0, 49.5)                              | 32.8 (25.7, 40.0)                                   |
| 24 months                                       | 24.7 (13.0, 38.5)                              | 23.9 (16.2, 32.3)                                   |
| 30 months                                       | NE ( NE, NE)                                   | 23.9 (16.2, 32.3)                                   |
| 36 months                                       | NE ( NE, NE)                                   | NE ( NE, NE)                                        |

Data cut-off as of Jan 4th, 2021.

[a] Based on Kaplan-Meier method.

[b] Stratified by geographic region (North America versus Asia versus ROW) and Histology (SCC versus

adenocarcinoma) according to IWRS.

[c] Based on stratified proportional hazards model (cemiplimab vs chemotherapy).

Source: Table 14.2.1.1all.ema.ir1.q8

<div style=\"page-break-after: always\"></div>

Sensitivity analyses:

Table 49: Study 1676 - Sensitivity analysis of OS by censoring patients with any posttreatment immune checkpoint inhibitors

|                                                                     | Cemiplimab (N=304)           | Chemotherapy (N=304)   |
|---------------------------------------------------------------------|------------------------------|------------------------|
| Number of deaths,n (%)                                              | 180 (59.2%)                  | 184 (60.5%)            |
| Number of censored patients, n (%)                                  | 124 (40.8%)                  | 120 (39.5%)            |
| Median (95%C1), (months)[a]                                         | 12.1(10.3,13.8)              | 8.5 (7.5, 9.6)         |
| Stratified log-rank test one-sided p-value [b][c] HR (95% C1) [b][] | 0.00018 0.684 (0.554, 0.844) |                        |
| Estimated Survival Probability , % (95% CI)[a]                      |                              |                        |
| 6months                                                             | 69.9 (64.3,74.7)             | 66.5 (60.4, 71.9)      |
| 12months                                                            | 50.6 (44.5, 56.4)            | 32.6 (26.4, 39.0)      |
| 18months                                                            | 33.7 (27.3, 40.1)            | 15.9 (10.6, 22.3)      |
| 24months                                                            | 24.4 (17.8, 31.7)            | 10.5 (5.0,18.2)        |
| 30months                                                            | 24.4 (17.8, 31.7)            | NE( NE, NE)            |
| 36months                                                            | NE( NE, NE)                  | NE( NE, NE)            |

Source: Post text-tables, page 1197/1482

Data cut-off as of Jan 4th, 2021

The purpose of prespecifying a rank preserving structural failure time (RPSFT) sensitivity analysis on OS was to remove the crossover treatment benefit in the chemotherapy arm in the case that many patients in the chemotherapy arm crossed over to PD-1/PD-L1 treatment outside of this study. Given only 15.1% patients in the chemotherapy arm received post-progression PD-L1 treatment outside of the study, this analysis was not performed after database lock. Nevertheless, the MAH provided the results of this analysis upon request.

Table 50: Sensitivity Analysis of OS Using RPSFT Method (FAS) Patients with SCC and non-SCC Histology

|                                                                                                   | Cemiplimab (N=304)                             | Reconstructed Chemotherapy (N=304)   |
|---------------------------------------------------------------------------------------------------|------------------------------------------------|--------------------------------------|
| Psi                                                                                               | -0.3705                                        |                                      |
| Exp(Psi)                                                                                          | 0.6904                                         |                                      |
| Number of deaths, n (%)                                                                           | 184 (60.5%)                                    | 181 (59.5%)                          |
| Number of censored patients, n (%)                                                                | 120 (39.5%)                                    | 123 (40.5%)                          |
| Median (95% CI), (months)[a] Stratified log-rank test one-sided p-value [b][c] HR (95% CI) [b][d] | 12.0 (10.3, 13.5) 0.00010 0.670 (0.542, 0.829) | 8.4 (7.5, 9.4)                       |
| Estimated Survival Probability , %(95% CI)[a]                                                     |                                                |                                      |
| 6 months                                                                                          | 69.6 (64.0, 74.5)                              | 65.3 (59.4, 70.6)                    |
| 12 months                                                                                         | 50.2 (44.1, 56.0)                              | 30.8 (24.6, 37.2)                    |
| 18 months                                                                                         | 33.4 (27.2, 39.7)                              | 15.8 ( 9.5, 23.5)                    |
| 24 months                                                                                         | 23.6 (17.1, 30.6)                              | NE ( NE, NE)                         |
| 30 months                                                                                         | 23.6 (17.1, 30.6)                              | NE ( NE, NE)                         |
| 36 months                                                                                         | NE ( NE, NE)                                   | NE ( NE, NE)                         |

Data cut-off as of Jan 4th, 2021.

[a] Based on Kaplan-Meier method.

<div style=\"page-break-after: always\"></div>

| Cemiplimab   | Reconstructed Chemotherapy   |
|--------------|------------------------------|
| (N=304)      | (N=304)                      |

[b] Stratified by geographic region (North America versus Asia versus ROW) and Histology (SCC versus adenocarcinoma) according to IWRS.

[c] One-sided p-value converted from stratified log-rank test two-sided p-value.

[d] Based on stratified proportional hazards model (cemiplimab vs chemotherapy).

Source: Table 14.2.1.1all.rpsft

Table 51: Study 1676 - Sensitivity analysis of PFS including subsequent anticancer therapy as PFS event

|                                                                      | Cemiplimab (N=304)          | Chemotherapy (N=304)   |
|----------------------------------------------------------------------|-----------------------------|------------------------|
| Number ofevents, n (%)                                               | 254 (83.6%)                 | 276 (90.8%)            |
| Progressive Disease, n (%)                                           | 211 (69.4%)                 | 209 (68.8%)            |
| Number of deaths,n (%)                                               | 31 (10.2%)                  | 42 (13.8%)             |
| Subsequent Anti-Cancer Therapy,n (%)                                 | 12 (3.9%)                   | 25 (8.2%)              |
| Number ofcensored patients,n(%)                                      | 50 (16.4%)                  | 28 (9.2%)              |
| Median (95% CI), (months)[a]                                         | 2.8 (2.6, 3.8)              | 2.8 (2.6, 3.0)         |
| Stratified log-rank test one-sided p-value [b][c] HR (95% C1) [b][d] | 0.00004 0.706 (0.592,0.841) |                        |
| Estimated Event-Free Probability ,%(95%CI)[a]                        |                             |                        |
| 6months                                                              | 31.1 (25.9, 36.4)           | 18.3 (14.0, 23.0)      |
| 12 months                                                            | 18.5 (14.2, 23.4)           | 5.5(3.2,8.8)           |
| 18months                                                             | 12.7(8.7,17.5)              | 1.2(0.3, 3.5)          |
| 24months                                                             | 10.2 (6.4,15.1)             | NE( NE, NE)            |
| 30months                                                             | 8.1 (4.1, 14.0)             | NE( NE, NE)            |
| 36months                                                             | NE( NE, NE)                 | NE(NE, NE)             |

Source: Post text-tables, page 1237/1482

Data cut-off as of Jan 4th, 2021

Table 52: Study 1676 - Sensitivity analysis of PFS including clinical progression as PFS event

|                                                                      | Cemiplimab (N=304)          | Chemotherapy (N=304)   |
|----------------------------------------------------------------------|-----------------------------|------------------------|
| Number ofevents, n (%)                                               | 254 (83.6%)                 | 275 (90.5%)            |
| Progressive Disease - Radiographic, n (%)                            | 210 (69.1%)                 | 211 (69.4%)            |
| Progressive Disease -Clinical,n (%)                                  | 19 (6.3%)                   | 34 (11.2%)             |
| Number of deaths,n (%)                                               | 25 (8.2%)                   | 30(9.9%)               |
| Number of censored patients, n (%)                                   | 50 (16.4%)                  | 29 (9.5%)              |
| Median (95%C1),(months)[a]                                           | 2.7 (2.5, 3.4)              | 2.8 (2.6, 3.0)         |
| Stratified log-rank test one-sided p-value [b][c] HR (95% C1) [b][d] | 0.00010 0.719 (0.603,0.857) |                        |
| Estimated Event-Free Probability , % (95% CI)[a]                     |                             |                        |
| 6months                                                              | 31.4 (26.3, 36.7)           | 19.7 (15.3, 24.5)      |
| 12months                                                             | 18.6 (14.2, 23.4)           | 5.2(3.0, 8.5)          |
| 18months                                                             | 13.3 (9.2, 18.1)            | 0.9 (0.1, 3.7)         |
| 24months                                                             | 9.9 (6.1, 14.8)             | NE( NE, NE)            |
| 30months                                                             | 7.9 (3.9,13.8)              | NE( NE, NE)            |
| 36months                                                             | NE( NE, NE)                 | NE( NE, NE)            |

Source: Post-text tables, page 1240/1482

Data cut-off as of Jan 4th, 2021

<div style=\"page-break-after: always\"></div>

## Summary of main study(ies)

The following table summarises the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 21: Summary of Efficacy for Study 1676

| R2810-ONC-1676: An open-label, randomised, phase III clinical trial of cemiplimab vs. investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma   | R2810-ONC-1676: An open-label, randomised, phase III clinical trial of cemiplimab vs. investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma   | R2810-ONC-1676: An open-label, randomised, phase III clinical trial of cemiplimab vs. investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma   | R2810-ONC-1676: An open-label, randomised, phase III clinical trial of cemiplimab vs. investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma                                                                                                                                                | R2810-ONC-1676: An open-label, randomised, phase III clinical trial of cemiplimab vs. investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma                                                                                                                                                | R2810-ONC-1676: An open-label, randomised, phase III clinical trial of cemiplimab vs. investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                            | EudraCT number 2017-000350-19; IND number 133224; NCT03257267                                                                                                               | EudraCT number 2017-000350-19; IND number 133224; NCT03257267                                                                                                               | EudraCT number 2017-000350-19; IND number 133224; NCT03257267                                                                                                                                                                                                                                                            | EudraCT number 2017-000350-19; IND number 133224; NCT03257267                                                                                                                                                                                                                                                            | EudraCT number 2017-000350-19; IND number 133224; NCT03257267                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                      | Phase III, multicentre, open-label, randomised 1:1, active control. Cross-over not allowed.                                                                                 | Phase III, multicentre, open-label, randomised 1:1, active control. Cross-over not allowed.                                                                                 | Phase III, multicentre, open-label, randomised 1:1, active control. Cross-over not allowed.                                                                                                                                                                                                                              | Phase III, multicentre, open-label, randomised 1:1, active control. Cross-over not allowed.                                                                                                                                                                                                                              | Phase III, multicentre, open-label, randomised 1:1, active control. Cross-over not allowed.                                                                                                                                                                                                                              |
|                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase:                                                                                                                           | Duration of main phase: Duration of Run-in phase:                                                                                                                           | Not applicable, event driven Not applicable Not applicable                                                                                                                                                                                                                                                               | Not applicable, event driven Not applicable Not applicable                                                                                                                                                                                                                                                               | Not applicable, event driven Not applicable Not applicable                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                                                  | Duration of Superiority                                                                                                                                                     | Extension phase:                                                                                                                                                            | Duration of Superiority                                                                                                                                                                                                                                                                                                  | Duration of Superiority                                                                                                                                                                                                                                                                                                  | Duration of Superiority                                                                                                                                                                                                                                                                                                  |
| Treatment groups                                                                                                                                                            | Cemiplimab arm                                                                                                                                                              | Cemiplimab arm                                                                                                                                                              | Cemiplimab 350 mg IV Q3W for up to 96W n=304                                                                                                                                                                                                                                                                             | Cemiplimab 350 mg IV Q3W for up to 96W n=304                                                                                                                                                                                                                                                                             | Cemiplimab 350 mg IV Q3W for up to 96W n=304                                                                                                                                                                                                                                                                             |
| Treatment groups                                                                                                                                                            | Investigator's choice chemotherapy arm                                                                                                                                      | Investigator's choice chemotherapy arm                                                                                                                                      | Investigator's choice chemotherapy, for up to 96W; n=304 • Pemetrexed 500 mg/m 2 Q3W; n=111 • Topotecan 1.0 mg/m 2 on days 1-5 Q3W; n=21 • Irinotecan 100 mg/m 2 weekly x4 followed by 10-14 days rest Q42D; n=19 • Gemcitabine 1000 mg/m 2 on days 1 and 8 Q3W; n=121 • Vinorelbine 30 mg/m 2 on days 1 and 8 Q3W; n=32 | Investigator's choice chemotherapy, for up to 96W; n=304 • Pemetrexed 500 mg/m 2 Q3W; n=111 • Topotecan 1.0 mg/m 2 on days 1-5 Q3W; n=21 • Irinotecan 100 mg/m 2 weekly x4 followed by 10-14 days rest Q42D; n=19 • Gemcitabine 1000 mg/m 2 on days 1 and 8 Q3W; n=121 • Vinorelbine 30 mg/m 2 on days 1 and 8 Q3W; n=32 | Investigator's choice chemotherapy, for up to 96W; n=304 • Pemetrexed 500 mg/m 2 Q3W; n=111 • Topotecan 1.0 mg/m 2 on days 1-5 Q3W; n=21 • Irinotecan 100 mg/m 2 weekly x4 followed by 10-14 days rest Q42D; n=19 • Gemcitabine 1000 mg/m 2 on days 1 and 8 Q3W; n=121 • Vinorelbine 30 mg/m 2 on days 1 and 8 Q3W; n=32 |
| Endpoints and definitions                                                                                                                                                   | Primary                                                                                                                                                                     | OS                                                                                                                                                                          | Time from randomisation to the date of death by any cause.                                                                                                                                                                                                                                                               | Time from randomisation to the date of death by any cause.                                                                                                                                                                                                                                                               | Time from randomisation to the date of death by any cause.                                                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                   | Secondary                                                                                                                                                                   | INV-PFS                                                                                                                                                                     | Time from randomisation to the date of the first documented tumour progression using RECIST 1.1 per investigator assessment, or death due to any cause.                                                                                                                                                                  | Time from randomisation to the date of the first documented tumour progression using RECIST 1.1 per investigator assessment, or death due to any cause.                                                                                                                                                                  | Time from randomisation to the date of the first documented tumour progression using RECIST 1.1 per investigator assessment, or death due to any cause.                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                   | Secondary                                                                                                                                                                   | INV-ORR                                                                                                                                                                     | Number of patients with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) using RECIST 1.1 per investigator assessment divided by the number of patients in the efficacy analysis set.                                                                                          | Number of patients with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) using RECIST 1.1 per investigator assessment divided by the number of patients in the efficacy analysis set.                                                                                          | Number of patients with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) using RECIST 1.1 per investigator assessment divided by the number of patients in the efficacy analysis set.                                                                                          |
| Database lock                                                                                                                                                               | 18-FEB-2021                                                                                                                                                                 | 18-FEB-2021                                                                                                                                                                 | 18-FEB-2021                                                                                                                                                                                                                                                                                                              | 18-FEB-2021                                                                                                                                                                                                                                                                                                              | 18-FEB-2021                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                             | Results and Analysis                                                                                                                                                        | Results and Analysis                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                     |
| Analysis description                                                                                                                                                        |                                                                                                                                                                             |                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                          |
| Analysis population and time point description                                                                                                                              | ITT (N=608) at data cutoff 04-JAN-2021                                                                                                                                      | ITT (N=608) at data cutoff 04-JAN-2021                                                                                                                                      | ITT (N=608) at data cutoff 04-JAN-2021                                                                                                                                                                                                                                                                                   | ITT (N=608) at data cutoff 04-JAN-2021                                                                                                                                                                                                                                                                                   | ITT (N=608) at data cutoff 04-JAN-2021                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                             | Treatment group                                                                                                                                                             | Treatment group                                                                                                                                                             | Cemiplimab arm                                                                                                                                                                                                                                                                                                           | Cemiplimab arm                                                                                                                                                                                                                                                                                                           | Investigator's choice chemotherapy arm                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                             | Number of subjects                                                                                                                                                          | Number of subjects                                                                                                                                                          | 304                                                                                                                                                                                                                                                                                                                      | 304                                                                                                                                                                                                                                                                                                                      | 304                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                             | OS, patients with event (%)                                                                                                                                                 | OS, patients with event (%)                                                                                                                                                 | 184 (60.5)                                                                                                                                                                                                                                                                                                               | 184 (60.5)                                                                                                                                                                                                                                                                                                               | 211 (69.4)                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                             | Median OS a , months                                                                                                                                                        | Median OS a , months                                                                                                                                                        | 12.0                                                                                                                                                                                                                                                                                                                     | 12.0                                                                                                                                                                                                                                                                                                                     | 8.5                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                             | 95% CI                                                                                                                                                                      | 95% CI                                                                                                                                                                      | 10.3, 13.5                                                                                                                                                                                                                                                                                                               | 10.3, 13.5                                                                                                                                                                                                                                                                                                               | 7.5, 9.6                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                             | INV-PFS, patients with event (%)                                                                                                                                            | INV-PFS, patients with event (%)                                                                                                                                            | 253 (83.2)                                                                                                                                                                                                                                                                                                               | 253 (83.2)                                                                                                                                                                                                                                                                                                               | 269 (88.5)                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                             | Median INV-PFS a , months                                                                                                                                                   | Median INV-PFS a , months                                                                                                                                                   | 2.8                                                                                                                                                                                                                                                                                                                      | 2.8                                                                                                                                                                                                                                                                                                                      | 2.9                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                             | 95% CI                                                                                                                                                                      | 95% CI                                                                                                                                                                      | 2.6, 3.9                                                                                                                                                                                                                                                                                                                 | 2.6, 3.9                                                                                                                                                                                                                                                                                                                 | 2.7, 3.4                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                             | INV-ORR (n)                                                                                                                                                                 | INV-ORR (n)                                                                                                                                                                 | 16.4 (50)                                                                                                                                                                                                                                                                                                                | 16.4 (50)                                                                                                                                                                                                                                                                                                                | 6.3 (19)                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                             | 95% CI                                                                                                                                                                      | 95% CI                                                                                                                                                                      | 12.5, 21.1                                                                                                                                                                                                                                                                                                               | 12.5, 21.1                                                                                                                                                                                                                                                                                                               | 3.8, 9.6                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                                                                                                                                              |                                                                                                                                                                             |                                                                                                                                                                             | Comparison Cemiplimab arm vs. investigator's choice                                                                                                                                                                                                                                                                      | Comparison Cemiplimab arm vs. investigator's choice                                                                                                                                                                                                                                                                      | Comparison Cemiplimab arm vs. investigator's choice                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                                                                                                                                              | groups Stratified                                                                                                                                                           | groups Stratified                                                                                                                                                           | HR b                                                                                                                                                                                                                                                                                                                     | chemotherapy arm                                                                                                                                                                                                                                                                                                         | chemotherapy arm                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                                                                                                                                              | OS 95%                                                                                                                                                                      | OS 95%                                                                                                                                                                      | CI                                                                                                                                                                                                                                                                                                                       | 0.685                                                                                                                                                                                                                                                                                                                    | 0.685                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                                                                                                                                              |                                                                                                                                                                             |                                                                                                                                                                             | P-value c                                                                                                                                                                                                                                                                                                                | 0.560, 0.838 0.00011                                                                                                                                                                                                                                                                                                     | 0.560, 0.838 0.00011                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                                                                                                                                              | INV-PFS groups                                                                                                                                                              | INV-PFS groups                                                                                                                                                              | Comparison                                                                                                                                                                                                                                                                                                               | Cemiplimab arm vs. investigator's choice chemotherapy arm                                                                                                                                                                                                                                                                | Cemiplimab arm vs. investigator's choice chemotherapy arm                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | Stratified HR b   | 0.745                                                     |
|---------|-------------------|-----------------------------------------------------------|
|         | 95% CI            | 0.625, 0.890                                              |
|         | P-value c         | 0.00048                                                   |
| INV-ORR | Comparison groups | Cemiplimab arm vs. investigator's choice chemotherapy arm |
| INV-ORR | Odds ratio d      | 2.984                                                     |
| INV-ORR | 95% CI e          | 1.707, 5.215                                              |
| INV-ORR | P-value           | 0.00004                                                   |

## Notes:

a  Based on Kaplan-Meier method

b  Based on stratified proportional hazards model (cemiplimab vs. chemotherapy), stratification by geographic region

(North America vs Asia vs. ROW) and histology (SCC vs. AC) according to IWRS

c  1-sided p-value converted from stratified log-rank test two-sided p-value

d  Using geographic region and histology stratified Cochran-Mantel-Haenszel test

e  Clopper-Pearson exact confidence interval

## Supportive study - Study 1423

Study 1423 was the first-in-human (FIH) study of cemiplimab.  Planned treatment duration was 48 weeks, followed by a post-treatment follow-up period of approximately 5.5 months. The protocol contained a dose escalation portion and 25 expansion cohorts. The three cervical cancer patients in the dose escalation portion were not discussed as they received different doses of cemiplimab to the dose used in the expansion phase. Expansion cohorts 23 and 24 (EXP23 and EXP24) were designed to obtain additional clinical experience with cemiplimab in patients with relapsed/metastatic cervical cancer. Ten patients were enrolled in EXP23 and received 3 mg/kg cemiplimab IV every 2 weeks (Q2W) and 10 patients enrolled in EXP24 and received 3 mg/kg cemiplimab IV Q2W + radiation therapy (RT).

## Disposition, Demographics, and Baseline Characteristics

In EXP23, 9 out of 10 patients discontinued treatment prior to the analysis cut-off date with the main reason being disease progression/recurrence. The median age of the patients in EXP23 was 51.5 years (range: 31 to 76 years), 90% were white, all patients had an ECOG performance status of 0 (40.0%) or 1 (60.0%), and all patients had received prior cancer-related systemic therapy.

In EXP24, all 10 patients discontinued treatment prior to (or by) analysis cut-off date with the main reason being disease progression/recurrence. The median age of the patients in EXP24 was 48.6 years (range: 29 to 65 years), 8 patients were white, 1 black or African American and 1 Asian. All patients had an ECOG performance status of 0 (20.0%) or 1 (80.0%), and all patients had received prior cancerrelated systemic therapy and 8 out of 10 had prior cancer-related radiotherapy.

## Efficacy Results

The data cut-off date for this efficacy analysis was 30 April 2019.  All efficacy results were per investigator assessment. Patients were not tested for PD-L1 status prior to being randomized on the study.

The ORR for patients in EXP23 was 10.0% (1/10) and in EXP24 was 10.0% (1/10), partial responses in both cases.

The observed estimated DOR was 11.2 months for the responder in EXP23 and 6.4 months for the responder in EXP24.

The KM estimation of median PFS by investigator assessment was 1.9 months (95% CI [1.0, 9.0]) for EXP23 and 3.6 months (95% CI [0.6, 5.7]) for EXP24.

The KM estimation of median OS for EXP23 was 10.3 (2.1, NE) months; median OS for EXP24 was 8.0 (1.7, NE).

Combining the dose escalation portion of the study, in which objective responses were observed in 2 of 3

<div style=\"page-break-after: always\"></div>

cervical cancer patients per investigator assessment with cervical cancer EXP23 and EXP24, there were 4 responses among 23 cervical cancer patients. All 4 responses were in patients with squamous tumor histology.

## 2.4.2. Discussion on clinical efficacy

The MAH for cemiplimab, an anti-PD-1 immune checkpoint inhibitor, seeks an extension of indication to treat adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy . The application is based on results from Study 1676, an open-label, randomised 1:1, phase III trial that compared cemiplimab monotherapy vs. investigator's choice of chemotherapy (pemetrexed or topotecan or irinotecan or gemcitabine or vinorelbine) in women with recurrent or metastatic cervical cancer after progression to platinum-based chemotherapy with or without bevacizumab.

In study 1676, 608 patients were randomised between November 2017 and July 2020. Subjects were recruited regardless of PD-L1 expression status, but only squamous cell carcinoma (SCC) or adenocarcinoma/adenosquamous carcinoma (AC) histologies were allowed. The primary endpoint was overall survival (OS). Secondary endpoints were PFS, ORR, DOR and QoL.

## Design and conduct of clinical studies

The design of this pivotal trial was discussed with the CHMP via a scientific advice (SA) procedure in April 2017. Given the diverse treatment options in the control arm, the open-label nature of the trial was considered acceptable, as were the primary and secondary endpoints, frequency of response assessments, stratification factors and statistical analysis plan (SAP). ECOG PS was added as a stratification factor as of Amendment 2, but it was not to be included in the primary analysis model for efficacy. A cap on enrollment of AC histology was added as of Amendment 5 and sample size was changed accordingly.

Study participants: Inclusion/exclusion criteria appropriately reflect the population intended for treatment with cemiplimab.

As of Amendment 4 of the protocol (16-AUG-2018), the term 'platinum-refractory', defined as progressive disease within 6 months of last dose of platinum therapy, was removed from the protocol. Subsequently, the eligibility requirement regarding prior platinum therapy (inclusion criterion #2) stated that tumour progression or recurrence should have occurred after treatment with cisplatin or carboplatin. Nevertheless, the applicant clarified that 55% (331 out of 608) of patients recruited in Study 1676 discontinued platinum-based chemotherapy due to progression while on treatment, which justifies the proposed indication. No other important amendments to inclusion/exclusion criteria that would alter the B/R of cemiplimab in the intended indication were done along conduct of the pivotal study.  Treatments: All five choices of chemotherapy in the control arm are deemed acceptable. The regimen of cemiplimab in the experimental arm corresponds to the currently authorised dose and schedule and is considered acceptable (see discussion on clinical pharmacology). The fact that crossover was not allowed to avoid confounding survival is reasonable, noting that a sensitivity analysis of OS that censored patients who had received post-treatment immune checkpoint inhibitors was consistent with the primary analysis.

Endpoints: The objectives and endpoints of Study 1676 are deemed adequate for the targeted setting. Despite the open-label nature of the trial, considering the unmet medical need of the intended population (≥2L, low response rates from other products) and the fact that the primary endpoint is OS, response assessment by investigator is considered reasonable. The fact that PROs were collected is acknowledged, but since their clinical relevance in an open-label trial remains questionable, inclusion of their results in section 5.1 of the SmPC is not endorsed.

<div style=\"page-break-after: always\"></div>

Statistical methods: Sample size calculations are endorsed. The stratification factors (histology, geographic region, prior bevacizumab and ECOG PS) are clinically relevant and thus acceptable. Since prior bevacizumab and ECOG PS were not included in the statistical tests of OS and PFS, sensitivity analyses were provided (data not shown), along with the planned RPSFT analysis for OS. In both cases, results were concordant with those from the primary analysis. The statistical approach to control type I error due to multiple looks (2 IAs + final analysis) and testing of diverse hypotheses is endorsed. The SCC subpopulation (n=477) was prioritised over the ITT (N=608) across testing of all efficacy endpoints (OS, PFS, ORR). The requested indication does not specify histology, but this is acceptable when considering favourable results across both ITT and SCC. Changes to the SAP followed major amendments of the protocol which is acceptable.

Regarding the recruitment of patients with adenocarcinoma (AC) histology, capped as of Amendment 5 (08-MAR-2019), the MAH clarified that these patients have longer follow-up than those with SCC. There were no major changes in standard of care for AC patients after March 2019 and therefore patients with AC recruited before March 2019 are expected to be representative of those recruited afterwards.

Participant flow and recruitment: A total of 752 patients were screened for eligibility. Most of screen failures (87% out of 144) were due to not meeting inclusion/exclusion criteria. The screen failure rate (19%) is acceptable. 304 patients were randomised to cemiplimab and 304 to chemotherapy. 3% of patients from the ITT were randomised but never treated. It is not expected that this low proportion will impact the interpretation of efficacy endpoints. The unbalance among arms (13 in the chemotherapy arm vs 5 in cemiplimab) is understandable due to the open-label nature of the trial. From the patients randomised to chemotherapy, the preferred agents in decreasing order were: gemcitabine (40%), pemetrexed (37%), vinorelbine (10%), topotecan (7%) and irinotecan (6%). Median follow-up since randomisation (~18 months) was balanced between arms. At data cutoff date (4-JAN-2021), 78% of patients had been followed up for ≥ 12 months since randomisation.

Conduct of the study: Major protocol violations were scant and treatment-related: lack or reconsenting for continuing treatment beyond PD in the cemiplimab arm or SAEs reported ≥24h were the most frequent causes. Regarding major protocol amendments, the rationale to cap enrolment of patients with AC is not entirely followed. However, the overall proportions of SCC and AC in Study 1676 were consistent with global distribution of cervical cancer histologies and no significant differences in efficacy according to histology were seen. Two interim analyses were introduced late (06-MAY-2020) compared to the start of the study (05-SEP-2017) and close to the database lock (18-FEB-2021), apparently to provide an opportunity for an early efficacy analysis, but they were performed by an independent statistician prior to review by the IDMC.

Baseline data: Median age was 51 years (22 to 87 years); 63% were white, 29% asian, 3.5% black; 92% had received previous paclitaxel, while 49% had received prior bevacizumab; 47% had ECOG PS 0; 78% had SCC histology and 22% AC. Regarding the extent of disease at randomisation, 94% of patients had metastatic disease, while the remaining 6% had recurrent or persistent disease. The overall burden and distribution of disease according to RECIST 1.1 data is balanced between both arms of the trial. 43% had &gt;1 prior line of treatment in the recurrent or metastatic setting.

Patients from both arms seem to be balanced according to the period after prior platinum ( ≤ 6 months vs. &gt;6 months) and specific platinum compound (i.e., carboplatin, cisplatin). About 88% of patients had a platinum-f ree interval (PFI) ≤6 months. Tables that detail the platinum -free interval (PFI) by longest and shortest duration (some of them were re-treated with platinum) showed a balanced distribution between both arms of Study 1676. An ad hoc analysis of efficacy in terms of OS/PFS/ORR/DOR according to PFI (not presented in this report) suggest that the benefit of cemiplimab over chemotherapy seems to be maintained regardless of the time interval to progression after prior platinum therapy, even in the ≥12 months subgroup (for which retreatment with platinum could potentially be a choice).

<div style=\"page-break-after: always\"></div>

Discordances between stratification factors according to IWRS and clinical database were scarce (data not shown) and thus not expected to impact interpretation of efficacy results.

Overall, the baseline demographic and disease characteristics were consistent with inclusion/exclusion criteria and reflect the targeted population for treatment with cemiplimab.

## Efficacy data and additional analyses

OS: At data cutoff 04-JAN-2021 and with a median follow-up of 18.2 months, 395 deaths had occurred (65% of OS maturity) in the ITT population of Study 1676. The study met its primary endpoint, since the HR for OS showed superiority of cemiplimab over investigator's choice of chemotherapy in both SCC population [HR for OS 0.73 (95% CI 0.58, 0.91), p-value 0.00306] and ITT [HR for OS 0.68 (95% CI 0.56, 0.84), p-value 0.00011], as prespecified in hierarchical testing. The AC histology population representing 22% of the ITT population also exhibited a survival benefit, with an exploratory HR of 0.56 (95% CI 0.36, 0.85). For the ITT, K-M estimates of median OS were 12.0 months in the cemiplimab arm and 8.5 months in the chemotherapy arm. A median survival improvement of 4.5 months is considered a clinically relevant achievement of cemiplimab in the targeted advanced cervical cancer population.

In an updated exploratory OS analysis (data cut-off 04-JAN-2022) with median follow-up of 30.2 months and 76% of event maturity, the survival benefit from cemiplimab over chemotherapy was maintained (HR: 0.66, 95% CI 0.55, 0.79).

INV-assessed PFS: At considerable event maturity (86%) in the ITT, PFS was also statistically improved in the cemiplimab vs. the chemotherapy arm: HR 0.745 (95% CI 0.625, 0.89), p-value 0.00048. K-M estimates of PFS were almost equivalent in both arms (2.8 months in cemiplimab, 2.9 months in chemotherapy) as curves separated after the third month. This pattern of 'delayed' PFS benefit (i.e. less pronounced PFS improvement than OS improvement) has been seen with other immune checkpoint inhibitors, particularly for tumour types that exhibit high aggressiveness, e.g. extensive-stage small cell lung cancer (IMpower133, Horn et al, NEJM 2018; CASPIAN, Paz-Ares et al, Lancet 2019). Considering one third of patients from the cemiplimab arm and almost half from the chemotherapy arm received posttrial treatment anticancer systemic therapy, a PFS2 analysis would have been of value. However, time-toevent data for a PFS2 analysis are not available according to the MAH. Cytotoxic agents constituted the majority of post-trial treatments in both arms, although, expectably, a higher proportion of monoclonal antibodies (almost all immune checkpoint inhibitors) was used in the chemotherapy arm (60 patients, 20%) as compared to the cemiplimab arm (17 patients, 6%).

INV-assessed ORR/DOR: Acknowledging the advanced post-platinum setting, low response rates were observed in both arms: 16.4% in the cemiplimab arm vs. 6.3% in the chemotherapy arm, although a statistically significant CMH test was observed. Likewise, the few responses were more durable in the cemiplimab arm (mDOR 16.4 months, vs. 6.9 in the chemotherapy arm).

Ancillary analyses: OS and PFS advantage from cemiplimab over chemotherapy was observed across almost all the prespecified subgroups. Although the HR for OS in the recurrent/persistent subgroup exceeded 1, this subpopulation consisted of only 34 patients with 17 events.

Efficacy by PD-L1 status: An exploratory analysis on the relationship between PD-L1 expression according to the SP263 IHC assay and efficacy in terms of OS, PFS and ORR was done for a subgroup of the population of Study 1676. Evaluable samples were available for 254 patients (42%) from the ITT and balanced between arms.

Among these samples, 64% were PD-L1 ≥ 1% and 36% were PD-L1&lt;1%. At the updated exploratory OS analysis on 04-JAN-2022, the hazard ratio for the PD-L1 ≥ 1% group was 0.70 (95% CI: 0.48, 1.01) and 0.85 (95% CI: 0.53, 1.36) for the PD-L1&lt;1% group. Upon these data, it appears that the efficacy estimate is also compatible with benefit in the underpowered PD-L1&lt;1% subgroup; moreover, given what

<div style=\"page-break-after: always\"></div>

is known about PD-1 inhibitors, a detrimental effect of cemiplimab in the present treatment setting is not considered likely.

The evaluation of efficacy in subgroups is generally fraught with difficulty given that these will generally not be large enough for independent efficacy inferences. In an overall positive study, it is considered acceptable to use the most mature -and therefore statistically powerful- dataset to evaluate the impact of treatment in subgroups. While the pivotal study was overall positive, the magnitude of efficacy in subgroups indicate that also in this treatment setting PD-L1 expression is a relevant effect modifier.

Recognising that efficacy will increase with increasing PD-L1 expression, this is understood as a continuum, and it seems reasonable not to restrict use based on PD-L1 expression levels. OS by PD-L1 status, however, will be presented in section 5.1 of the SmPC, as an integral part of the description of the performance characteristics of cemiplimab in the intended treatment setting.

Treatment with cemiplimab beyond progression: Efficacy data presented for the subgroup of 70 patients (23% of the cemiplimab arm) who continued cemiplimab beyond progression as allowed per protocol suggest that they continued to derive an efficacy benefit. However, considering the fact that these patients are highly selected, these data will not be presented in the SmPC.

Supportive data from Study 1423: 20 patients from two advanced cervical cancer cohorts were treated in this FIH trial. Although data were clearly limited, efficacy signals (10% ORR) served to support the design of Study 1676.

## 2.4.3. Conclusions on the clinical efficacy

Study 1676 showed an advantage of cemiplimab vs. investigator's choice of chemotherapy choices in the treatment of patients with recurrent or metastatic cervical cancer with disease progression after platinum-based chemotherapy. While the pivotal study was overall positive, the magnitude of efficacy in subgroups indicate that PD-L1 expression is a relevant effect modifier, although a restricted indication is not deemed necessary.

## 2.5. Clinical safety

## 2.5.1. Introduction

The safety profile of cemiplimab has been characterised in patients with advanced solid malignancies who received cemiplimab monotherapy in 4 clinical studies. The toxicity profile of cemiplimab is characterised by immune-related mediated adverse reactions including hypothyroidism, hyperthyroidism pneumonitis, hepatitis, colitis and skin adverse reactions. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with cemiplimab treatment.

The summary of clinical safety (SCS) submitted by the MAH presented safety data from 5 studies: Study 1676 (confirmatory study for the cervical cancer indication), and studies 1423, 1540, 1620 and 1624, in patients who received at least 1 dose of cemiplimab as monotherapy. The following table summarises the studies included in the safety data pools.

<div style=\"page-break-after: always\"></div>

Table 53: Description of safety assessments on clinical studies

| Study Number Study Status Total Number of Centers With Treated Patients Country(ies)   | Study Population                                                                                                                                                                                                                                                                                                                                                                                                                                  | Study Phase Study Design                                                 | Dose and Schedule                                                                                                                                                                                       | Safety Assessments and Objectives/Endpoints                                                                                   |
|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| R2810-ONC-1676 Ongoing 97centers 14 countries                                          | Adult patients with recurrent, persistent or metastatic cervical cancerforwhichthereisnocurative intent option, andwhohave progressed or had recurrence after treatment with platinum therapy. (N=608;with 590patients in the safety analysis set [SAF])                                                                                                                                                                                          | Phase 3 Randomized, multicenter, open-label, pivotal study               | 350 mg cemiplimab administered intravenously over30minutes Q3W for up to 96 weeks (N=300) or investigator choice (IC) chemotherapy for up to 96 weeks (N=290)                                           | Safety is assessed through AEs,laboratory data,vital signs, and Eastern Cooperative Oncology Group (ECOG) performance status. |
| R2810-ONC-1423 Complete 38 centers 3countries                                          | Adult patients with advanced malignancies or who are incurable and have failed to respond to or showed tumor progression despite standard therapy. or patients who are not candidates for standard therapy, or for whom no available therapy is expected to convey clinical benefit, or for whom PD-1 blockade has been shown to be at least equivalent to standard of care. (N = 398 [FAS and SAF]; 130 patientsreceived cemiplimab monotherapy) | Phase 1 first-in-human (FIH), open-label, multicenter, repeat-dose study | Cemiplimab administered intravenously over 30 min every 2 weeks (Q2W) at: -3 mg/kg (n = 333) -1 mg/kg (n = 27) -10 mg/kg (n = 6) -200 mg (n = 20) Cemiplimab3mg/kgQ3W (n=12) Treatment duration:48weeks | Safety is assessed through AEs, laboratory data, vital signs, and ECOG performance status.                                    |

| Study Number Study Status Total Number of Centers With Treated Patients Country(ies)   | StudyPopulation                                                                                                                                                                                                                                                                                                      | Study Phase Study Design                                   | Dose and Schedule                                                                                                                                                                            | Safety Assessments and Objectives/Endpoints                                                |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| R2810-ONC-1540 Ongoing 35centers 3countries                                            | Adult patients with mCsCC (Group 1Phase 2 and Group 3) and locally advanced cutaneous squamous cell carcinoma (laCSCC) (Group 2) (N = 193 [FAS and SAF]; 59 in Group 1, 78 in Group 2, and 56 in Group 3)                                                                                                            | nonrandomized, 3-group,multicenter study                   | Cemiplimab administered intravenously over 30 min at: -3 mg/kg Q2W (Groups 1 and 2) -350 mg Q3W (Group 3) Treatment duration:up to 96 weeks for Groups 1 and 2 and up to 54 weeks in Group 3 | Safety is assessed through AEs,laboratory data, vital signs, and ECOG performance status.  |
| R2810-ONC-1620 Ongoing 49 centers 10 countries                                         | Adult patientswith mBCC(Group 1)Phase2 and unresectable laBCC (Group 2) (N = 138 [SAF]; 48 in Group 1 and 84 in Group 2)                                                                                                                                                                                             | nonrandomized, 2-group,multicenter study                   | Cemiplimab administered intravenously over 30 min at 350 mg Q3W Treatment duration: 93 weeks                                                                                                 | Safety is assessed through AEs, laboratory data, vital signs, and ECOG performance status. |
| R2810-ONC-1624 Ongoinga 138 centers 24 countries                                       | Adult patients,diagnosed with stage IIIB,IIIC, or stage IV squamous or non-squamous NSCLC, who are not eligible for definitive chemo/radiation,whose tumors express PD-L1 in ≥50% of tumor cells (using the PD-L1 IHC 22C3 pharmDx assay), and who have receivednopriorsystemictreatment for their advanced disease. | Phase 3 Randomized, multicenter, open-label, pivotal study | 350 mg cemiplimab administered intravenously over30 minutes Q3W for up to 108 weeks (N=355) or standard of care chemotherapy for 4 to 6 cycles (N=342)                                       | Safety is assessed through AEs,laboratory data, vital signs,and ECOG performance status.   |

Abbreviations: AE,adverse event; BCC,basal cell carcinoma;ECOG,Eastern Cooperative Oncology Group;FAS,Full analysis set;IC, investigator choice; laBCC.locally advanced basal cell carcinoma;laCSCC.1ocally advanced cutaneous squamous cell carcinoma;mBCCmetastatic basal cell carcinoma;mCSCC PD-1, programmed death-1 (receptor); PD-L1, programmed death ligand 1; Q2W, every 2 weeks; Q3W, every 3 weeks; SAF, safety analysis set

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR, Module 5.3.5.2 Study 1423 Fina1 CSR, Module 5.3.5.2 Study 1540 Interim CSR, Module 5.3.5.2

This study met endpoints.Study patients are being followed for long term survival

<div style=\"page-break-after: always\"></div>

Data from two safety data pools were presented as described below:

- Safety Pool 1 (Cervical Cancer population): All patients who received at least 1 dose of cemiplimab monotherapy in Study 1676. This pool included 300 patients. This is the primary pool for the analysis of safety of cemiplimab in patients with recurrent/metastatic cervical cancer.
- Safety Pool 2 (cemiplimab monotherapy population): All patients (n=1116) who received at least 1 dose of cemiplimab as monotherapy across Study 1676 (n=300), Study 1423 (n=130), Study 1540 (Groups 1, 2, and 3, n=193), Study 1620 (n=138) and Study 1624 (excluding crossover cemiplimab treatment, n=355). This pool is used to evaluate the frequency and characteristics of important risks of cemiplimab (imAEs and IRRs) and allows a broader assessment of the safety profile of cemiplimab monotherapy across dose levels and solid tumor indications.

Table 2 summarises the studies contained in each safety pool and the data cutoff dates.

Table 54: Integrated Databases by Each Pool

| Studies/Patients                                                           | Database Cutoff                                     | Safety Pool 1   | Safety Pool 2   |
|----------------------------------------------------------------------------|-----------------------------------------------------|-----------------|-----------------|
| Study 1676 (cervical):                                                     | 04 Jan 2021                                         | X               | X               |
| cemiplimabmonotherapy (N=300) Study 1423 (FIH): A1ll patients who received | 30 Apr 2019                                         |                 | X               |
| Study 1540 (CSCC): Patients in Group 1, Group 2, and Group 3 (N = 193)     | 20 Sep 2018 (Groups 1 and 3); 10 0ct 2018 (Group 2) |                 |                 |
| Study 1620 (BCC): A1l patients (N = 138)                                   | 30 Jun 2020                                         |                 |                 |
| Study 1624 (NSCLC): Cemiplimab monotherapy (N =355)                        | 01 Mar 2020                                         |                 | X               |

<div style=\"page-break-after: always\"></div>

## 2.5.2. Patient exposure

Table 55: Patient Disposition in Study 1676 (Safety Analysis Set) -Total Population

|                                              | Cemiplimab (N=300)   | Chemotherapy (N=290)   |
|----------------------------------------------|----------------------|------------------------|
| Treatment ongoing, n (%)                     | 37 (12.3%)           | 7 (2.4%)               |
| Off treatment, n (%)                         | 263 (87.7%)          | 283 (97.6%)            |
| Treatment completed                          | 13 (4.3%)            | 0                      |
| Treatment discontinued                       | 250 (83.3%)          | 283 (97.6%)            |
| Primary reason for treatment discontinuation |                      |                        |
| Adverse event                                | 25 (8.3%)            | 15 (5.2%)              |
| Death                                        | 14 (4.7%)            | 17 (5.9%)              |
| Non-compliance with study drug(s)            | 1 (0.3%)             | 0                      |
| Subject decision                             | 8 (2.7%)             | 10 (3.4%)              |
| Physician decision                           | 0                    | 2 (0.7%)               |
| Disease progression                          | 199 (66.3%)          | 229 (79.0%)            |
| Withdrawal of consent                        | 3 (1.0%)             | 10 (3.4%)              |
| Study ongoing, n (%)                         | 53 (17.7%)           | 11 (3.8%)              |
| Off study, n (%)                             | 247 (82.3%)          | 279 (96.2%)            |
| Study completed                              | 7 (2.3%)             | 0                      |
| Study discontinued                           | 240 (80.0%)          | 279 (96.2%)            |
| Primary reason for study discontinuation     |                      |                        |
| Adverse event                                | 8 (2.7%)             | 7 (2.4%)               |
| Death                                        | 89 (29.7%)           | 94 (32.4%)             |
| Lost to follow-up                            | 2 (0.7%)             | 2 (0.7%)               |
| Non-compliance with study drug(s)            | 1 (0.3%)             | 0                      |
| Subject decision                             | 34 (11.3%)           | 41 (14.1%)             |
| Physician decision                           | 1 (0.3%)             | 1 (0.3%)               |
| Disease progression                          | 98 (32.7%)           | 117 (40.3%)            |
| Withdrawal of consent                        | 7 (2.3%)             | 17 (5.9%)              |

Abbreviation: N, number of patients

Data cutoff as of 04 Jan 2021 for all patients in Study 1676.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.1.5.2all

<div style=\"page-break-after: always\"></div>

Table 56: Treatment Exposure in Study 1676 (Safety Analysis Set) - Total Population

|                              | Cemiplimab (N=300)   | Chemotherapy (N=290)   |
|------------------------------|----------------------|------------------------|
| Duration of Exposure (weeks) |                      |                        |
| 1                            | 300                  | 290                    |
| Mean (SD)                    | 26.49 (26.033)       | 14.37 (13.038)         |
| Median                       | 15.15                | 10.05                  |
| Q1 : Q3                      | 6.50 : 36.10         | 5.10 : 19.00           |
| Min-Max                      | 1.4 : 100.7          | 1.0 : 81.9             |
| Duration of Exposure, n (%)  |                      |                        |
| ≥3 weeks                     | 298 (99.3%)          | 270 (93.1%)            |
| ≥6 weeks                     | 266 (88.7%)          | 204 (70.3%)            |
| ≥ 12 weeks                   | 185 (61.7%)          | 125 (43.1%)            |
| ≥ 18 weeks                   | 141 (47.0%)          | 79 (27.2%)             |
| ≥ 24 weeks                   | 111 (37.0%)          | 49 (16.9%)             |
| ≥ 36 weeks                   | 81 (27.0%)           | 21 (7.2%)              |
| ≥ 48 weeks                   | 58 (19.3%)           | 10 (3.4%)              |
| ≥ 72 weeks                   | 28 (9.3%)            | 1 (0.3%)               |
| ≥96 weeks                    | 8 (2.7%)             | 0                      |
| Duration of Exposure, n (%)  |                      |                        |
| 0-<3weeks                    | 2 (0.7%)             | 20 (6.9%)              |
| 3-<6weeks                    | 32 (10.7%)           | 66 (22.8%)             |
| 6 -< 12 weeks                | 81 (27.0%)           | 79 (27.2%)             |
| 12 -<24 weeks                | 74 (24.7%)           | 76 (26.2%)             |
| 24 -< 36 weeks               | 30 (10.0%)           | 28 (9.7%)              |
| 36 -< 48 weeks               | 23 (7.7%)            | 11 (3.8%)              |
| 48 -<72weeks                 | 30 (10.0%)           | 9 (3.1%)               |
| 72 -<96 weeks                | 20 (6.7%)            | 1 (0.3%)               |
| ≥96 weeks                    | 8 (2.7%)             | 0                      |

Abbreviation: SD, standard deviation.

Data cutoff as of 04 Jan 2021 for all patients in Study 1676.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.1.4.1all

<div style=\"page-break-after: always\"></div>

Table 57: Treatment Exposure for Cemiplimab Pooled Data Sets (Safety Analysis Set)

|                              | Pool l All Cervical Patients (N =300)   | Pool2 All Monotherapy Patients (N =1116)   |
|------------------------------|-----------------------------------------|--------------------------------------------|
| Duration of Exposure (weeks) |                                         |                                            |
| n1                           | 300                                     | 1116                                       |
| Mean (SD)                    | 26.49 (26.033)                          | 34.08 (28.099)                             |
| Median                       | 15.15                                   | 26.90                                      |
| Q1: Q3                       | 6.50: 36.10                             | 10.75:48.80                                |
| Min-Max                      | 1.4: 100.7                              | 0.3: 144.4                                 |
| Duration of Exposure, n (%)  |                                         |                                            |
| ≥ 0 weeks                    | 300 (100%)                              | 1116 (100%)                                |
| ≥6 weeks                     | 266 (88.7%)                             | 1010 (90.5%)                               |
| ≥ 12 weeks                   | 185 (61.7%)                             | 817 (73.2%)                                |
| ≥ 24 weeks                   | 111 (37.0%)                             | 591 (53.0%)                                |
| ≥36 weeks                    | 81 (27.0%)                              | 448 (40.1%)                                |
| ≥48 weeks                    | 58 (19.3%)                              | 321 (28.8%)                                |
| ≥60 weeks                    | 41 (13.7%)                              | 196 (17.6%)                                |
| ≥ 72 weeks                   | 28 (9.3%)                               | 150 (13.4%)                                |
| ≥ 84 weeks                   | 17 (5.7%)                               | 102 (9.1%)                                 |
| ≥96 weeks                    | 8 (2.7%)                                | 35 (3.1%)                                  |
| ≥108 weeks                   | 0                                       | 6 (0.5%)                                   |
| ≥120 weeks                   | 0                                       | 2 (0.2%)                                   |
| ≥132 weeks                   | 0                                       | 1 (<0.1%)                                  |
| ≥ 144 weeks                  | 0                                       | 1 (<0.1%)                                  |
| ≥156 weeks                   | 0                                       | 0                                          |

Duration of exposure (weeks) = minimum of [last dose date - first dose date + (14 or 21 based on Q2W or Q3W dosing schedule)]/7 and (data cutoff date or death date - first dose date + 1) / 7.

Abbreviations: Max, maximum; Min, minimum; Q1, quarter 1; Q2W, every 2 weeks; Q3, quarter 3; Q3W, every 3 weeks; SD, standard deviation

Data cutoff as of 04 Jan 2021 for all patients in Study 1676; data cutoff as of 30 Jun 2020 for Study 1620; data cutoff as of 01 Mar 2020 for Study 1624; data cutoff as of 30 Apr 2019 for Study 1423; data cutoff as of 20 Sep 2018 for Group 1 and Group 3 patients in Study 1540; and data cutoff as of 10 Oct 2018 for Group 2 patients in Study 1540.

Source: ISS Table 14.1.4.1

<div style=\"page-break-after: always\"></div>

## 2.5.3. Adverse events

Summary of AEs in Study 1676 and cemiplimab monotherapy pool:

Table 58: Summary of treatment-emergent adverse events in study 1676 total population (safety analysis set) and pool 2

|                                                                              | Cemiplimab (N=300)   | Chemotherapy (N=290)   | All CemiplimabMonotherapyPatients (N=1116)   |
|------------------------------------------------------------------------------|----------------------|------------------------|----------------------------------------------|
| Number of TEAEs                                                              | 1969                 | 2356                   | 8435                                         |
| Number of NCI grade 3/4/5 TEAEs                                              | 299                  | 385                    | 1029                                         |
| Number ofseriousTEAEs                                                        | 147                  | 133                    | 587                                          |
| Number of patients with any TEAE, n (%)                                      | 265 (88.3%)          | 265 (91.4%)            | 1030 (92.3%)                                 |
| Number of patients with any NCI grade 3/4/5 TEAE, n (%)                      | 135 (45.0%)          | 155 (53.4%)            | 472 (42.3%)                                  |
| Number of patients with any serious TEAE, n (%)                              | 89 (29.7%)           | 78 (26.9%)             | 335 (30.0%)                                  |
| Number of patients who discontinued study treatment due to TEAEs, n (%)      | 26 (8.7%)            | 15 (5.2%)              | 92 (8.2%)                                    |
| Number of patients with any TEAE leading to a dose interruption/delay, n (%) | 75 (25.0%)           | 114 (39.3%)            | 331 (29.7%)                                  |
| Number of patients with any TEAE leading to a dose reduction, n (%)          | 0                    | 58 (20.0%)             | 6 (0.5%)                                     |
| Number of patients with any TEAE resulting in death, n (%)                   | 5 (1.7%)             | 2 (0.7%)               | 54 (4.8%)                                    |

Datacut-offasof04Jan2021.

TEAE:Treatment-EmergentAdverseEvents

NCI grades were coded using CTCAE Version 4.03.

A patient is counted only once for multiple occurrences within a category.

<div style=\"page-break-after: always\"></div>

All-grade and highgrade (≥G3) AEs in Study 1676 and cemiplimab monotherapy pool:

Table 59: Treatment-emergent adverse events by SOC, PT, and NCI Grade in Study 1676 (All Grades in &gt;5% of patients in any treatment arm or Grade ≥3 in &gt;2% of patient in any treatment arm in study 1676) (Safety analysis set) and pool 2

|                                                      | Cemiplimab (N=300)   | Cemiplimab (N=300)   | Chemotherapy (N=290)   | Chemotherapy (N=290)   | All Cemiplimab Monotherapy Patients (N=1116)   | All Cemiplimab Monotherapy Patients (N=1116)   |
|------------------------------------------------------|----------------------|----------------------|------------------------|------------------------|------------------------------------------------|------------------------------------------------|
| System Organ Class, n (%) Preferred Term, n (%)      | All Grades           | Grades 3/4/5         | All Grades             | Grades 3/4/5           | All Grades                                     | Grades 3/4/5                                   |
| Number of patients with any TEAE, n (%)              | 265 (88.3%)          | 135 (45.0%)          | 265 (91.4%)            | 155 (53.4%)            | 1030 (92.3%)                                   | 472 (42.3%)                                    |
| Gastrointestinal disorders                           |                      |                      |                        |                        |                                                |                                                |
| Nausea                                               | 55 (18.3%)           | 1 (0.3%)             | 97 (33.4%)             | 6 (2.1%)               | 155 (13.9%)                                    | 2 (0.2%)                                       |
| Vomiting                                             | 48 (16.0%)           | 2 (0.7%)             | 68 (23.4%)             | 7(2.4%)                | 108 (9.7%)                                     | (0.3%)                                         |
| Constipation                                         | 45 (15.0%)           | 0                    | 59 (20.3%)             | 1 (0.3%)               | 133 (11.9%)                                    | (0.2%)                                         |
| Diarrhoea                                            | 32 (10.7%)           | 3 (1.0%)             | 39 (13.4%)             | 4 (1.4%)               | 168 (15.1%)                                    | 7 (0.6%)                                       |
| Abdominal pain                                       | 29(9.7%)             | 3 (1.0%)             | 33 (11.4%)             | 3 (1.0%)               | 83 (7.4%)                                      | 6(0.5%)                                        |
| Stomatitis                                           | 12 (4.0%)            | 1 (0.3%)             | 22 (7.6%)              | 3 (1.0%)               | 30 (2.7%)                                      | 1 (<0.1%)                                      |
| General disorders and administration site            |                      |                      |                        |                        |                                                |                                                |
| conditions Fatigue                                   | 50 (16.7%)           | 4 (1.3%)             | 45 (15.5%)             | 4 (1.4%)               | 235 (21.1%)                                    | 18 (1.6%)                                      |
| Pyrexia                                              | 35 (11.7%)           | 1 (0.3%)             | 61 (21.0%)             | 0                      | 89 (8.0%)                                      | 2 (0.2%)                                       |
| Asthenia                                             | 33 (11.0%)           | 7 (2.3%)             | 44 (15.2%)             | 3 (1.0%)               | 80 (7.2%)                                      | 12 (1.1%)                                      |
| General disorders and administration site conditions |                      |                      |                        |                        |                                                |                                                |
| Oedema peripheral                                    | 19 (6.3%)            | 1 (0.3%)             | 16 (5.5%)              | 0                      | 65 (5.8%)                                      | 1 (<0.1%)                                      |
| Infections and infestations Urinary tract infection  | 35 (11.7%)           | 15 (5.0%)            | 25 (8.6%)              | 8 (2.8%)               | 79 (7.1%)                                      | 23 (2.1%)                                      |
| Metabolism and nutrition disorders                   |                      |                      |                        |                        |                                                |                                                |
| Decreased appetite                                   | 45 (15.0%)           | 1 (0.3%)             | 46 (15.9%)             | 2 (0.7%)               | 147 (13.2%)                                    | 6(0.5%)                                        |
| Hypoalbuminaemia                                     | 21 (7.0%)            | 4 (1.3%)             | 18 (6.2%)              | 4 (1.4%)               | 60 (5.4%)                                      | 8 (0.7%)                                       |
| Hypokalaemia                                         | 18 (6.0%)            | 8(2.7%)              | 17 (5.9%)              | 7(2.4%)                | 55 (4.9%)                                      | 17 (1.5%)                                      |
| Hyperglycaemia                                       | 4 (1.3%)             | 1 (0.3%)             | 16 (5.5%)              | 3 (1.0%)               | 39 (3.5%)                                      | 8 (0.7%)                                       |
| Blood and lymphatic system disorders                 |                      |                      |                        |                        |                                                |                                                |
| Anaemia                                              | 75 (25.0%)           | 36 (12.0%)           | 129 (44.5%)            | 78 (26.9%)             | 181 (16.2%)                                    | 63(5.6%)                                       |
| Neutropenia                                          | 6 (2.0%)             | 3 (1.0%)             | 44 (15.2%)             | 26 (9.0%)              | 14 (1.3%)                                      | 5 (0.4%)                                       |
| Blood and lymphatic system disorders                 |                      |                      |                        |                        |                                                |                                                |
| Leukopenia                                           | 4 (1.3%)             | 1 (0.3%)             | 13 (4.5%)              | 7 (2.4%)               | 10 (0.9%)                                      | 3 (0.3%)                                       |
| Thrombocytopenia                                     | 2 (0.7%)             | 1 (0.3%)             | 16 (5.5%)              | 9 (3.1%)               | 18 (1.6%)                                      | 1 (<0.1%)                                      |
| Musculoskeletal andconnectivetissue                  |                      |                      |                        |                        |                                                |                                                |
| disorders Back pain                                  | 33 (11.0%)           | 4 (1.3%)             | 25 (8.6%)              | 2 (0.7%)               | 99 (8.9%)                                      | 5(0.4%)                                        |
| Arthralgia                                           | 31 (10.3%)           | (0.3%)               | 8(2.8%)                | 0                      | 137 (12.3%)                                    | 3(0.3%)                                        |
| Pain in extremity                                    | 18 (6.0%)            | 2 (0.7%)             | 7 (2.4%)               | 2 (0.7%)               | 65 (5.8%)                                      | 6(0.5%)                                        |
| Investigations                                       |                      |                      |                        |                        |                                                |                                                |
| Blood creatinine increased                           | 20 (6.7%)            | 4 (1.3%)             | 17 (5.9%)              | 1 (0.3%)               | 73 (6.5%)                                      | 7 (0.6%)                                       |
| Alanine aminotransferaseincreased                    | 13 (4.3%)            | 2 (0.7%)             | 20 (6.9%)              | 2 (0.7%)               | 69(6.2%)                                       | 9 (0.8%)                                       |
| Aspartate aminotransferase increased                 | 12 (4.0%)            | 2 (0.7%)             | 19 (6.6%)              | 0                      | 66 (5.9%)                                      | 15 (1.3%)                                      |
| Neutrophil count decreased                           | 2 (0.7%)             | 1 (0.3%)             | 26 (9.0%)              | 12 (4.1%)              | 8 (0.7%)                                       | 2 (0.2%)                                       |
| Investigations                                       |                      |                      | 14 (4.8%)              |                        |                                                |                                                |
| Whitebloodcellcount decreased                        | 2 (0.7%)             |                      |                        | 6 (2.1%)               | 10 (0.9%)                                      | 0                                              |
| Respiratory, thoracic and mediastinal disorders      |                      |                      |                        |                        |                                                |                                                |
| Dyspnoea                                             | 26 (8.7%)            | 5 (1.7%)             | 17 (5.9%)              | 1 (0.3%)               | 104 (9.3%)                                     | 16 (1.4%)                                      |
| Cough                                                | 20 (6.7%)            | 1 (0.3%)             | 20 (6.9%)              | (0.3%)                 | 113 (10.1%)                                    | 2 (0.2%)                                       |
| Skin and subcutaneous tissue disorders               |                      |                      |                        |                        |                                                |                                                |
| Rash                                                 | 18 (6.0%)            | 3 (1.0%)             | 19 (6.6%)              | 0                      | 88 (7.9%)                                      | 6(0.5%)                                        |
| Pruritus                                             | 16 (5.3%)            | 0                    | 15 (5.2%)              | 1 (0.3%)               | 122 (10.9%)                                    | 1 (<0.1%)                                      |
| Nervous system disorders Headache                    | 22 (7.3%)            | 1 (0.3%)             | 17 (5.9%)              | 0                      | 85 (7.6%)                                      | 4 (0.4%)                                       |

<div style=\"page-break-after: always\"></div>

| Renal and urinary disorders Hydronephrosis           | 9 (3.0%)   | 7 (2.3%)   | 4 (1.4%)   | 2 (0.7%)   | 11 (1.0%)   | 7 (0.6%)   |
|------------------------------------------------------|------------|------------|------------|------------|-------------|------------|
| Reproductive system and breast disorders Pelvic pain | 14 (4.7%)  | 1 (0.3%)   | 16 (5.5%)  | 3 (1.0%)   | 20 (1.8%)   | 1 (<0.1%)  |
| Psychiatric disorders Insomnia                       | 19 (6.3%)  | 0          | 16 (5.5%)  | 1 (0.3%)   | 64 (5.7%)   | 0          |
| Endocrinedisorders Hypothyroidism                    | 18 (6.0%)  | 1 (0.3%)   | 0          | 0          | 85 (7.6%)   | 1 (<0.1%)  |

Datacut-off asof 04Jan 2021.

TEAE:Treatment-emergent adverse event.

All adverse events were coded using the MedDRA Version 23.1.NCI gradeswere coded using CTCAE Version 4.03.

Apatient is counted only onceformultiple occurrenceswithin asystem organ class/preferred term.

For SOCs, the table is sorted by decreasing frequency of all grades in the cemiplimab group. Within each SOC, PTs are sorted by decreasing frequency of all grades in the cemiplimab group.

## 2.5.4. Serious adverse event/deaths/other significant events

## 2.5.4.1. SAEs in Study 1676 and cemiplimab monotherapy pool

Table 60: Serious TreatmentEmergent Adverse Events by SOC and PT in Study 1676 (in ≥1% of Patients in Any Treatment Arm in Study 1676) (Safety Analysis Set) and Pool 2

| System Organ Class, n (%) Preferred Term, n (%)      | Cemiplimab (N=300)   | Chemotherapy (N=290)   | All Cemiplimab Monotherapy Patients (N=1116)   |
|------------------------------------------------------|----------------------|------------------------|------------------------------------------------|
| Number of patients with any serious TEAE, n (%)      | 89 (29.7%)           | 78 (26.9%)             | 335 (30.0%)                                    |
| Infections and infestations                          |                      |                        |                                                |
| Urinary tract infection                              | 12 (4.0%)            | 10 (3.4%)              | 21 (1.9%)                                      |
| Pneumonia                                            | 4 (1.3%)             | 3 (1.0%)               | 31(2.8%)                                       |
| Pyelonephritis                                       | 3 (1.0%)             | 3 (1.0%)               | 4 (0.4%)                                       |
| Gastrointestinal disorders                           |                      |                        |                                                |
| Vomiting                                             | 1 (0.3%)             | 3 (1.0%)               | 1 (<0.1%)                                      |
| General disorders and administration site conditions |                      |                        |                                                |
| Pyrexia                                              | 4 (1.3%)             | 5 (1.7%)               | 9 (0.8%)                                       |
| Renal and urinary disorders                          |                      |                        |                                                |
| Acute kidney injury                                  | 5 (1.7%)             | 3 (1.0%)               | 9 (0.8%)                                       |
| Haematuria                                           | 3 (1.0%)             | (0.3%)                 | 5 (0.4%)                                       |
| Hydronephrosis                                       | 3 (1.0%)             | 0                      | 3 (0.3%)                                       |
| Hepatobiliary disorders                              |                      |                        |                                                |
| Autoimmune hepatitis                                 | 4 (1.3%)             | 0                      | 8(0.7%)                                        |
| Immune-mediated hepatitis                            | 3 (1.0%)             | 0                      | 6 (0.5%)                                       |
| Respiratory, thoracic and mediastinal disorders      |                      |                        |                                                |
| Pneumonitis                                          | 3 (1.0%)             | 1 (0.3%)               | 20 (1.8%)                                      |
| Blood and lymphatic system disorders                 |                      |                        |                                                |
| Febrile neutropenia                                  | 3 (1.0%)             | 5 (1.7%)               | 4 (0.4%)                                       |
| Anaemia                                              | 2 (0.7%)             | 14 (4.8%)              | 8(0.7%)                                        |
| Thrombocytopenia                                     | 0                    | 3 (1.0%)               | 0                                              |
| Investigations                                       |                      |                        |                                                |
| Blood creatinine increased                           | 3 (1.0%)             | 1(0.3%)                | 5 (0.4%)                                       |

Data cut-off as of 04Jan 2021.

TEAE: Treatment-emergent adverse event.

All adverseeventswerecodedusingMedDRAVersion23.1.

A patient is counted only once for multiple occurrences within a system organ class/preferred term.

For SOCs, the table is sorted by decreasing frequency in the cemiplimab group. Within each SOC, PTs are sorted by decreasing frequency in the cemiplimab group.

<div style=\"page-break-after: always\"></div>

## 2.5.4.2. AEs resulting in death in Study 1676

Table 61: Summary of Treatment-Emergent Adverse Events Resulting in Death by System Organ Class and Preferred Term in Study 1676 (Safety Analysis Set) - Total Population

| System Organ Class, n (%) Preferred Term, n (%)            | Cemiplimab (N=300)   | Chemotherapy (N=290)   |
|------------------------------------------------------------|----------------------|------------------------|
| Number of patients with any TEAE resulting in death, n (%) | 5 (1.7%)             | 2 (0.7%)               |
| General disorders and administration site conditions       | 2 (0.7%)             | 2 (0.7%)               |
| Death                                                      | 1 (0.3%)             | 0                      |
| Sudden death                                               | 1 (0.3%)             | 0                      |
| Multiple organ dysfunction syndrome                        | 0                    | 1 (0.3%)               |
| Performance status decreased                               | 0                    | 1 (0.3%)               |
| Nervous system disorders                                   | 2 (0.7%)             | 0                      |
| Cerebrovascular accident                                   | 1 (0.3%)             | 0                      |
| Ischaemic stroke                                           | 1 (0.3%)             | 0                      |
| Infections and infestations                                | 1 (0.3%)             | 1 (0.3%)               |
| Pneumonia                                                  | 1 (0.3%)             | 0                      |
| Neutropenic sepsis                                         | 0                    | 1 (0.3%)               |

Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event

All AEs were coded using MedDRA Version 23.1. A patient is counted only once for multiple occurrences within a SOC/PT.

For SOCs, the table is sorted by decreasing frequency in the cemiplimab group. Within each SOC, PTs are sorted by decreasing frequency in the cemiplimab group.

Data cutoff as of 04 Jan 2021 for all patients in Study 1676.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.3.2.3.1all

## 2.5.4.3. Adverse events of special interest

Adverse events of special interest for this study included the following:

- Grade ≥ 2 infusion related reactions
- Grade ≥ 2 allergic/hypersensitivity reaction
- Grade ≥ 3 immune-mediated AEs
- An immune-mediated AE of any grade in a patient previously treated with a PI3-K inhibitor

<div style=\"page-break-after: always\"></div>

Table 62: Summary of Treatment-Emergent Adverse Events of Special Interest (based on AESI Question in CRF) (Safety Analysis Set) - Patients with SCC and AC Histology

|                                                                                                 | Cemiplimab (N=300)   |   Chemotherapy (N=290) |
|-------------------------------------------------------------------------------------------------|----------------------|------------------------|
| Number of treatment-emergent AESIs                                                              | 41                   |                      0 |
| Number of NCI grade 3/4/5 treatment-emergent AESIs                                              | 34                   |                      0 |
| Number of serious treatment-emergent AESIs                                                      | 14                   |                      0 |
| Number of patients with any treatment-emergent AESI, n (%)                                      | 34 (11.3%)           |                      0 |
| Number of patients with any NCI grade 3/4/5 treatment-emergent AESI, n (%)                      | 29 (9.7%)            |                      0 |
| Number of patients with any serious treatment-emergent AESI, n (%)                              | 14 (4.7%)            |                      0 |
| emergent AESIs, n (%)                                                                           | 12 (4.0%)            |                      0 |
| Number of patients with any treatment-emergent AESI leading to a dose interruption/delay, n (%) | 14 (4.7%)            |                      0 |
| Number of patients with any treatment-emergent AESI leading to a dose reduction, n (%)          | 0                    |                      0 |
| Number of patients with any treatment-emergent AESI resulting in death, n (%)                   | 0                    |                      0 |

Data cutoff as of 04 Jan 2021.

AC=adenocarcinoma/adenosquamous histology; AESI=Adverse event of special interest; SCC=squamous cell carcinoma.

NCI grades were coded using CTCAE Version 4.03.

A patient is counted only once for multiple occurrences within a category.

Source: PTT 14.3.2.6.1all

<div style=\"page-break-after: always\"></div>

## Infusion-Related Reactions

Table 63: Summary of Infusion Reactions (Safety Analysis Set) - Patients with SCC and AC Histology

|                                                                                           | Cemiplimab (N=300)   | Chemotherapy (N=290)   |
|-------------------------------------------------------------------------------------------|----------------------|------------------------|
| Number of infusion reactions                                                              | 8                    | 38                     |
| Number ofNCI grade 3/4/5 infusion reactions                                               | 0                    | 1                      |
| Number of serious infusion reactions                                                      | 0                    | 0                      |
| Number of patients with any infusion feaction, n (%)                                      | 8 (2.7%)             | 13 (4.5%)              |
| Number of patients with any NCI grade 3/4/5 infusion reaction, n (%)                      | 0                    | 1 (0.3%)               |
| Number of patients with any serious infusion feaction, n (%)                              | 0                    | 0                      |
| Number of patients who discontinued study treatment due to infusion reactions, n (%)      | 0                    | 2 (0.7%)               |
| Number of patients with any infusion reaction leading to a dose interruption/delay, n (%) | 5 (1.7%)             | 9 (3.1%)               |
| Number of patients with any infusion feaction leading to a dose reduction, n (%)          | 0                    | 0                      |
| Number of patients with any infusion reaction resulting in death, n (%)                   | 0                    | 0                      |

Data cutoff as of 04 Jan 2021.

AC=adenocarcinoma/adenosquamous histology; NCI=National Cancer Institute; SCC=squamous cell carcimoma.

Infusion reaction: any AE that occurs during the infusion or within 2 hours after the infusion is completed. NCI grades were coded using CTCAE Version 4.03.

Source: PTT 14.3.2.7.1all.

Table 64: Summary of Sponsor-Identified Infusion Reactions by System Organ Class, Preferred Term, and NCI Grade (Safety Analysis Set)

|                                                                                    | Pool 1 All Cervical Patients (N=300)   | Pool 1 All Cervical Patients (N=300)   | Pool 2 All Monotherapy Patients (N=1116)   | Pool 2 All Monotherapy Patients (N=1116)   |
|------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------------------|
| System Organ Class Preferred Term, n (%)                                           | All Grades                             | Grades 3/4/5                           | All Grades                                 | Grades 3/4/5                               |
| Number of infusion reactions (based on sponsor definition)                         | 22                                     | -                                      | 105                                        | 1                                          |
| Number of patients with any infusion reaction (based on sponsor definition), n (%) | 20 (6.7%)                              | 0                                      | 83 (7.4%)                                  | 1 (<0.1%)                                  |
| Injury, poisoning and procedural complications                                     | 8 (2.7%)                               | 0                                      | 33 (3.0%)                                  | 0                                          |
| Infusion-related reaction                                                          | 8 (2.7%)                               | 0                                      | 33 (3.0%)                                  | 0                                          |
| Gastrointestinal disorders                                                         | 9 (3.0%)                               | 0                                      | 23 (2.1%)                                  | 0                                          |
| Nausea                                                                             | 6 (2.0%)                               | 0                                      | 14 (1.3%)                                  | 0                                          |
| Vomiting                                                                           | 4 (1.3%)                               | 0                                      | 8 (0.7%)                                   | 0                                          |
| Abdominal pain                                                                     | 1 (0.3%)                               | 0                                      | 4 (0.4%)                                   | 0                                          |

<div style=\"page-break-after: always\"></div>

|                                                      | Pool 1 All Cervical Patients (N=300)   | Pool 1 All Cervical Patients (N=300)   | Pool 2 All Monotherapy Patients (N=1116)   | Pool 2 All Monotherapy Patients (N=1116)   |
|------------------------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------------------|
| System Organ Class Preferred Term, n (%)             | All Grades                             | Grades 3/4/5                           | All Grades                                 | Grades 3/4/5                               |
| General disorders and administration site conditions | 3 (1.0%)                               | 0                                      | 15 (1.3%)                                  | 0                                          |
| Pyrexia                                              | 3 (1.0%)                               | 0                                      | 12 (1.1%)                                  | 0                                          |
| Chills                                               | 0                                      | 0                                      | 4 (0.4%)                                   | 0                                          |
| Skin and subcutaneous tissue disorders               | 0                                      | 0                                      | 7 (0.6%)                                   | 0                                          |
| Rash                                                 | 0                                      | 0                                      | 6 (0.5%)                                   | 0                                          |
| Erythema                                             | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Respiratory, thoracic and mediastinal disorders      | 0                                      | 0                                      | 5 (0.4%)                                   | 1 (<0.1%)                                  |
| Dyspnoea                                             | 0                                      | 0                                      | 4 (0.4%)                                   | 1 (<0.1%)                                  |
| Wheezing                                             | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Immune system disorders                              | 0                                      | 0                                      | 3 (0.3%)                                   | 0                                          |
| Hypersensitivity                                     | 0                                      | 0                                      | 2 (0.2%)                                   | 0                                          |
| Drug hypersensitivity                                | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Musculoskeletal and connective tissue disorders      | 0                                      | 0                                      | 3 (0.3%)                                   | 0                                          |
| Back pain                                            | 0                                      | 0                                      | 3 (0.3%)                                   | 0                                          |
| Vascular disorders                                   | 0                                      | 0                                      | 2 (0.2%)                                   | 0                                          |
| Flushing                                             | 0                                      | 0                                      | 2 (0.2%)                                   | 0                                          |

Abbreviations:  AE,  adverse  event;  CTCAE,  Common  Terminology  Criteria  for  Adverse  Events;  MedDRA,  Medical Dictionary for Regulatory Activities; NCI, National Cancer Institute; PT, preferred term; SOC, system organ class

All AEs were coded using MedDRA Version 23.1. NCI grades were coded using CTCAE Version 4.03.

A patient is counted only once for multiple occurrences within a SOC/PT.

For SOCs, the table is sorted by d ecreasing frequency of all grades in the total group. Within each SOC, PTs are sorted by decreasing frequency in the total group.

Data cutoffs: 04 Jan 2021 in Study 1676; 01 Mar 2020 for patients in Study 1624; 30 Apr 2019 for patients in Study 1423; 20 Se p 2018 for all patients in Group 1 and Group 3 and 10 Oct 2018 for Group 2 in Study 1540; and 30 Jun 2020 for all patients in Study 1620.

Source: ISS Table 14.3.2.5.1 and ISS Table 14.3.2.5.4

<div style=\"page-break-after: always\"></div>

## Treatment-Emergent Sponsor Identified Immune-Mediated Adverse Events

Table 65: Summary of Treatment-Emergent Sponsor-Identified Immune-Mediated Adverse Events (imAEs Requiring Systemic Corticosteroids and Endocrine-Related imAEs Based on Sponsor-Provided List; Safety Analysis Set)

|                                                                                                                                              | Chemotherapy (n=290)   | Pool 1 All Cervical Patients (N=300)   | Pool 2 All Monotherapy Patients (N=1116)   |
|----------------------------------------------------------------------------------------------------------------------------------------------|------------------------|----------------------------------------|--------------------------------------------|
| Number of treatment-emergent sponsor-identified imAEs                                                                                        | 2                      | 63                                     | 328 a                                      |
| Number of NCI grade 3/4/5 treatment -emergent sponsor-identified imAEs                                                                       | 2                      | 18                                     | 82 a                                       |
| Number of serious treatment-emergent sponsor- identified imAEs                                                                               | 2                      | 15                                     | 69 a                                       |
| Number of patients with any treatment-emergent sponsor-identified imAE, n (%)                                                                | 2 (0.7%)               | 47 (15.7%)                             | 229 (20.5%)                                |
| Number of patients with any NCI grade 3/4/5 treatment-emergent sponsor-identified imAE, n (%)                                                | 2 (0.7%)               | 16 (5.3%)                              | 71 (6.4%)                                  |
| Number of patients with any serious treatment- emergent sponsor-identified imAE, n (%)                                                       | 2 (0.7%)               | 15 (5.0%)                              | 61 (5.5%)                                  |
| Number of patients who discontinued study treatment due to treatment-emergent sponsor- identified imAE, n (%)                                | 2 (0.7%)               | 15 (5.0%)                              | 51 (4.6%) a                                |
| Number of patients with any treatment-emergent sponsor-identified imAE leading to a drug interruption/delay, n (%)                           | 0                      | 8 (2.7%)                               | 80 (7.2%)                                  |
| Number of patients with any treatment-emergent sponsor-identified imAE leading to a dose reduction, n (%)                                    | 0                      | 0                                      | 3 (0.3%)                                   |
| Number of patients with any treatment-emergent sponsor-identified imAE leading to both a drug interruption/delay and a dose reduction, n (%) | 0                      | 0                                      | 3 (0.3%)                                   |
| Number of patients with any treatment-emergent sponsor-identified imAE resulting in death, n (%)                                             | 0                      | 0                                      | 4 (0.4%) a                                 |

Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; imAE, immune-mediated adverse event; NCI, National Cancer Institute

NCI grades were coded using CTCAE Version 4.03.

A patient is counted only once for multiple occurrences within a category.

Data cutoffs: 04 Jan 2021 in Study 1676; 01 Mar 2020 for patients in Study 1624; 30 Apr 2019 for patients in Study 1423; 20 Sep 2018 for all patients in Group 1 and Group 3 and 10 Oct 2018 for Group 2 in Study 1540; and 30 Jun 2020 for all patients in Study 1620.

Source: ISS Table 14.3.2.4.1 and R2810-ONC-1624 Primary Analysis CSR Erratum a Two additional identified imAEs of Myocarditis (grade 5) and Immune-mediated hepatitis (grade 4) were identified by the sponsor during medical review of cases and added to

Table 65 (R2810-ONC-1624 Primary Analysis CSR Erratum).

<div style=\"page-break-after: always\"></div>

Table 66: Treatment-Emergent Sponsor Identified Immune-Mediated Adverse Events by System Organ Class, Preferred Term and NCI Grade (ImAEs Requiring Systemic Corticosteroids or Immunosuppressants, or Endocrine-related ImAEs Based on Sponsor Provided List (Safety Analysis Set) -Patients with SCC and AC Histology

|                                                                                                | Cemiplimab (IN=300)   | Cemiplimab (IN=300)   | Chemotherapy (IN=290)   | Chemotherapy (IN=290)   |
|------------------------------------------------------------------------------------------------|-----------------------|-----------------------|-------------------------|-------------------------|
| System Organ Class, n (%) Preferred Term, n (%)                                                | All Grades            | Grades 3/4/6          | All Grades              | Grades 3/4/5            |
| (9t's) gt (el Sl) Ltpuaeiame-juauqeay Ame pym sjuayed go lequnN sponsor identified imAE, n (%) |                       |                       | 2 (0.7%)                | 2 (0.7%)                |
| Endocrine disorders                                                                            | 24 (8.0%)             | 1 (0.3%)              | 0                       | 0                       |
| Hypothyroidism                                                                                 | 18 (6.0%)             | 1 (0.3%)              | 0                       | 0                       |
| Hyperthyroidism                                                                                | 9 (3.0%)              | 0                     | 0                       | 0                       |
| Thyroiditis                                                                                    | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Hepatobiliary disorders                                                                        | 10 (3.3%)             | 10 (3.3%)             | 0                       | 0                       |
| Imwmune-mediatedhepatitis                                                                      | 4 (1.3%)              | 4 (1.3%)              | 0                       | 0                       |
| Autoimmune hepatihis                                                                           | 3 (1.0%)              | 3 (1.0%)              | 0                       | 0                       |
| Hepatic fmction abnormal                                                                       | 1 (0.3%)              | 1 (0.3%)              | 0                       | 0                       |
| Hepatitis                                                                                      | 1 (0.3%)              | 1 (0.3%)              | 0                       | 0                       |
| Hepatotoxicity                                                                                 | 1 (0.3%)              | 1 (0.3%)              | 0                       | 0                       |
| Skin and subcutaneous tissue disorders                                                         | 5 (1.7%)              | 1 (0.3%)              | 0                       | 0                       |
| Rash                                                                                           | 3 (1.0%)              | 1 (0.3%)              | 0                       | 0                       |
| Dermatitis                                                                                     | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Rash prwitic                                                                                   | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Gashrointestinal disorders                                                                     | 4 (1.3%)              | 1 (0.3%)              | 0                       | 0                       |
| Colitis                                                                                        | 2 (0.7%)              | 1 (0.3%)              | 0                       | 0                       |
| Diarrhoea                                                                                      | 2 (0.7%)              | 0                     | 0                       | 0                       |
| Respiatory, thoracic, and mediastinal disorders                                                | 4 (1.3%)              | 2 (0.7%)              | 1 (0.3%)                | 1 (0.3%)                |
| Pneumonitis                                                                                    | 4 (1.3%)              | 2 (0.7%)              | 1 (0.3%)                | 1 (0.3%)                |
| Investigations                                                                                 | 2 (0.7%)              | 1 (0.3%)              | 0                       | 0                       |
| Alanine aminohansferase increased                                                              | 1 (0.3%)              | 1 (0.3%)              | 0                       | 0                       |
| Blood thyroid stimulating hormone increased                                                    | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Musculoskeletal and comnective tissue disorders                                                | 2 (0.7%)              | 1 (0.3%)              | 0                       | 0                       |
| Arthritis                                                                                      | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Polyartluitis                                                                                  | 1 (0.3%)              | 1 (0.3%)              | 0                       | 0                       |
| Renal and winary disorders                                                                     | 2 (0.7%)              | 0                     | 1 (0.3%)                | 1 (0.3%)                |
| Acute kidney injuy                                                                             | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Nephritis                                                                                      | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Renal failue                                                                                   | 0                     | 0                     | 1 (0.3%)                | 1 (0.3%)                |
| Cardiae disorders                                                                              | 1 (0.3%)              | 0                     | 0                       | 0                       |
| Autoimwune pericarditis                                                                        | 1 (0.3%)              | 0                     | 0                       | 0                       |

Data cutoff as of4 Jan 2021.

AC=adenocarcinoma/adenosquamous histology: imAE=Immune-mediated Adverse Event, SCC=squamous cell carcinoma.

All adverse events were coded using the MedDRA Version 23.1. NCI gade were coded using CICAE Version 4.03.

A patient is counted only once for mltiple occuurences within a system organ class/prefemed term For SOCs, the table is sorted by decreasing fequency of all grades in the cemiplimab group. Within each

SOC, PTs are sorted by decreasing frequency of all gades in the cemiplimab group.

Sowrce: PTT 14.3.2.5.4all

<div style=\"page-break-after: always\"></div>

Table 67: Summary of Treatment-Emergent Sponsor-Identified Immune-Mediated Adverse Events by Composite/Preferred Term and NCI Grade (Safety Analysis Set)

|                                                        | Pool 1 All Cervical Patients (N=300)   | Pool 1 All Cervical Patients (N=300)   | Pool 2 All Monotherapy Patients (N=1116)   | Pool 2 All Monotherapy Patients (N=1116)   |
|--------------------------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------------------|
| Composite*/Preferred Term, n (%)                       | All Grades                             | Grades 3/4/5                           | All Grades                                 | Grades 3/4/5                               |
| Number of patients with any treatment-emergent sponsor | 47 (15.7%)                             | 16 (5.3%)                              | 229 (20.5%)                                | 71 (6.4%)                                  |
| identified imAE, n (%) Hypothyroidism*                 | 18 (6.0%)                              | 1 (0.3%)                               | 79 (7.1%)                                  | 1 (<0.1%)                                  |
| Hyperthyroidism*                                       | 9 (3.0%)                               | 0                                      | 36 (3.2%)                                  | 0                                          |
| Immune-mediated pneumonitis*                           | 4 (1.3%)                               | 2 (0.7%)                               | 30 (2.7%)                                  | 10 (0.9%)                                  |
| Immune-mediated hepatitis*                             | 10 (3.3%)                              | 10 (3.3%)                              | 27 (2.4%) a                                | 24 (2.2%) a                                |
| Immune-mediated colitis*                               | 4 (1.3%)                               | 1 (0.3%)                               | 23 (2.1%)                                  | 9 (0.8%)                                   |
| Immune-mediated skin reaction*                         | 5 (1.7%)                               | 1 (0.3%)                               | 18 (1.6%)                                  | 8 (0.7%)                                   |
| Arthralgia                                             | 0                                      | 0                                      | 10 (0.9%)                                  | 0                                          |
| Blood thyroid stimulating hormone increased            | 1 (0.3%)                               | 0                                      | 7 (0.6%)                                   | 0                                          |
| Immune-mediated nephritis*                             | 2 (0.7%)                               | 0                                      | 7 (0.6%)                                   | 2 (0.2%)                                   |
| Arthritis*                                             | 2 (0.7%)                               | 1 (0.3%)                               | 6 (0.5%)                                   | 2 (0.2%)                                   |
| Thyroiditis*                                           | 1 (0.3%)                               | 0                                      | 6 (0.5%)                                   | 0                                          |
| Myocarditis*                                           | 0                                      | 0                                      | 5 (0.4%) a                                 | 4 (0.4%) a                                 |
| Adrenal insufficiency*                                 | 0                                      | 0                                      | 3 (0.3%)                                   | 3 (0.3%)                                   |
| Immune-mediated hypophysitis*                          | 0                                      | 0                                      | 3 (0.3%)                                   | 2 (0.2%)                                   |
| Neuropathy peripheral*                                 | 0                                      | 0                                      | 3 (0.3%)                                   | 1 (<0.1%)                                  |
| Pericarditis*                                          | 1 (0.3%)                               | 0                                      | 3 (0.3%)                                   | 2 (0.2%)                                   |
| Pruritus*                                              | 0                                      | 0                                      | 3 (0.3%)                                   | 1 (<0.1%)                                  |
| Stomatitis                                             | 0                                      | 0                                      | 3 (0.3%)                                   | 0                                          |
| Myositis*                                              | 0                                      | 0                                      | 2 (0.2%)                                   | 0                                          |
| Autoimmune demyelinating disease*                      | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Blood alkaline phosphatase increased                   | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Blood thyroid stimulating hormone decreased            | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Encephalitis*                                          | 0                                      | 0                                      | 1 (<0.1%)                                  | 1 (<0.1%)                                  |
| Immune-mediated thrombocytopenia*                      | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Meningitis*                                            | 0                                      | 0                                      | 1 (<0.1%)                                  | 1 (<0.1%)                                  |
| Muscular weakness                                      | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Myalgia                                                | 0                                      | 0                                      | 1 (<0.1%)                                  | 1 (<0.1%)                                  |
| Paraneoplastic encephalomyelitis                       | 0                                      | 0                                      | 1 (<0.1%)                                  | 1 (<0.1%)                                  |
| Polymyalgia rheumatica                                 | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Sjogren's syndrome                                     | 0                                      | 0                                      | 1 (<0.1%)                                  | 0                                          |
| Type 1 diabetes mellitus*                              | 0                                      | 0                                      | 1 (<0.1%)                                  | 1 (<0.1%)                                  |

Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; imAE, immune-mediated adverse event; MedDRA, Medical Dictionary for Regulatory Activities; NCI, National Cancer Institute; PT, preferred term; Regeneron, Regeneron Pharmaceuticals, Inc.

All AEs were coded using MedDRA Version 23.1. NCI grades were coded using CTCAE Version 4.03.

* Each composite term includes multiple MedDRA PTs based on Regeneron defined list. Refer to ISS Table 14.3.2.4.11.

a Two additional identified imAEs of Myocarditis (grade 5) and Immune-mediated hepatitis (grade 4) were identified by the sponsor during medical review of cases and added to Table 67 (R2810-ONC-1624 Primary Analysis CSR Erratum).

A patient is counted only once for multiple occurrences within a composite term/PT.

The table is sorted by decreasing f requency of all grades in the total group.

Data cutoffs: 04 Jan 2021 in Study 1676; 01 Mar 2020 for patients in Study 1624; 30 Apr 2019 for patients in Study 1423; 20 Sep 2018 for all patients in Group 1 and Group 3 and 10 Oct 2018 for Group 2 in Study 154 0; and 30 Jun 2020 for all patients in Study 1620.

Source: ISS Table 14.3.2.4.1, ISS Table 14.3.2.4.10, and R2810-ONC-1624 Primary Analysis CSR Erratum

<div style=\"page-break-after: always\"></div>

## 2.5.4.4. Adverse drug reactions

The adverse drug reaction (ADR) table is based on safety data from Study 1676 (Pool 1) and from integrated safety data (Pool 2). Adverse drug reactions were defined as AEs that met at least 1 of the following criteria:

- TEAEs that occurred in at least 10% of patients in either Pool 1 or Pool 2
- Identified imAEs occurring in at least 1 patient in Pool 2
- Infusion-related reactions occurring in at least 1 patient (using the PT IRR) in Pool 2

Table 68: Adverse Drug Reactions Occurring in At Least 10% of Patients in the Cemiplimab Arm in Study 1676 (Safety Analysis Set) - Total Population

| Adverse Reactions                                    | Cemiplimab (N=300)   | Cemiplimab (N=300)   | Chemotherapy (N=290)   | Chemotherapy (N=290)   |
|------------------------------------------------------|----------------------|----------------------|------------------------|------------------------|
| SOC                                                  | All Grades           | Grade 3/4            | All Grades             | Grade 3/4              |
| PT                                                   | N (%)                | N (%)                | N (%)                  | N (%)                  |
| Number of patients with any TEAE, n (%)              | 265 (88.3%)          | 135 (45.0%)          | 265 (91.4%)            | 155 (53.4%)            |
| Gastrointestinal disorders                           | 151 (50.3%)          | 23 (7.7%)            | 185 (63.8%)            | 28 (9.7%)              |
| Nausea                                               | 55 (18.3%)           | 1 (0.3%)             | 97 (33.4%)             | 6 (2.1%)               |
| Vomiting                                             | 48 (16.0%)           | 2 (0.7%)             | 68 (23.4%)             | 7 (2.4%)               |
| Constipation                                         | 45 (15.0%)           | 0                    | 59 (20.3%)             | 1 (0.3%)               |
| Diarrhoea                                            | 32 (10.7%)           | 3 (1.0%)             | 39 (13.4%)             | 4 (1.4%)               |
| General disorders and administration site conditions | 124 (41.3%)          | 19 (6.3%)            | 152 (52.4%)            | 11 (3.8%)              |
| Fatigue                                              | 50 (16.7%)           | 4 (1.3%)             | 45 (15.5%)             | 4 (1.4%)               |
| Pyrexia                                              | 35 (11.7%)           | 1 (0.3%)             | 61 (21.0%)             | 0                      |
| Asthenia                                             | 33 (11.0%)           | 7 (2.3%)             | 44 (15.2%)             | 3 (1.0%)               |
| Infections and infestations                          | 107 (35.7%)          | 30 (10.0%)           | 87 (30.0%)             | 30 (10.3%)             |
| Urinary tract infection                              | 35 (11.7%)           | 15 (5.0%)            | 25 (8.6%)              | 8 (2.8%)               |
| Metabolism and nutrition disorders                   | 92 (30.7%)           | 20 (6.7%)            | 88 (30.3%)             | 14 (4.8%)              |
| Decreased appetite                                   | 45 (15.0%)           | 1 (0.3%)             | 46 (15.9%)             | 2 (0.7%)               |
| Blood and lymphatic system disorders                 | 87 (29.0%)           | 41 (13.7%)           | 157 (54.1%)            | 101 (34.8%)            |
| Anaemia                                              | 75 (25.0%)           | 36 (12.0%)           | 129 (44.5%)            | 78 (26.9%)             |
| Musculoskeletal and connective tissue disorders      | 83 (27.7%)           | 10 (3.3%)            | 65 (22.4%)             | 6 (2.1%)               |
| Back pain                                            | 33 (11.0%)           | 4 (1.3%)             | 25 (8.6%)              | 2 (0.7%)               |
| Arthralgia                                           | 31 (10.3%)           | 1 (0.3%)             | 8 (2.8%)               | 0                      |

Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; MedDRA, Medical Dictionary for Regulatory Activities; NCI, National Cancer Institute PT, preferred term; SOC, system organ class

All AEs coded using the MedDRA Version 23.1. NCI grade were coded using CTCAE Version 4.03.

Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03

A patient is counted only once for multiple occurrences within a system organ class/preferred ter m.

For system organ class, the table was sorted by decreasing frequency of all grades in the cemiplimab arm. Within each system organ class, preferred terms are sorted by decreasing frequency in the cemiplimab arm.

Data cutoff as 04 Jan 2021 in Study 1676.

a. Fatigue is a composite term that includes Fatigue, Asthenia, and Malaise

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTT 14.3.1.2.4all

<div style=\"page-break-after: always\"></div>

Table 69: Adverse Drug Reactions Occurring in At Least 10% of Cemiplimab-Treated Patients in Study 1676 (Pool 1) or Pool 2 (Safety Analysis Set)

| System organ class                                   | Pool 1 All Cervical Patients (N=300)   | Pool 1 All Cervical Patients (N=300)   | Pool 2 All Monotherapy Patients (N=1116)   | Pool 2 All Monotherapy Patients (N=1116)   |
|------------------------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------------------|
| Composite/Preferred term                             | All Grades                             | Grades 3/4/5                           | All Grades                                 | Grades 3/4/5                               |
| Number of patients with any TEAE, n (%)              | 265 (88.3%)                            | 135 (45.0%)                            | 1030 (92.3%)                               | 472 (42.3%)                                |
| Gastrointestinal disorders                           | 151 (50.3%)                            | 23 (7.7%)                              | 506 (45.3%)                                | 58 (5.2%)                                  |
| Nausea                                               | 55 (18.3%)                             | 1 (0.3%)                               | 155 (13.9%)                                | 2 (0.2%)                                   |
| Vomiting                                             | 48 (16.0%)                             | 2 (0.7%)                               | 108 (9.7%)                                 | 3 (0.3%)                                   |
| Abdominal pain*                                      | 45 (15.0%)                             | 4 (1.3%)                               | 124 (11.1%)                                | 9 (0.8%)                                   |
| Constipation                                         | 45 (15.0%)                             | 0                                      | 133 (11.9%)                                | 2 (0.2%)                                   |
| Diarrhoea*                                           | 32 (10.7%)                             | 3 (1.0%)                               | 168 (15.1%)                                | 7 (0.6%)                                   |
| General disorders and administration site conditions | 124 (41.3%)                            | 19 (6.3%)                              | 484 (43.4%)                                | 57 (5.1%)                                  |
| Fatigue*                                             | 83 (27.7%)                             | 11 (3.7%)                              | 312 (28.0%)                                | 30 (2.7%)                                  |
| Pyrexia*                                             | 40 (13.3%)                             | 1 (0.3%)                               | 95 (8.5%)                                  | 2 (0.2%)                                   |
| Infections and infestations                          | 107 (35.7%)                            | 30 (10.0%)                             | 427 (38.3%)                                | 122 (10.9%)                                |
| Urinary tract infection*                             | 49 (16.3%)                             | 19 (6.3%)                              | 99 (8.9%)                                  | 28 (2.5%)                                  |
| Upper respiratory tract infection*                   | 24 (8.0%)                              | 0                                      | 112 (10.0%)                                | 3 (0.3%)                                   |
| Metabolism and nutrition disorders                   | 92 (30.7%)                             | 20 (6.7%)                              | 365 (32.7%)                                | 82 (7.3%)                                  |
| Decreased appetite                                   | 45 (15.0%)                             | 1 (0.3%)                               | 147 (13.2%)                                | 6 (0.5%)                                   |
| Blood and lymphatic system disorders                 | 87 (29.0%)                             | 41 (13.7%)                             | 246 (22.0%)                                | 84 (7.5%)                                  |
| Anaemia                                              | 75 (25.0%)                             | 36 (12.0%)                             | 181 (16.2%)                                | 63 (5.6%)                                  |
| Musculoskeletal and connective tissue disorders      | 83 (27.7%)                             | 10 (3.3%)                              | 367 (32.9%)                                | 32 (2.9%)                                  |
| Musculoskeletal pain*                                | 72 (24.0%)                             | 6 (2.0%)                               | 315 (28.2%)                                | 19 (1.7%)                                  |
| Respiratory, thoracic and mediastinal disorders      | 62 (20.7%)                             | 8 (2.7%)                               | 331 (29.7%)                                | 64 (5.7%)                                  |
| Cough*                                               | 24 (8.0%)                              | 1 (0.3%)                               | 126 (11.3%)                                | 2 (0.2%)                                   |
| Skin and subcutaneous tissue disorders               | 60 (20.0%)                             | 5 (1.7%)                               | 374 (33.5%)                                | 20 (1.8%)                                  |
| Rash*                                                | 37 (12.3%)                             | 5 (1.7%)                               | 223 (20.0%)                                | 18 (1.6%)                                  |
| Pruritus*                                            | 16 (5.3%)                              | 0                                      | 123 (11.0%)                                | 1 (<0.1%)                                  |

Abbreviations: PT, preferred term; SOC, system organ class

* Each composite term includes multiple MedDRA preferred terms based on Regeneron defined list.

All AEs were coded using MedDRA Version 23.1. NCI grades were coded using CTCAE Version 4.03.

A patient is counted only once for multiple occurrences within a SOC/PT.

For SOCs, the table is sorted by decreasing frequency of all grades in the total group. Within each SOC, PTs are sorted by decreasing frequency in the total group.

Data cutoffs: 04 Jan 2021 in Study 1676;01 Mar 2020 for patients in Study 1624; 30 Apr 2019 for patients in Study 1423; 20 Sep 2018 for all patients in Group 1 and Group 3 and 10 Oct 2018 for Group 2 in Study 1540; and 30 Jun 2020 for all patients in Study 162

Source: ISS Table 14.3.2.7.2.

<div style=\"page-break-after: always\"></div>

## 2.5.5. Laboratory findings

## Summary of laboratory findings

Table 70: Selected TreatmentEmergent Laboratory Abnormalities in ≥15 % in All Grades in Study 1676 (Safety Analysis Set) - Total Population

|                                                                                         | Cemiplimab (N=300)   | Cemiplimab (N=300)   | Chemotherapy (N=290)   | Chemotherapy (N=290)   |
|-----------------------------------------------------------------------------------------|----------------------|----------------------|------------------------|------------------------|
| Parameter (CTCAE Term)                                                                  | All Grades n/N (%)   | Grades¾ n/N (%)      | All Grades n/N (%)     | Grades¾ n/N (%)        |
| Liver Function                                                                          |                      |                      |                        |                        |
| Number of patients with at least one                                                    | 209/294 (71.1%)      | 27/294 (9.2%)        | 187/271                | 24/271 (8.9%)          |
| lab abnormality                                                                         |                      |                      | (69.0%)                |                        |
| Alanine aminotransferase increased                                                      | 71/294 (24.1%)       | 10/294 (3.4%)        | 97/271 (35.8%)         | 4/271 (1.5%)           |
| Hypoalbuminemia                                                                         | 115/293 (39.2%)      | 9/293 (3.1%)         | 98/271 (36.2%)         | 12/271 (4.4%)          |
| Alkaline phosphatase increased                                                          | 103/293 (35.2%)      | 10/293 (3.4%)        | 81/269 (30.1%)         | 5/269 (1.9%)           |
| Aspartate aminotransferase increased                                                    | 87/294 (29.6%)       | 12/294 (4.1%)        | 84/271 (31.0%)         | 3/271 (1.1%)           |
| Electrolytes                                                                            |                      |                      |                        |                        |
| Number of patients with at least one                                                    | 199/294 (67.7%)      | 42/294 (14.3%)       | 154/271                | 32/271 (11.8%)         |
| lab abnormality Hypercalcemia (Uncorrected                                              | 45/294 (15.3%)       | 3/294 (1.0%)         | (56.8%) 27/271 (10.0%) | 2/271 (0.7%)           |
| Calcium)                                                                                |                      |                      |                        |                        |
| Hypocalcemia (Uncorrected Calcium)                                                      | 76/294 (25.9%)       | 5/294 (1.7%)         | 69/271 (25.5%)         | 4/271 (1.5%)           |
| Hyperkalemia                                                                            | 40/294 (13.6%)       | 7/294 (2.4%)         | 41/271 (15.1%)         | 2/271 (0.7%)           |
| Hypokalemia                                                                             | 58/294 (19.7%)       | 14/294 (4.8%)        | 52/271 (19.2%)         | 11/271 (4.1%)          |
| Hyponatremia                                                                            | 93/294 (31.6%)       | 18/294 (6.1%)        | 71/271 (26.2%)         | 15/271 (5.5%)          |
| Hematology                                                                              |                      |                      |                        |                        |
| Number of patients with at least one lab abnormality                                    | 210/293 (71.7%)      | 83/293 (28.3%)       | 254/278 (91.4%)        | 137/278 (49.3%)        |
| Anemia                                                                                  | 156/293 (53.2%)      | 49/293 (16.7%)       | 212/278 (76.3%)        | 83/278 (29.9%)         |
| White blood cell decreased                                                              | 45/293 (15.4%)       | 4/293 (1.4%)         | 151/277 (54.5%)        | 38/277 (13.7%)         |
| Lymphocyte count decreased                                                              | 107/293 (36.5%)      | 42/293 (14.3%)       | 154/278 (55.4%)        | 61/278 (21.9%)         |
| Neutrophil count decreased                                                              | 20/293 (6.8%)        | 7/293 (2.4%)         | 115/278 (41.4%)        | 44/278 (15.8%)         |
| Platelet count decreased                                                                | 38/293 (13.0%)       | 6/293 (2.0%)         | 78/278 (28.1%)         | 19/278 (6.8%)          |
| Other Chemistry                                                                         |                      |                      |                        |                        |
| Number of patients with at least one                                                    | 237/294 (80.6%)      | 12/294 (4.1%)        | 210/272                | 10/272 (3.7%)          |
| lab abnormality                                                                         |                      |                      | (77.2%)                |                        |
| Creatinine (Creatinine increased)                                                       | 200/294 (68.0%)      | 9/294 (3.1%)         | 188/272 (69.1%)        | 8/272 (2.9%)           |
| Fasting Glucose (Hyperglycemia)                                                         | 91/228 (39.9%)       | 2/228 (0.9%)         | 72/193 (37.3%)         | 3/193 (1.6%)           |
| Coagulation                                                                             |                      |                      |                        |                        |
| Number of patients with at least one                                                    | 5/18 (27.8%)         | 0/18                 | 4/23 (17.4%)           | 0/23                   |
| lab abnormality Activated Partial Thromboplastin Time (Activated partial thromboplastin | 5/18 (27.8%)         | 0/18                 | 4/23 (17.4%)           | 0/23                   |

Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; NCI, National Cancer Institute

NCI grades were coded using CTCAE Version 4.03.

Percentages are based on the number of patients with at least 1 postbaseline value available for that parameter.

Postbaseline value is for on-treatment period only.

A patient is counted only once for multiple occurrences for the same parameter.

Data cutoff as of 04 Jan 2021 for all patients in Study 1676.

Sources: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTTs 14.3.3.1.1all, 14.3.3.2.1all, 14.3.3.3.1all, 14.3.3.4.1all, and 14.3.3.5.1all.

<div style=\"page-break-after: always\"></div>

## 2.5.6. Safety in special populations

## Intrinsic factors:

Incidence of AEs according to age subgroups:

Table 71: Distribution of AEs, SAEs, and Discontinuations According to Age Group (Safety Analysis Set) - Pool 2

|                                                                        | Age: <65 years (N=640)   | Age: 65 to 74 years (N=289)   | Age: 75 to 84 years (N=154)   | Age: ≥85 years (N=33)   | Total (N=1116)   |
|------------------------------------------------------------------------|--------------------------|-------------------------------|-------------------------------|-------------------------|------------------|
| Number of TEAEs                                                        | 4575                     | 2223                          | 1275                          | 362                     | 8435             |
| Number of patients with any TEAE, n (%)                                | 575 (89.8%)              | 270 (93.4%)                   | 152 (98.7%)                   | 33 (100%)               | 1030 (92.3%)     |
| Number of serious TEAEs                                                | 282                      | 146                           | 113                           | 46                      | 587              |
| Number of patients with any serious TEAE, n (%)                        | 172 (26.9)               | 87 (30.1%)                    | 57 (37.0%)                    | 19 (57.6%)              | 335 (30.0%)      |
| Fatal                                                                  | 28 (4.4%)                | 19 (6.6%)                     | 3 (1.9%)                      | 4 (12.1%)               | 54 (4.8%)        |
| Life-threatening                                                       | 13 (2.0%)                | 10 (3.5%)                     | 7 (4.5%)                      | 4 (12.1%)               | 34 (3.0%)        |
| Hospitalization/prolonged existing hospitalization                     | 160 (25.0%)              | 75 (26.0%)                    | 55 (35.7%)                    | 19 (57.6%)              | 309 (27.7%)      |
| Disability/incapacity                                                  | 9 (1.4%)                 | 0                             | 2 (1.3%)                      | 1 (3.0%)                | 12 (1.1%)        |
| Congenital abnormality or birth defect                                 | 0                        | 0                             | 0                             | 0                       | 0                |
| Other (medically significant)                                          | 5 (0.8%)                 | 6 (2.1%)                      | 5 (3.2%)                      | 2 (6.1%)                | 18 (1.6%)        |
| Number of patients who discontinued study treatment due to TEAE, n (%) | 47 (7.3%)                | 22 (7.6%)                     | 16 (10.4%)                    | 7 (21.2%)               | 92 (8.2%)        |

Abbreviations: TEAE, treatment-emergent adverse event.

Data cutoffs: 04 Jan 2021 in Study 1676; 01 Mar 2020 for patients in Study 1624; 30 Apr 2019 for patients in Study 1423; 20 Sep 2018 for all patients in Group 1 and Group 3 and 10 Oct 2018 for Group 2 in Study 1540; and 30 Jun 2020 for all patients in Study 1620.

A patient is only counted once for multiple occurrences within a category.

Source: ISS Table 14.3.2.8.1.p2

<div style=\"page-break-after: always\"></div>

Table 72: Summary of Treatment-Emergent Adverse Events by PD-L1 Status in Study 1676 (Safety Analysis Set) - Patients with SCC and non-SCC Histology

|                                                                              | Cemiplimab   | Cemiplimab   | Cemiplimab    | Cemiplimab   | Chemotherapy   | Chemotherapy   | Chemotherapy   | Chemotherapy   |
|------------------------------------------------------------------------------|--------------|--------------|---------------|--------------|----------------|----------------|----------------|----------------|
|                                                                              | PD-L1 ≥1%    | PD-L1 <1%    | PD-L1 Unknown | Total        | PD-L1 ≥1%      | PD-L1 <1%      | PD-L1 Unknown  | Total          |
|                                                                              | (N=115)      | (N=67)       | (N=118)       | (N=300)      | (N=117)        | (N=65)         | (N=108)        | (N=290)        |
| Number of TEAEs                                                              | 795          | 453          | 721           | 1969         | 975            | 624            | 757            | 2356           |
| Number of NCI grade 3/4/5 TEAEs                                              | 111          | 57           | 131           | 299          | 144            | 82             | 159            | 385            |
| Number of serious TEAEs                                                      | 48           | 38           | 61            | 147          | 50             | 39             | 44             | 133            |
| Number ofpatients with anyTEAE,n (%)                                         | 105 (91.3%)  | 58 (86.6%)   | 102 (86.4%)   | 265 (88.3%)  | 110 (94.0%)    | 60 (92.3%)     | 95 (88.0%)     | 265 (91.4%)    |
| Number of patients with any NCI grade 3/4/5 TEAE, n (%)                      | 53 (46.1%)   | 33 (49.3%)   | 49 (41.5%)    | 135 (45.0%)  | 66 (56.4%)     | 34 (52.3%)     | 55 (50.9%)     | 155 (53.4%)    |
| Number of patients with any serious TEAE, n (%)                              | 30 (26.1%)   | 26 (38.8%)   | 33 (28.0%)    | 89 (29.7%)   | 31 (26.5%)     | 21 (32.3%)     | 26 (24.1%)     | 78 (26.9%)     |
| Number of patients who discontinued study treatment due to TEAEs, n (%)      | 10 (8.7%)    | 4 (6.0%)     | 12 (10.2%)    | 26 (8.7%)    | 5 5(4.3%)      | 6(9.2%)        | 4 (3.7%)       | 15 (5.2%)      |
| Number of patients with any TEAE leading to a dose interruption/delay, n (%) | 24 (20.9%)   | 19 (28.4%)   | 32 (27.1%)    | 75 (25.0%)   | 42 (35.9%)     | 28 (43.1%)     | 44 (40.7%)     | 114 (39.3%)    |
| Number of patients with any TEAE leading to a dose reduction, n (%)          | 0            | 0            | 0             | 0            | 31 (26.5%)     | 12 (18.5%)     | 15 (13.9%)     | 58 (20.0%)     |
| Number of patients with any TEAE resulting in death, n (%)                   | 3 (2.6%)     | 0            | 2 (1.7%)      | 5 (1.7%)     | 2 (1.7%)       | 0              | 0              | 2 2(0.7%)      |

Data cut-off as of 04 Jan 2021.

TEAE:Treatment-EmergentAdverseEvents

NCI grades were coded using CTCAE Version 4.03.

A patient is counted only once for multiple occurrences within a category.

Table 73: Treatment-Emergent Adverse Events of Special Interest by PD-L1 Status in Study 1676 Based on CRF Collected Criteria (Safety Analysis Set) - Patients with SCC and non-SCC Histology

|                                                                  | Cemiplimab   | Cemiplimab   | Cemiplimab    | Cemiplimab   | Chemotherapy   |
|------------------------------------------------------------------|--------------|--------------|---------------|--------------|----------------|
|                                                                  | PD-L1 ≥1%    | PD-L1<1%     | PD-L1 Unknown | Total        | Total          |
|                                                                  | (N=115)      | (N=67)       | (N=118)       | (N=300)      | (N=290)        |
| Numberofpatientswith anytreatment-emergent AESI, n (%)           | 14 (12.2%)   | 6 (9.0%)     | 14 (11.9%)    | 34 (11.3%)   | 0              |
| Grade2orgreaterinfusion-relatedreactions                         | 3 (2.6%)     | 0            | 1 (0.8%)      | 4 (1.3%)     | 0              |
| Grade2orgreater allergicreactions                                | 0            | 0            | 2(1.7%)       | 2 (0.7%)     | 0              |
| Grade3orgreaterimmune-relatedtoxicities                          | 11 (9.6%)    | 6 (9.0%)     | 12 (10.2%)    | 29 (9.7%)    | 0              |
| AnirAEofanygradeinapatientpreviously treatedwith aPI3-Kinhibitor | 0            | 0            | 0             | 0            | 0              |

Datacut-off asof04Jan2021.

AESI:Adverse event of specialinterest.

A patient is counted only oncefor multiple occurrences within aCRFreported criteria.

## 2.5.7. Safety related to drug-drug interactions and other interactions

No pharmacokinetic drug-drug interaction studies were submitted which was considered acceptable (see discussion on clinical pharmacology).

<div style=\"page-break-after: always\"></div>

## 2.5.8. Discontinuation due to adverse events

Table 74: Summary of Treatment-Emergent Adverse Events Resulting in Treatment Discontinuation by System Organ Class and Preferred Term in Study 1676 (Safety Analysis Set) -Total Population

|                                                  | Cemiplimab        | Cemiplimab      | Chemotherapy   | Chemotherapy    |
|--------------------------------------------------|-------------------|-----------------|----------------|-----------------|
| System Organ Class, n (%) Preferred Term, n (%)  | n (%)             | Rate per 100 PY | n (%)          | Rate per 100 PY |
| Number of patients with any TEAE resulting in    | 26 (8.7%)         | 17.09           | 15 (5.2%)      | 18.95           |
| treatment discontinuation, n (%)                 |                   |                 |                |                 |
| Hepatobiliary disorders                          | 8 (2.7%)          | 5.25            | 0              | 0.00            |
| Autoimmune hepatitis                             | 3 (1.0%)          | 1.97            | 0              | 0.00            |
| Immune-mediated hepatitis                        | 3 (1.0%)          | 1.97            | 0              | 0.00            |
| Hepatic function abnormal                        | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Hepatitis                                        | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Respiratory, thoracic and mediastinal disorders  | 5 (1.7%)          | 3.28            | 1 (0.3%)       | 1.25            |
| Pneumonitis                                      | 5 (1.7%)          | 3.28            | 1 (0.3%)       | 1.25            |
| Infections and infestations                      | 4 (1.3%)          | 2.63            | 1 (0.3%)       | 1.25            |
| COVID-19 pneumonia                               | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Gastroenteritis                                  | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Pelvic abscess                                   | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Peritonitis                                      | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Pneumonia                                        | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Pyomyositis                                      | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Gastrointestinal disorders                       | 3 (1.0%)          | 1.97            | 2 (0.7%)       | 2.52            |
| Colitis                                          | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Gastritis                                        | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Pancreatic                                       | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| mass Pancreatitis chronic                        | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Diverticular perforation                         | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| Nausea                                           | 0                 | 0.00            | 1 (0.3%)       | 1.26            |
| Vomiting                                         | 0                 | 0.00            | 1 (0.3%)       | 1.26            |
| Blood and lymphatic system disorders             | 2 (0.7%)          | 1.31            | 2 (0.7%)       | 2.51            |
| Anaemia                                          | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Disseminated intravascular coagulation           | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Febrile neutropenia                              | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Neutropenia                                      | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| Thrombocytopenia                                 | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| Endocrine disorders                              | 2 (0.7%)          | 1.31            | 0              | 0.00            |
| Hypothyroidism                                   | 2 (0.7%)          | 1.31            | 0              | 0.00            |
| Investigations                                   | 2 (0.7%)          | 1.31            | 0              | 0.00            |
| Alanine aminotransferase increased               | 1 (0.3%)          | 0.66            | 0 0            | 0.00 0.00       |
| Amylase increased Platelet count decreased       | 1 (0.3%) 1 (0.3%) | 0.66 0.66       | 0              | 0.00            |
| Cardiac disorders                                | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Autoimmune pericarditis                          | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Cardiac failure                                  | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| General disorders and administration site        | 1 (0.3%)          | 0.66            | 2 (0.7%)       | 2.51            |
| conditions                                       |                   |                 |                |                 |
| Non-cardiac chest pain                           | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Fatigue                                          | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| Malaise                                          | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| Injury, poisoning and procedural complications   | 1 (0.3%)          | 0.66            | 2 (0.7%)       | 2.51            |
| Spinal compression fracture                      | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Infusion-related reaction                        | 0                 | 0.00            | 2 (0.7%)       | 2.51            |
| Metabolism and nutrition disorders               | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Decreased appetite                               | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Musculoskeletal and connective tissue disorders  | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Polyarthritis                                    | (0.3%)            | 0.66            | 0              | 0.00            |
| Muscular weakness                                | 1 0               | 0.00            | 1 (0.3%)       | 1.25            |
| Renal and urinary disorders                      | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25            |
| Acute kidney injury                              | 1 (0.3%)          | 0.66            | 0              | 0.00            |
| Renal failure                                    | 0                 | 0.00            | 1 (0.3%)       | 1.25            |
| Vascular disorders                               | 1 (0.3%)          | 0.66            | 1 (0.3%)       | 1.25 0.00       |
| Superior vena cava syndrome Deep vein thrombosis | 1 (0.3%)          | 0.66 0.00       | 0 1 (0.3%)     | 1.25            |
| Immune system                                    | 0                 | 0.00            | 1              | 1.25            |
| disorders                                        | 0                 |                 | (0.3%)         |                 |

<div style=\"page-break-after: always\"></div>

|                                                 | Cemiplimab (N=300)   | Cemiplimab (N=300)   | Chemotherapy (N=290)   | Chemotherapy (N=290)   |
|-------------------------------------------------|----------------------|----------------------|------------------------|------------------------|
| System Organ Class, n (%) Preferred Term, n (%) | n (%)                | Rate per 100 PY      | n (%)                  | Rate per 100 PY        |
| Anaphylactic reaction                           | 0                    | 0.00                 | 1 (0.3%)               | 1.25                   |
| Nervous system disorders                        | 0                    | 0.00                 | 3 (1.0%)               | 3.77                   |
| Headache                                        | 0                    | 0.00                 | 1 (0.3%)               | 1.26                   |
| Neurotoxicity                                   | 0                    | 0.00                 | 1 (0.3%)               | 1.25                   |
| Transient ischaemic attack                      | 0                    | 0.00                 | 1 (0.3%)               | 1.25                   |
| Psychiatric disorders                           | 0                    | 0.00                 | 1 (0.3%)               | 1.25                   |
| Agoraphobia                                     | 0                    | 0.00                 | 1 (0.3%)               | 1.25                   |

Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; PY, patient-years; SOC, system organ class; TEAE, treatment-emergent adverse event

All AEs were coded using MedDRA Version 23.1.

A patient is counted only once for multiple occurrences within a SOC/PT.

For SOCs, the table is sorted by decreasing frequency in the total group. Within each SOC, PTs are sorted by decreasing frequ ency in the total group. Data cutoff as of 04 Jan 2021 for all patients in Study 1676.

Source: Module 5.3.5.1 Study 1676 Primary Analysis CSR PTTs 14.3.1.2.9all and 14.3.1.2.16all

Table 75: Patient disposition (safety analysis set)

|                                              | Pool1 All CervicalPatients (N=300)   | Pool 2 All Monotherapy Patients (N=1116)   |
|----------------------------------------------|--------------------------------------|--------------------------------------------|
| Treatment Ongoing, n (%)                     | 37 (12.3%)                           | 260 (23.3%)                                |
| Off Treatment, n (%)                         | 263 (87.7%)                          | 856 (76.7%)                                |
| Treatment Completed                          | 13 (4.3%)                            | 110 (9.9%)                                 |
| Treatment Discontinued                       | 250 (83.3%)                          | 746 (66.8%)                                |
| Primary Reason for Treatment Discontinuation |                                      |                                            |
| ADVERSE EVENT                                | 25 (8.3%)                            | 89 (8.0%)                                  |
| PREGNANCY                                    | 0                                    | 0                                          |
| DEATH                                        | 14 (4.7%)                            | 57 (5.1%)                                  |
| LOST TOFOLLOW-UP                             | 0                                    | 6 (0.5%)                                   |
| NON-COMPLIANCE                               | 1 (0.3%)                             | 5 (0.4%)                                   |
| SUBJECT DECISION                             | 8 (2.7%)                             | 32 (2.9%)                                  |
| SPONSOR DECISION                             | 0                                    | 0                                          |
| PHYSICIAN DECISION                           | 0                                    | 17 (1.5%)                                  |
| PROGRESSIVEDISEASE                           | 199 (66.3%)                          | 507 (45.4%)                                |
| WITHDRAWAL OF CONSENT                        | 3 (1.0%)                             | 17 (1.5%)                                  |
| CR OR PR OR SD                               | 0                                    | 0                                          |
| CONFIRMED CR                                 | 0                                    | 2 (0.2%)                                   |
| OTHER                                        | 0                                    | 14 (1.3%)                                  |

Data cut-off as of 04 Jan 2021 for Study 1676; Data cut-off as of 30 Jun 2020 for Study 1620; Data cut-off as of 01 Mar 2020 for Study 1624; Data cut-off as of 30 Apr 2019 for Study 1423; Data cut-off as of 20 Sep 2018 for h As  sd z do   o 01 o s o- 1 t1 s  sd g o pe 1 do

<div style=\"page-break-after: always\"></div>

The most frequent reasons for discontinuations in the cemiplimab arm were primarily immune-mediated events: hepatobiliary disorders in 8 (2.7%) patients (autoimmune/immune-mediate/other hepatitis, abnormal hepatic function) and respiratory disorders in 5 (1.7%) (pneumonitis).

Less frequent reasons for discontinuing cemiplimab were: infections 4 (1.3%) patients (pneumonias, various abdominal infections), gastrointestinal disorders 3 (1%) patients (colitis, gastritis, pancreatitis), blood and lymphatic disorders 2 (0.7%) patients (anaemia, febrile neutropenia) and endocrine disorders 2 (0.7%) patients (hypothyroidism).

In the chemotherapy arm , the reasons for discontinuations were more varied, the most frequent being: gastrointestinal disorders 2 (0.7%) patients, blood and lymphatic disorders 2 (0.7%) patients, general disorders (fatigue, malaise) 2 (0.7%) patients, infusion-related reactions 2 (0.7%) patients and nervous system disorders 3 (1%) patients.

## 2.5.9. Post marketing experience

Cemiplimab is approved in several countries for the treatment of adult patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Cemiplimab is also approved in some countries for BCC and first line treatment of NSCLC with high PD-L1 expression. Cumulatively up to 27 March 2021, a total of 3945 patients (3349 patients from Regeneron studies and 596 patients from non-Regeneron sponsored studies) have been treated with investigational cemiplimab monotherapy, combination therapy, or comparator product in multiple clinical trials. The cumulative exposure to cemiplimab in clinical studies is estimated to be 97,072 patient weeks (82,266 patient-weeks in Regeneron studies and 14,806 patient-weeks in non-Regeneron studies).

Based on the sales figures through 31 March 2021, the global cumulative exposure to cemiplimab was estimated to be 6484 patient-years.

The list of important identified risks for cemiplimab discussed in the Periodic Safety Update Report are Immune-related adverse reactions and Infusion-related reactions. The important potential risks for cemiplimab are lack of effect due to anti-drug antibodies and embryo-fetal toxicity (not a risk in the EU risk management plan). The missing information for cemiplimab are long-term safety data (risk management plan safety concern), use in pregnant women and use in breast-feeding women.

Since initial approval in the US in September 2018, no new safety concerns/important risks were identified from post marketing data.

## 2.5.10. Discussion on clinical safety

For the safety assessment, the MAH has provided data from the safety dataset (n=300 in the cemiplimab arm and n=290 in the chemotherapy arm) at the second interim analysis (~65% of OS events observed) of the ongoing study 1676 in patients with cervical cancer with progression after prior platinum treatment. The safety data cutoff (DCO) for this submission was 04 January 2021.

Also, pooled safety data from 5 studies was submitted: 1676 (current study), 1423, 1540, 1620 and 1624 in patients who received at least 1 dose of cemiplimab as monotherapy, the majority of whom received the currently authorised dose of 350 mg Q3W. Data from the cemiplimab arm of study 1676 represented safety pool 1 (n=300) and data from the 5 monotherapy studies comprised the safety pool 2 (n=1116). The size of safety data pools is considered sufficient for a meaningful safety assessment.

<div style=\"page-break-after: always\"></div>

Exposure: By the DCO, 87.7% patients in the cemiplimab arm and 97.6% in the chemotherapy arm were off treatment and 82.3% and 96.2% respectively were off study. In both arms most patients discontinued treatment primarily due to disease progression, only 4.3% in the cemiplimab arm completed the maximum allowed treatment (96 weeks). The main reasons for being off study in both arms were either death, 29.7% and 32.4%, or disease progression, 32.7% and 40.3%. The extent of on-treatment and onstudy is considered sufficient for a meaningful safety assessment. The median and mean duration of treatment exposure were higher in the cemiplimab arm (15 and 26.5 (26) weeks) compared to the chemotherapy arm (10 and 14.4 (13) weeks) in study 1676. In the cemiplimab arm vs the chemotherapy arm, 61.7% vs 43.1% were on treatment ≥12 weeks, 37% vs 16.9% more than 24 weeks and 19.3% vs 3.4% more than 48 weeks. Patients were on treatment longer in the cemiplimab arm compared to the chemotherapy arm, which suggests better tolerability of cemiplimab.

Exposure for patients with known PD-L1 status (updated n=371 biomarker dataset) across both arms appeared slightly longer for those with PD-L1 ≥ 1% in both arms.

AEs: Most patients experienced an AE of any grade in the pivotal trial, 88.3% in the cemiplimab arm and 91.4% in the chemotherapy arm, and 45% vs 53.4% experienced AEs of grade ≥3. In both categories, frequencies were higher in the chemotherapy arm.

SAEs and AEs resulting in death were observed in 29.7% vs 26.9% and 1.7% vs 0.7% in the cemiplimab vs the chemotherapy arm respectively. Discontinuation due to AEs was observed in 8.7% vs 5.2%. In these 3 categories, the observed frequencies were higher in the cemiplimab arm, and were comparable to those observed in the cemiplimab monotherapy pool.

High-grade AEs: With regards to AEs ≥grade 3 , the five most frequent in the cemiplimab arm were: anaemia 12%, urinary tract infection 5%, hypokalaemia 2.7%, asthenia 2.3% and hydronephrosis 2.3%. In the chemotherapy arm the five most frequent were: anaemia 26.9%, neutropenia 9%, thrombocytopenia 3.1%, urinary tract infection 2.8% and vomiting 2.4%.

The observed frequencies and categories of highgrade (≥G3) AEs were as expected. The overall incidence of high-grade events between the cemiplimab arm of Study 1676 and the cemiplimab monotherapy pool were overall comparable.

SAEs occurred in 29.7% of patients from the cemiplimab arm and in 26.9% of the chemotherapy arm. The most frequent SAE in both arms was infections: 10.7% vs, 11.4%, respectively. The most frequent infections were urinary tract infections (4% vs 3.4%), pneumonia (1.3% vs 1%) and pyelonephritis (1% in both arms). Gastrointestinal disorders (4.3% vs 4.8%) were equally frequent. Autoimmune/immunemediated hepatitis, a known imAE with incidence of 2.6%, only occurred in the cemiplimab arm. Pneumonitis was also more frequent in the cemiplimab arm (1% vs 0.3%) whereas haematologic SAEs (1.7% vs 6.9%) occurred with a higher frequency in the chemotherapy arm, with febrile neutropenia (1% vs 1.7%), anaemia (0.7% vs 4.8%) and thrombocytopenia (0% vs 1%) being the most frequent. The pattern in the distribution, frequency and type of the SAEs in the two arms was reflective of immunotherapy and chemotherapy, respectively, and were as expected.

AEs resulting in death: In study 1676, from the narratives of the patients with AEs resulting in death in the cemiplimab arm it is agreed that in 4 out of 5 patients, the deaths do not seem to be treatment related. In the case of a 39-year-old patient that died from pneumonia, not enough data could be obtained to rule out the possibility of immune-related pneumonitis. In the chemotherapy arm, 2 patients experienced TEAEs resulting in death, both incidences considered as treatment-related by the investigator.

AESIs: In the study protocol, 4 types of events were defined as AESIs whereof data only on 2 of these 4 have been presented in the dossier (CSR): infusion related reactions (IRR) and imAEs. The data presented was sponsor-identified and not investigator-identified.

<div style=\"page-break-after: always\"></div>

IRRs: As expected, the incidence of IRRs was higher in the chemotherapy arm (4.5%) compared to the cemiplimab arm (2.7%). 0 vs 1 (0.3%) in the cemiplimab arm and chemotherapy arm respectively were grade ≥3, no patient in either arm experienced serious IRRs, 0 vs 2 (0.7%) patients discontinued treatment due to IRRs and 5 (1.7%) vs 9 (3.1%) had dose interruptions/delay due to IRRs. The frequencies of IRRs were similar between safety pool 1 and 2, 2.7 % vs 3% respectively. The symptoms were mostly gastro-intestinal (nausea 2% vs 1.3%, vomiting 1.3% vs 0.7%, abdominal pain 0.3% vs 0.4%) and pyrexia (1% vs 1.1%) and were as expected similar between the 2 pools.

imAEs: As expected, the incidence of imAEs was higher in the cemiplimab arm (15.7%) than in the chemotherapy arm (0.7%). About a third of imAEs were high-grade and/or serious, and the same proportion discontinued cemiplimab because of imAEs. Slightly fewer patients (15.7%) in pool 1 had any imAE compared to pool 2 (20.5%). Any grade ≥3 imAEs (5.3% vs 6.4%), serious imAEs (5% vs 5.5%) or discontinuations due to imAEs (5% vs 4.6%) were comparable between pool 1 and 2. The most frequent imAEs in the cemiplimab arm were endocrine disorders 8%, hepatobiliary disorders 3.3% and skin and subcutaneous disorders 1.7%, same as in pool 2. No new or unexpected frequencies of known IRRs or imAEs were registered in study 1676.

## ADRs:

The ADRs nausea, vomiting and abdominal pain together with urinary tract infections occurred with a higher frequency in the cemiplimab arm of study 1676 compared to the chemotherapy arm and to pool 2. This could be explained by the pattern of dissemination and location of cervical cancer.

General disorders (fatigue, pyrexia and asthenia), infections (except for urinary tract infections that occurred with a higher frequency), metabolic and nutrition disorders (decreased appetite) and musculoskeletal disorders (musculoskeletal pain) all occurred with similar frequencies in the 2 pools.

Respiratory and skin disorders occurred with lower frequencies in pool 1 compared to pool 2.

Patients with cervical cancer exhibited higher rates of ADR anaemia across both cemiplimab and chemotherapy arms, noting nearly double risk of any-grade and ≥ G3 anaemia from chemotherapy. Of note, anaemia was part of the medical history of 37% of patients from the cemiplimab arm and 36% of the chemotherapy arm. All ADRs are appropriately listed in Table 2 from section 4.8 of the SmPC.

The incidences of ADRs have already been updated in the SmPC section 4.8 based on a larger safety dataset (N=1198) as part of the recently approved renewal application (see EMEA/H/C/004844/R/0029). Hence no further update of section 4.8 of the SmPC is warranted.

Laboratory findings: The laboratory findings in study 1676 were as expected and in line with the higher rate of haematological toxicity in the chemotherapy arm and hepatotoxicity in the cemiplimab arm.

Incidence of AEs according to age subgroups: As expected, the largest differences were in general observed between the group of &lt;65 years and ≥85 years, but not considered to require a specific warning.

AEs according to PD-L1 expression subgroups: Particularly concerning the cemiplimab arm, there does not seem to be a specific pattern of toxicity that would indicate higher rates of all-grade, high-grade, G5 AEs, imAEs and AEs leading to discontinuation in the PD-L1&lt;1% vs. PD-L1 ≥ 1% subpopulations. Of note, although SAEs occurred in 39% vs. 28% of patients (PD-L1&lt;1% and PD-L1 ≥ 1% subgroups, respectively), it cannot be concluded that this difference would be attributable to PD-L1% expression per se taking into account that absolute numbers of patients in these subgroups were low.

Discontinuation due to AEs: The discontinuation rate of 8.7% in the cemiplimab arm was higher than in the chemotherapy arm (5.2%) and was also slightly higher than what was seen with cemiplimab for 1L advanced NSCLC (6.5%, study 1624), noting that in the current study the treatment was given in second

<div style=\"page-break-after: always\"></div>

or ulterior lines in a heavily pretreated population. Also, compared to other PD-1 inhibitors, the current discontinuation rate is at the same/low end level.

## 2.5.11. Conclusions on clinical safety

In conclusion, chemotherapy exhibited a more toxic profile regarding AEs and grade ≥3 AEs compared to the PD-1 inhibitor cemiplimab in Study 1676. The opposite pattern was seen with regards to SAEs, treatment discontinuation and AEs associated with death, in which, treatment with cemiplimab resulted in higher frequencies compared to chemotherapy. This pattern is what would be expected from treatment with a PD-1 inhibitor bearing in mind that immune-mediated AEs -although relatively infrequent- can have fatal outcomes. Overall, toxicity from cemiplimab is considered manageable.

No new events or concerning high frequencies of any known events were reported in study 1676. Importantly, the incidence of AEs across categories of any-grade, high-grade, SAEs, G5 AEs and AEs leading to discontinuation does not seem to exhibit a relationship to known PD-L1 status.

## 2.5.12. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 3.0 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 3.0 with the following content:

## Safety concerns

Table 76: Summary of Safety Concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                 |
|------------------------------|--------------------------------------------|
| Important Identified Risks   | imARs                                      |
| Important Potential Risks    | Lack of effect due to anti-drug antibodies |
| Missing Information          | Long-term safety data                      |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

## Risk minimisation measures

Table 77: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                               | Risk Minimisation Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Proposed Pharmacovigilance                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risk: Immune-mediated Adverse Reactions | Routine risk communication messages: SmPC sections 4.4 and 4.8 Routine risk minimisation activities recommending specific clinical measures to address the risk: See SmPC sections 4.2 and 4.4 See PL sections 2 and 3 Other routine risk minimisation measures beyond the Product Information: Legal status: Cemiplimab is supplied subject to restricted medical prescription, and treatment must be initiated and supervised by physicians experienced in the treatment of cancer. Additional risk minimisation measures: Patient Guide and Alert Card              | Activities Routine pharmacovigilance Use of specific follow-up questionnaire for spontaneous postmarketing reports of imARs Additional pharmacovigilance activities: Study short name and title: R2810-ONC-1540: A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Cell Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma |
| Important Identified Risk: Infusion-related Reactions        | Routine communication messages: SmPC sections 4.4 and 4.8 PL sections 2 and 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC sections 4.2, 4.3, and 4.4. PL sections 2 and 3 Other routine risk minimisation measures beyond the Product Information: Legal status: Cemiplimab is supplied subject to restricted medical prescription and treatment must be initiated and supervised by physicians experienced in the treatment of cancer. Additional risk minimisation measures: Patient Guide and Alert Card | Routine pharmacovigilance Use of specific follow-up questionnaire for spontaneous post- authorisation reports of infusion-related reactions Additional pharmacovigilance activities: Study short name and title: R2810-ONC-1540: A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Cell Death-1 (PD-1), in Patients with Advanced Cutaneous         |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                        | Risk Minimisation Activities                                                                                                                                                                                                                                                                         | Proposed Pharmacovigilance Activities                                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                       |                                                                                                                                                                                                                                                                                                      | Squamous Cell Carcinoma (Group 6)                                                                                                                                                                                                                                                                   |
| Important Potential Risk: Lack of Effect due to Anti- drug Antibodies | Routine communication messages SmPC section 4.8 Other routine risk minimisation measures beyond the Product Information: Legal status: Cemiplimab is subject to restricted medical prescription and treatment must be initiated and supervised by physicians experienced in the treatment of cancer. | Routine pharmacovigilance Additional pharmacovigilance activities: Study short name and title: R2810-ONC-1540: A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Cell Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma                        |
| Long-Term Safety Data                                                 | Not applicable                                                                                                                                                                                                                                                                                       | Routine pharmacovigilance Additional pharmacovigilance activities: Study short name and title: R2810-ONC-1540: A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Cell Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma (Groups 1, 2, 3 and 6) |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1 and 5.1 of the SmPC have been updated. The MAH has taken the opportunity to make minor changes to the product information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The current Type II variation is in relation to an addition of a new therapeutic indication. The application is not related to a change in legal status or to a new presentation, and no particular critical safety issues

<div style=\"page-break-after: always\"></div>

have been identified with Libtayo. Proposed changes to the package leaflet are thus minimal and it is consequently agreed that a separate user consultation with target patient groups is not required.

## 3. Benefit-Risk Balance

## 3.1.1. Disease or condition

The indication is for the t reatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

The aim of such therapy is to improve overall survival (OS) and progression free survival (PFS).

## 3.1.2. Available therapies and unmet medical need

The preferred first line (1L) approach for persistent, recurrent or metastatic cervical cancer in Europe involves platinum-based chemotherapy, often with paclitaxel, and in some cases, adding bevacizumab, or pembrolizumab (if tumour PDL1 expression CPS ≥1). When progressive disease occurs, single -agent chemotherapy -topotecan, vinorelbine, pemetrexed, irinotecan, ifosfamide, among others- can be considered in second or ulterior lines, although none of the available choices has shown significant survival improvements (median OS &lt;9 months).

## 3.1.3. Main clinical studies

The current application is based on results from Study 1676, an open-label, randomised 1:1, phase III trial that compared cemiplimab monotherapy vs. investigator's choice of chemotherapy (pemetrexed or topotecan or irinotecan or gemcitabine or vinorelbine) in women with recurrent or metastatic cervical cancer after progression to platinum-based chemotherapy with or without bevacizumab. 608 patients were recruited between November 2017 and July 2020, regardless of PD-L1 expression status, but only squamous cell carcinoma (SCC) or adenocarcinoma/adenosquamous carcinoma (AC) histologies were allowed. The primary endpoint was overall survival (OS). Secondary endpoints were PFS, ORR, DOR and QoL.

## 3.2. Favourable effects

- The study met its primary endpoint. After 65% of OS events and with a median follow-up of 18.2 months on data cut-off 04-JAN-2021, improved survival from cemiplimab (mOS 12.0 months) over investigator's choice of chemotherapy (mOS 8.5 months) was shown: HR for OS 0.68 (95% CI 0.56, 0.84), p-value 0.00011. The survival benefit was evident across both SCC and AC subpopulations of the trial, all prespecified subgroups and sensitivity analyses. In an updated exploratory OS analysis (data cut-off 04-JAN-2022) with median follow-up of 30.2 months and 76% of event maturity, the survival benefit from cemiplimab over chemotherapy was maintained (HR: 0.66, 95% CI 0.55, 0.79).
- PFS at 86% of event maturity was also statistically improved in the cemiplimab arm [HR 0.745 (95% CI 0.625, 0.89), p-value 0.00048], although K-M estimates of median PFS were almost equivalent in both arms: 2.8 for cemiplimab and 2.9 for chemotherapy.
- Albeit responses were scant (16% from cemiplimab and 6% from chemotherapy), ORR was also statistically improved for cemiplimab vs. chemotherapy.

<div style=\"page-break-after: always\"></div>

- An exploratory OS analysis of the 254 patients with known PD-L1 status (i.e., biomarker-available population, 42% of the ITT) was presented. Among these samples, 64% were PD-L1 ≥ 1% and 36% were PD-L1&lt;1%. At the most updated exploratory OS analysis on 04-JAN-2022, the hazard ratio for the PD-L1 ≥ 1% group was 0.70 (95% CI: 0.48, 1.01) and 0.85 (95% CI: 0.53, 1.36) for the PDL1&lt;1% group.

## 3.3. Uncertainties and limitations about favourable effects

- The magnitude of efficacy in subgroups indicate that PD-L1 expression might act as a relevant effect modifier. Recognising that efficacy will increase with increasing PD-L1 expression, this is understood as a continuum

## 3.4. Unfavourable effects

- Most patients in both arms of Study 1676 experienced an AE of any grade. The most frequent AEs in the cemiplimab arm were: anaemia 25%, nausea 18.3%, fatigue 16.7% and vomiting 16%. The most frequent AEs in the chemotherapy arm were: anaemia 44.5%, nausea 33.4%, vomiting 23.4%, pyrexia 21%. AEs and AEs of grade ≥3 were more frequent in the chemotherapy arm.
- The most prevalent grade ≥3 AEs were as expected: anaemia, urinary tract infection and hypokalaemia in the cemiplimab arm, while all events in the chemotherapy arm fall within the category of blood &amp; lymphatic disorders.
- SAEs, AEs resulting in death and discontinuation due to AEs were slightly more frequent in the cemiplimab arm.
- SAEs were registered in 29.7% (cemiplimab) vs 26.9% (chemotherapy). The most frequent SAEs in both arms were infections (10.7%/11.4%) and gastrointestinal disorders (4.3%/4.8%). Autoimmune/immune-mediated hepatitis (1.3%/1%) only occurred in the cemiplimab arm. Of note, the incidence of hepatitis as a composite term (including autoimmune hepatitis, immune-mediated hepatitis, hepatic function abnormal, hepatitis, hepatotoxicity, hepatic failure and hepatocellular injury) is 2.6%. Pneumonitis was more frequent in the cemiplimab arm (1%/0.3%) whereas haematologic SAEs (1.7%/6.9%) were more frequent in the chemotherapy arm.
- AEs resulting in death in the cemiplimab arm (1.7%) occurred in 4 out of 5 patients, not considered to be treatment-related. In the chemotherapy arm (0.7%, 2 patients), both fatalities were considered treatment-related.
- 15.7% of patients in the cemiplimab arm vs 0.7% in the chemotherapy arm experienced any imAE, grade ≥3 5.3% vs 0.7%, serious imAEs and discontinuation 5% vs 0.7%. Fewer patients in pool 1 (15.7%) had any imAE compared to pool 2 (20.5%). In line with the established imAEs profile of cemiplimab, the most frequent imAEs were endocrine disorders 8%, hepatobiliary disorders 3.3% and skin &amp; subcutaneous disorders 1.7%.
- Particularly in the cemiplimab arm, no specific pattern of toxicity that would indicate higher rates of all-grade, high-grade, G5 AEs, imAEs and AEs leading to discontinuation in the PD-L1&lt;1% vs. PD-DL1 ≥ 1% subpopulations seems present although SAEs occurred in 39% vs. 28% of patients (PD-L1&lt;1% and PD-DL1 ≥ 1% subgroups).

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Not applicable.

## 3.6. Effects Table

Table 78: Effects Table for cemiplimab in the treatment of patients with recurrent or metastatic cervical cancer and disease progression after chemotherapy (Study 1676, data cut-off: 04-JAN-2021)

| Effect                            | Short description                                | Unit                              | Treatment Cemiplimab n=304        | Control Chemotherapy n=304        | Uncertainties / Strength of evidence                     | References                        |
|-----------------------------------|--------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|----------------------------------------------------------|-----------------------------------|
| Favourable Effects                | Favourable Effects                               | Favourable Effects                | Favourable Effects                | Favourable Effects                | Favourable Effects                                       | Favourable Effects                |
| OS                                | Median overall survival                          | Months (95% CI)                   | 12.0 (10.3, 13.5)                 | 8.5 (7.5, 9.6)                    | Stratified HR 0.685 (95% CI 0.56, 0.84), p-value 0.00011 | Table 25/ CSR                     |
| PFS-INV                           | Median progression free survival by investigator | Months (95% CI)                   | 2.8 (2.6, 3.9)                    | 2.9 (2.7, 3.4)                    | Stratified HR 0.745 (95% CI 0.62, 0.89), p-value 0.00048 | Table 26/ CSR                     |
| ORR-INV                           | Overall response rate by investigator            | % (n)                             | 16.4 (50)                         | 6.3 (19)                          | Odds ratio 2.984 (95% CI 1.71, 5.22) p-value 0.00004     | Table 28/ CSR                     |
| Unfavourable Effects - study 1676 | Unfavourable Effects - study 1676                | Unfavourable Effects - study 1676 | Unfavourable Effects - study 1676 | Unfavourable Effects - study 1676 | Unfavourable Effects - study 1676                        | Unfavourable Effects - study 1676 |
|                                   | Description                                      | %                                 | Cemiplimab (n=300)                | Chemotherapy (n=290)              |                                                          |                                   |
|                                   | AEs                                              | %                                 | 88                                | 91                                |                                                          |                                   |
|                                   | AEs ≥grade 3                                     | %                                 | 45                                | 53                                |                                                          |                                   |
|                                   | SAEs                                             | %                                 | 30                                | 27                                |                                                          |                                   |
|                                   | imAEs                                            | %                                 | 16                                | 0.7                               |                                                          |                                   |
|                                   | AEs leading to discontinuation                   | %                                 | 9                                 | 5                                 |                                                          |                                   |
|                                   | AEs with outcome of death                        | %(n)                              | 1.7 (5)                           | 0.7 (2)                           |                                                          |                                   |

Abbreviations: OS overall survival; PFS progression free survival; ORR overall response rate; HR hazard ratio; CI confidence interval; CSR clinical study report; AE adverse event;

Notes: Stratification for the OS and PFS analyses was based on 2 out of 4 stratification factors: region of the world and histology.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Cervical cancer still represents a major public health problem in Europe despite availability of HPV vaccines and widespread screening programs, noting five-year relative survival of ~62% between 20002007. Surgery and chemoradiotherapy constitute the mainstay of treatment for local/locoregional disease, while systemic therapy with cisplatin plus paclitaxel and bevacizumab remains the preferred approach to recurrent or metastatic disease, regardless of histology. While the addition of bevacizumab was supported by a survival benefit shown at the GOG 240 study (Tewari et al, NEJM 2014), the role of added immunotherapy in first line has been recently established (Keytruda EPAR).

Diverse single-agent approaches assayed beyond progression to initial systemic treatment have shown modest response rates, although none has proved a significant survival advantage.

<div style=\"page-break-after: always\"></div>

Upon this major unmet medical need, and considering promising efficacy data from phase I Study 1423, the MAH for Libtayo designed and successfully conducted Study 1676, which compared cemiplimab vs. investigator's choice of chemotherapy (among gemcitabine, pemetrexed, vinorelbine, topotecan or irinotecan) in the targeted population of women with recurrent or metastatic cervical cancer with progressive disease after initial chemotherapy.

While a positive outcome favouring cemiplimab was seen across the primary (OS) and secondary efficacy endpoints, the magnitude of efficacy in subgroups indicate that PD-L1 expression might act as a relevant effect modifier in this setting: data from the exploratory survival analysis in patients from the trial with available PD-L1 samples suggests that efficacy improves with increasing PD-L1 expression.

Regarding safety, the overall toxicity profile of cemiplimab is in line with its anti-PD-1 mechanism of action, and compares favourably with chemotherapy in Study 1676. Immune-mediated AEs occurred in a substantial proportion of patients treated with cemiplimab, albeit mostly of low-grade and thus manageable. Overall, safety results from cemiplimab in Study 1676 (n=300) are similar to those of the safety pool from the cemiplimab monotherapy trials (n=1116). Of note, no new events or concerningly high frequencies of any known events were registered in the cited pivotal trial.

## 3.7.2. Balance of benefits and risks

Ultimately, a median survival improvement of ~4 months is considered a clinically relevant achievement of cemiplimab for women with advanced cervical cancer after progression to first line chemotherapy with platinum compounds.

The observed safety profile of cemiplimab appears consistent with the one expected for its pharmacological class. Toxicity is considered manageable and acceptable with no new events or concerningly high frequencies of any known events registered in study 1676.

## 3.7.3. Additional considerations on the benefit-risk balance

Acknowledging that exploratory data suggest that PD-L1 expression is a relevant effect modifier, efficacy estimates indicate that survival benefits were also observed in the underpowered PD-L1&lt;1% subgroup. Overall, it was deemed reasonable not to restrict the therapeutic indication (see section 4.1 of SmPC) based on PD-L1 expression levels.

## 3.8. Conclusions

The overall B/R of cemiplimab as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy, is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by a majority of 29 out of 30 votes, the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include monotherapy treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy for Libtayo; sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH has taken the opportunity to make minor changes to the product information. Version 3.0 of the RMP is approved.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

Divergent position to the majority recommendation is appended to this report.

<div style=\"page-break-after: always\"></div>

## APPENDIX DIVERGENT POSITION DATED 13 OCTOBER 2022

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION DATED 13 OCTOBER 2022 LIBTAYO EMEA/H/C/004844/II/0026

The undersigned member of the CHMP did not agree with the CHMP's positive opinion recommending the variation to the terms of the marketing authorisation of LIBTAYO.

The reason for divergent opinion was the following:

Study 1676 demonstrated a benefit in overall survival for cemiplimab compared to investigators' choice of chemotherapy. PD-L1 is a possible predictor of response, based on the mechanism of action and on external data with other immunotherapies, and therefore it is considered of interest to investigate and scrutinize the relative sub-groups. Yet, the trial recruited patients irrespective of PD-L1 status but PD-L1 status was not routinely collected and it is missing or not sufficiently reliable in about 60% of the population and based on a non-validated assay, limiting the interpretation of the results in relevant sub-groups. This is regarded as a relevant limitation of the study design, preventing a thorough assessment of the B/R in the overall population.

Notwithstanding the above-mentioned limitations, taking into account the totality of evidence, a positive B/R could be agreed in the PD-L1-positive subgroup. On the contrary, the absence of external data backing a benefit in the PD-L1 low expressors/negative population and a hazard ratio for overall survival of 0.846 (0.527; 1.357) in this sub-population versus comparators with undemonstrated efficacy on this end-point make the data/trial inadequate and insufficiently robust to inform on a benefit in the PD-L1 negative population.

Armando Genazzani